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Abstract 
Investigating the roles of the p63 isoforms in the microRNA biogenesis pathway: 
        Implications in tumorigenesis and pluripotency 
Publication No.______ 
Deepavali Chakravarti, M.S. 
Supervisory Professor: Elsa Flores, Ph.D. 
MicroRNAs play roles in various biological processes like development, 
tumorigenesis, metastasis and pluripotency. My thesis work has demonstrated roles for p63, a 
p53 family member, in the upstream regulation of microRNA biogenesis. The p63 gene has a 
complex gene structure and has multiple isoforms. The TAp63 isoforms contain an acidic 
transcription activation domain. The ΔNp63 isoforms, lack the TA domain, but have a proline 
rich region critical for gene transactivation. To understand the functions of these isoforms, the 
Flores lab generated TAp63 and ΔNp63 conditional knock out mice.  Using these mice and 
tissues and cells from these mice we have found that TAp63 transcriptionally regulates Dicer 
while ΔNp63 transcriptionally regulates DGCR8.  TAp63 -/- mice are highly tumor prone.  
These mice develop metastatic mammary adenocarcinomas, squamous cell carcinomas, and 
lung adenocarcinomas to distant sites including the liver, lungs, and brain.  I found that TAp63 
suppresses metastasis by transcriptionally activating Dicer. TAp63 and Dicer levels were very 
low or lost in high grade human tumors like mammary adenocarcinomas, squamous cell 
carcinomas, and lung adenocarcinomas. Expression of Dicer in these tumor cell lines reduced 
their invasiveness. Using ΔNp63 -/- mice, I found that ΔNp63 transcriptionally activates 
DGCR8, resulting in a miRNA profile that is critical to reprogram cells to pluripotency.  
Analysis of epidermal cells derived from  ΔNp63 -/- mice revealed that these cells expressed 
markers of  pluripotency, including Sox2, Oct 4 and  Nanog; however, genome-wide analysis 
revealed a novel profile of genes that are common between ΔNp63 -/- epidermal cells and 
embryonic stem cells.  I also found that mouse cells depleted of ΔNp63 form chimeric mice 
and teratomas in SCID mice, demonstrating that ΔNp63 deficient cells are pluripotent.  
Further, I found that restoration of DGCR8 in ΔNp63 -/- epidermal cells reduces their 
 vi 
 
pluripotency and induces terminal differentiation.  I also demonstrated that iMS (induced 
multipotent stem) cells could be generated using human keratinocytes by knockdown of 
∆Np63 or DGCR8. Taken together, my work has placed p63 and its isoforms at a critical node 
in controlling miRNA biogenesis. 
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1.1. The p53 family 
 In 1979 the p53 protein was identified by several laboratories simultaneously (1, 2). It 
was identified as a protein being bound to the SV40 large T antigen (2, 3). In 1984 the cDNA 
was cloned (4-7). For the longest time it was thought to be an oncogene due to its 
overexpression in mutated and tumorigenic cells(8, 9). In the late 1980’s researchers started to 
realize that the p53 cDNA that was cloned had mutations in several site. This was followed by 
the realization that the experiments performed with this mutated p53 protein cDNA was the 
reason why the cells transfected with the p53 protein ended up becoming transformed (10, 11). 
Thus began the search for the wild-type protein. In 1989 Dr. Arnie Levine’s lab cloned the 
wild-type p53 and showed that it could suppress transformation (12, 13). By the late 1980’s it 
was identified not as an oncogene but as a tumor suppressor (12, 13). More than 50% of 
human tumors exhibit loss or mutation of the p53 protein(14). Since then researchers had been 
looking for other p53 family members in the hope that this could lead to discovery of more 
tumor suppressors, which are potentially not mutated in tumors. The p53 knock–out mouse 
exhibits early tumorigenesis as expected, but seemed to have less developmental defects, 
suggesting the role of p53 to be mainly limited to tumorigenesis (15). Although, recently there 
has been an exponential increase in literature on p53’s role in development and stem cell 
maintenance (Ref), the functions of p53 are diverse and the most intriguing feature is its role in 
tumor suppression. Soon researchers started to realize that apoptosis and senescence was 
triggered even in the absence of p53 (16-18). Therefore the identification of p63 and p73 was 
very exciting in the field of cancer biology and tumor suppression. Researchers thought these 
like p53 could contribute to tumor suppression.  
 Unlike p53 these proteins are not frequently mutated in tumors and therefore 
theoretically could compensate for p53 loss. Interestingly this was soon found to be not 
completely true. Both proteins have structural similarities to p53 in their gene structure. Like 
p53 the full length protein has a transactivation domain, a DNA binding domain and an 
oligomerization domain. Additionally it has a sterile alpha motif domain (SAM) at its C-
terminus.  
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1.2. Phylogeny of p63/p73 
Although the p63/73 proteins were identified first in mice, modified forms of these 
proteins are present in lower organisms (19-21). In fact an ancestor of p53 has been found in 
single cell flagellates and in metazoans (20). This ancestral gene resembles p63/73 more than 
p53. All these members have a SAM domain like p63/73 (19, 22). The main function of this 
gene is the protection of the female germ-line in many organisms. This function of p63/73 has 
also been conserved in mice as has been demonstrated by the construction of knock-out mouse 
models. With the evolution of bony fishes, there was a duplication of this ancestral gene and 
p63 and p73 genes evolved as separate genes with their own identities. From bony fishes to 
amphibians, reptiles and mammals, there is more selection pressure leading to another 
duplication (23). This time the protein product was expressed in somatic cells and it came to 
be known as p53. In lower organisms like the sea anemone (the gene is called nvp63) (24) and 
fruit-flies (called dmp53) (22, 25), the main function of the p63/73 gene seems to be in 
guarding the female gamete form DNA damage and induction of apoptosis in case of severe 
damage in these lower organisms (26). In C.elegans this hybrid gene (CEP-1) not only 
protects the germline but also regulates glucose activity and longevity (25). Finally in higher 
organisms like bony fishes for example zebrafish, amphibians, reptile, birds and mammals this 
group of hybrid genes gave rise to three distinct family members, p53, p63 and p73 (23). Each 
member in the family has individual functions but also overlapping functions. p53, p63 and 
p73 ensures germline fidelity. p63 plays a major role in development in mice. p73 plays roles 
in development of the immune system, the neuronal system and also fertility in mice. These 
members together can induce apoptosis, cell death and have tumors suppressive roles. They 
are also important in the maintenance of the genomic integrity (27, 28). 
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1.3. p63 gene structure 
The p63 gene has 15 exons. This protein was cloned in 1998 for the first time (29-31). 
In humans it is located at 3q27-29 and in mouse at chromosome 16 between anonymous DNA 
markers D16Mit1 and D16Mit3 (30). The full-length protein has three main domains, the 
transactivation domain, the DNA binding domain and the oligomerization domain. 
Additionally it has a sterile alpha motif domain (SAM domain)(Figure 1) (30). The 
transactivation domain renders the proteins their transcriptional activity, the DNA binding 
domain helps them to bind to the DNA and the oligomerization domain is important for their 
interaction within the family members. They can form homo oligomers or hetero oligomers 
(32). The p63 proteins belong to the p53 family of proteins and resembles p53 protein in most 
of its domains. It has high resemblance to p53 in its transactivation domain (25%) DNA 
binding domain (68%) and the oligomerization domain (35%) (30). The protein has two main 
isoforms. The full–length protein is called TAp63. It retains the N-terminal acidic 
transactivation (TA) domain (30) and is thought to be transcriptionally the most active form. 
The N-terminally truncated isoform is known as the ΔNp63 isoform. It lacks the N-terminal 
domain but can still transactivate targets by a 33 amino acid proline rich N-terminal domain 
(30, 31). The promoter of TAp63 is located at exon 1 while the promoter of ΔNp63 is located at 
an intronic site in a cryptic promoter denoted exon 3’. These proteins have various other 
spliced isoforms at the C-terminus like α, β and γ. Together there are 6 different p63 isoforms 
(Figure 1).  
  
 5 
 
 
 
 
 
 
p63 gene has four domains, transactivation domain (TA), DNA binding domain(DBD), 
oligomerization domain(OD) and sterile alpha motif domain(SAM) (present only in the α 
isoforms). TAp63 contains all the domains including the transactivation domain (Exon1-3). 
ΔNp63 lacks the TA domain, but has an internal promoter within exon 3’. C-terminal spliced 
variants for both isoforms are marked α,β,γ.  Exon1 is non-coding. Domains of the p53 gene is 
depicted in green and percent identity is denoted. 
Modified and reproduced with permission from the copyright clearance center, p63 steps into 
the limelight: crucial roles in the suppression of tumorigenesis and metastasis, Nat Rev 
Cancer. 2013 Feb;13(2):136-43. doi: 10.1038/nrc3446. 
 
Figure 1: p63 gene structure and similarity to p53 gene 
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1.4. Germline heterozygous p63 mutations in humans 
p63 has been shown to be extremely important in development in organisms. p63 
mutations in humans are heterozygous. In humans, point mutation of this protein causes severe 
epidermal abnormalities and is associated with various syndromes like cleft lip and palate, 
limb malformations, ectodermal dysplasia and mammary gland hypoplasia.  The different 
syndromes related to p63 mutations, that have been described are EEC (ectrodactyly, 
ectodermal dysplasia and clefting) (33), AEC (ankyloblepharon, ectodermal dyplasia and 
clefting) (34, 35), LMS (limb-mammary syndrome) (36), ADULT (acro-dermato-ungual-
lacrimo-tooth) (37, 38), SHFM (split hand/foot malformation)(39-41), Rapp-Hodgkin’s 
syndrome (42) and Hay-Wells syndrome (43). Many of these mutations in humans 
phenotypically resemble the p63 knock-out mouse, albeit with much less severity. Most of 
these malformations are the cause of mutations in the DNA-binding domain or the SAM 
domain of p63. SAM domains are thought to be important for protein-protein interaction. The 
functions of the p63 SAM domain has not been well studied yet. One point mutation has been 
found in patients with the EEC syndrome. This reduces the transcriptional potential of p63 due 
to reduction in DNA binding ability. LMS diseases are characterized by frame-shift mutations 
in exon 13 and exon14. This leads to a truncated protein, which does not have the TID domain 
and parts of the SAM domain in the α form of the protein. The β and γ isoforms are unaffected 
by this truncation. In AEC predominant mutation is in the SAM domain causing loss of 
protein-protein interaction. In ADULT patients the main isoform affected is the ΔNp63, 
although there are mutations present in the DNA binding domain as well. Taken together these 
mutations seemed to be similar to the mutations in p53, in which most of the hot-spot 
mutations are in the DNA binding transactivation domain. (Reviewed in (44)) 
 
1.5. Role of p63 in Human Tumorigenesis 
Prior to work from our lab, the role of p63 in tumorigenesis was not well understood. 
There is literature which indicates that p63 is an oncogene (45, 46). In many human tumors 
p63 expression has been shown to be increased (47-51). In human head and neck squamous 
cell carcinomas (45), nasopharyngeal carcinomas (47), urinary tract (52), mammary 
 7 
 
adenocarcinomas (53), lung (50) ovarian tumors (54) and prostate tumors (55) p63 is 
overexpressed. Interestingly in many metastatic tumors p63 has been shown to be lost (53, 56, 
57). The antibody used in many of these studies does not distinguish between ΔNp63 and 
TAp63. Therefore these studies are difficult to interpret. In some studies, ΔNp63 has been 
shown to be lost in invasive tumors of the bladder (82% of the invasive bladder carcinomas) 
(58),(59). In many CML patients p63 have been shown to have point mutations specifically the 
the patients who progressed to blast crisis (12%) (60). In some tumors p63 locus was shown to 
be amplified (61, 62). Significant progress in sequencing has identified mutations in the p63 
locus from tumor samples. Recently a paper from TCGA demonstrated amplification of the 
p63 locus and amplification of specifically ΔNp63 mRNA in lung squamous cell carcinomas 
(63). Another study showed that atleast 8% of the head and neck squamous cell carcinoma 
samples carried mutations or amplifications in the p63 gene (64). TAp63 has specifically been 
shown to be lost in metastatic lung and mammary adenocarcinomas (100% of the samples 
tested from grade IV tumor samples) (59, 65). There is a reduced expression of TAp63 in high 
grade head and neck squamous cell carcinomas (65). In all of these studies p63 have been 
implicated as an oncogene at times and tumor suppressor at other times.  
 
1.6. The p63 knock-out mouse models and contradictory phenotypes 
Two different groups generated the p63
 -/-
 mice in 1999. Both these groups demonstrated 
that the total p63
 -/-
 mice exhibit developmental defects (30, 66). They had craniofacial 
abnormalities, cleft palate, limb development defects and defects in the formation of all the 
different epithelial structures like mammary glands, lacrymal glands and salivary glands. They 
lack eyelids and tooth primordial (29, 66). The mice in the McKeon lab were generated by 
replacing exon 6,7,8 and the flanking introns with a neomycin resistant cassette, thereby 
deleting the DNA binding domain of the protein. Upon detailed analysis Frank McKeon’s 
groups at Harvard found that the embryos at E18.5 days expressed patches of rudimentary 
epidermis. These cells expressed early basal layer marker like keratin5 and differentiation 
marker like loricrin (30). Later on they performed clonogenicity assays with the epidermal 
cells from the thymus of these animals and detected loss of proliferation in these cells (30, 67). 
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They thus concluded that p63 is required for the proliferative potential of basal layer of skin 
and also of the transient amplifying cells (67).  
The other mouse model generated in Alan Bradley’s lab had a similar phenotype, but 
upon analysis of the epidermis did not show expression of any of the later differentiation 
markers. These mice were generated by mutating the p63 gene using the embryonic cell 
technology. By this technology they developed two target vectors pTV6H(90) and 
pTV12E(60). These target the p63 gene at two different points creating a transcript truncated 
at exon 6 (Brdm1) which would produce a protein lacking the DNA binding domain and the 
other vector would generate a recombinant allele that truncates the p63 mRNA at exon 10 
(Brdm2). This transcript would give rise to a protein with intact DNA binding domain, but 
without the highly conserved 3’region of the p63 protein (66). In these mice they detected very 
faint expression of keratin 14 in the single layered epidermis of the newborn mice. They 
attributed this phenotype to the role of p63 in the regulation of commitment to stratification. 
Recently this model has been characterized to be a hypomorph and not a complete null (68-
70). Thus the two mice demonstrate contrasting phenotypes muddling the interpretation for the 
role of p63 in stem cell maintenance or stem cell differentiation. This led to the path of the 
development of the isoform specific knock-out mouse models, which could specifically dissect 
the role for TAp63 and ΔNp63. 
 
1.6.1. TAp63 knock-out mouse models 
One of the major reasons for this difficulty in  interpretation of p63’s role in human 
cancer  is the existence of multiple isoforms of p63. It became evident that in order to truly 
understand the role of p63, isoform specific knock-out mouse models would have to be 
generated. This was done first in the lab of Dr. Frank McKeon in 2006 (71). This mouse is a 
total knock-out for TAp63. Exon 2 and exon 3 were deleted by insertion of a neomycin 
cassette. This mouse did not present any phenotypic abnormality (71). TAp63 expression is 
very high in the ovary and the oocyte nuclei of the wild-type mice but not in the testis. 
Therefore to delineate the function of TAp63 in the female germ line, the mice were irradiated 
with various doses of radiation at p5. At lower dosage (0.1Gy) no apoptosis was observed in 
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the in the oocytes. But at higher dosage like 0.45Gy and 4.5 Gy all the oocytes in the 
primordial follicles died due to apoptosis both in the wild-type and p53
 -/-
 mice. The TAp63
 -/-
 
mice were resistant to such loss of oocytes, suggesting that TAp63 and not p53 is the main 
mediator of apoptosis in the female germ cells (71).  
The other TAp63
 -/-
 mouse was made by the lab of Dr. Elsa Flores in 2009. This mouse 
has a deletion in exon 2. These mice have several phenotypic abnormalities. They develop a 
premature ageing phenotype (72). They exhibit alopecia and kyphosis as early as 6 months of 
age.  Defects in hair regeneration are observed in young mice at 1 month of age. They show 
reduced hair follicle density. Also these mice have defects in wound healing (72). On further 
analysis these mice demonstrate a defect in stem cell regulation. The proliferation of stem cells 
in the dermal papilla and dermal sheath are under the regulation of TAp63. These cells are 
called SKPs (skin precursor cells). The loss of TAp63 therefore causes them to hyperproliferate 
initially and then to undergo senescence. This explains the premature ageing in these mice and 
the defects in wound healing (72).  
 
1.6.2. ΔNp63 knock-out mouse models 
  ΔNp63 has been shown to be the predominant p63 isoform that is expressed in the 
basal layer of the skin and other tissue epithelium (73). Unlike TAp63, the expression of which 
is hardly detectable in tissue under stress-free conditions, this isoform is expressed at all times. 
Therefore the hypothesis was that ΔNp63 is the main player among the two isoforms and most 
of the phenotypic abnormalities of the total p63 knock-out mice can be attributed to the loss of 
this isoform. Recently a ΔNp63 knock-out mouse model has also been published (74). This 
model was developed in the lab of Dr. Satrajit Sinha. They substituted exon-3’ with a GFP 
cassette (ΔNp63gfp/gfp), which carries the promoter for ΔNp63 specifically. Thus these mice lose 
the ΔNp63 expression while retaining the TAp63 expression. Phenotypically these mice are 
similar to the p63
 -/-
 animals. They develop truncated forelimbs and do not develop hind limbs. 
They have craniofacial abnormalities, palate formation and defects in epithelial tissue 
formation. These mice die a few hours after birth. They show defects in stratified epidermis 
formation (74). Interestingly a more detailed analysis revealed patched of epidermis like 
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structure covering the embryos at E14.5dpc and E18.5 dpc. Analysis of the epidermis from the 
E18.5 embryos showed expression of K8 a marker of simple epithelium and K5 a marker of 
the basal layer of epidermis. These patches expressed keratin 1 and keratin 10, markers of the 
spinous layer. They also observed expression of other terminal differentiation markers in these 
patches, like loricrin, involucrin and filaggrin. Surprisingly when they co-stained from keratin 
5 and keratin 1 or keratin 10, they observed double positive cells. They thus concluded that 
these mice exhibit improper accelerated terminal differentiation in the epidermis (74). They 
also checked for expression of integrins α6, α5 and collagen IV. The expression of all the 
proteins important in regulating cell adhesion and maintaining cell-cell junction, was low in  
these mice. To explain the differentiation pattern of the epidermis in these animals, they 
analyzed the Notch pathway and determined that ΔNp63 regulates the Notch pathway and that 
the accelerated differentiation seen in the patches of epidermis in these animals is a result of 
the activation of the Notch pathway through over expression of Notch 2 and Notch 3(74).  
 
1.7. Role of p63 in stem cell biology 
1.7.1. The Epidermis 
The skin is the outermost barrier of the body. This layer protects the organism from 
loss of water, pathogens and the environmental stresses (75-77). The skin is divided into two 
major layers; the dermis and the epidermis. The epidermis constitutes of the bottom basal 
layer, the spinous layer, the granular layer and the cornified layer. The basal layer can be 
identified by the expression of keratin 5 and keratin 14. The basal layer contains some of the 
epithelial stem cells. This layer gives rise to all the other layers of the epidermis. The outer 
layer from the basal layer is the spinous layer. This layer expresses keratin 1/keratin10. The 
basal layer and the spinous layer together form the Malphigian layer. These two layers give 
rise to the granular layer. As the name suggests the granular layer is comprised of keratin 
granules. The granular layer can be identified by its expression of filaggrin. This layer does not 
divide at all. This layer gives rise to the more differentiated cornified layer. The outermost 
layer is known as the cornified layer. This layer expresses loricrin or involucrin. All the 
outermost three layers are generated from the basal layer, which continuously cycles and is 
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mitotically active. All the layers of the epidermis are well-defined segregate from each other 
(76, 78). 
 
1.7.2. p63 and stem cell  
p63 is one of the major proteins expressed in the basal layer of skin. The ΔNp63 
isoform is predominantly expressed in the basal layer, while TAp63 is expressed in the dermal 
sheath and the dermal papillae and also in the hair follicles (72, 79). The McKeon lab 
investigated the role of p63 in stem cell maintenance with the help of their total p63 knock-out 
mouse. The p63
 -/-
 mouse developed in their lab has a hypoplastic thymus (67). They analyzed 
the epithelial cells from the thymus at different embryonic stages and compared their 
proliferative capacity to that of the wild type. They show that the epidermal cells from the 
thymus are defective in proliferation. When passaged, they lose the capacity to form 
holoclones and mainly form paraclones and meroclones signifying the loss of the stem cell 
population. In comparison epidermal cells from the wild-type thymus forms an increased 
number of holoclones (67). They immunostained the single layered epidermis from the 
embryos and as mentioned earlier found that these express both markers of late differentiation 
like loricrin and involucrin, but not keratin 5, basal cell marker. They therefore concluded the 
loss of p63 leads to a defect in stem cell renewal. In wild-type epidermis the stem cells 
undergo asymmetric division to give rise to transiently amplifying (TA) cells and a multipotent 
stem cell. These transiently amplifying cells have limited stemness and behave like 
progenitors. These divide and form the more differentiated cells and more transiently 
amplifying cells, thus maintaining a sufficient number of TA cells and differentiated cells. In 
the p63
 -/-
 embryos, all the stem cells undergo symmetric division giving rise to only 
transiently amplifying cells, which divide and form the more differentiated cells. In this way 
they exhaust their proliferation capacity and eventually senesce. The basal cells in the 
epidermis according to their hypothesis behaves like these TA cells which are absent in the 
p63
 -/-
 embryos giving rise to the more differentiated cells (67). 
  The TAp63
 -/-
 mice develop a full thickness epidermis. They are born and the median 
age of survival is 12 months (65, 72). Recently it was shown that TAp63 is expressed in the 
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hair follicle stem cell niche in the dermal sheathe and the dermal papillae where skin derived 
precursor cells reside (72) (Figure 2). The loss of TAp63 causes hyperproliferation in the 
precursor stem cells and eventually leads to senescence. This causes premature ageing in the 
TAp63
 -/-
 mice. Thirty three percent of these mice develop blisters and skin ulcerations by 1 
month of age. By 10 months of age eighty six percent of the mice develop kyphosis and 
alopecia compared to ten percent of the wild-type mice. They also exhibit wound-healing 
defects due to the loss of proliferation potential of the SKPs (72).   
ΔNp63 is the major isoform expressed in the basal layer (Figure 2), where it is thought 
regulate self-renewal capacity of the adult skin stem cells or induce differentiation (30, 79). 
The role of ΔNp63 in stem cell regulation is yet to be delineated. The current understanding is 
that ΔNp63 regulates differentiation of the skin stem cells and loss of ΔNp63 causes a loss in a 
differentiated epidermis, craniofacial and other epithelial defects which induces post-natal 
death in the ΔNp63 knock-out mice due dehydration, desiccation and maternal neglect (74).  
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Figure 2: Role of p63 in stem cell maintenance in the dermis and epidermis 
Shown is the structure of the epidermis with basal layer keratin 5/14 (K5/K14), spinous layer 
expressing keratin10/1 (K10/K1), granular layer expressing filaggrin and cornified layer 
expressing loricrin and involucrin. The Sox-2 positive hair follicle dermal cells (SKPs) are 
marked in yellow in the dermal sheath and the dermal papilla. TAp63 is expressed in these 
cells.  ΔNp63 is expressed in the basal layer cells. These cells are proliferative and give rise to 
the top differentiated layers of the epidermis as indicated. 
Modified and adapted from http://en.wikipedia.org/wiki/Epidermis_(skin).  
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1.8. Stem cells 
Stem cells are capable of giving rise to a whole organism. These cells can give rise to all 
kinds of tissues of the body, skin, heart, lungs, muscle, bone, blood, sperm, egg and others. 
Stem cells can be derived from the inner cell mass of the blastocyst known as embryonic stem 
cells. The other types of stem cells are called adult stem cells. These are present in most of the 
adult tissues including the bone marrow, skin, brain and muscle. Stem cells can participate in 
wound healing and repair. They divide asymmetrically giving rise to an undifferentiated stem 
cell and a more differentiated daughter cell. These daughter cells then give rise to the more 
differentiated cells forming various tissues. This is how a constant pool of stem cells are 
maintained in the body for times of tissue damage. The stem cells derived from the blastocysts 
are known as pluripotent cells as each of these cells can give rise to cells of three tissue 
lineages ectoderm, endoderm and mesoderm. Whereas the adult stem cells may be multipotent 
(give rise to multiple tissue of one lineage like hematopoietic stem cells), oligopotent  (can 
give rise to only a few cell types of a lineage like myeloid or lymphoid precursors) or 
unipotent (can differentiate into cells of a specific tissue type, but with limited self-renewal 
capacity, like transiently amplifying cells of the epidermis) (80).  
   One of the important characteristic features of stem cells is their property of self-renewal. 
The two main proteins shown to be crucial in maintenance of this property are Oct-4(81) and 
Nanog (82). Oct-4(encoded by Pou5f1) is expressed at the four cell stage of the embryo and 
the pluripotent cells (83, 84). It is expressed at high levels in ES cells and its expression is 
important for the maintenance of self-renewal of these cells (85). Oct-4 is a transcription factor 
and regulates expression of downstream targets like Nanog, Utf1, Rex1, Sox-2, Fbx15 and of 
itself as well (86-89). Nanog is another transcription factor important for the regulation of self-
renewal and pluripotency (82). Like Oct-4 it can (88) also regulate the expression of Rex-1 a 
self-renewal associated protein (89). It can also regulate the expression of Oct-4. Oct-4, Sox-2 
and Nanog have been shown to be the most important proteins in the maintenance of self-
renewal and pluripotency. 
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Apart from embryonic and adult stem cells, recently a lot of progress has been made in the 
field of reprogramming differentiated cells into pluripotent stem cells. These are called 
induced pluripotent cells or iPS cells. 
 
1.8.1. Induced pluripotent stem cells  
Recently Dr. John B Gurdon and Dr. Shinya Yamanaka was awarded the Nobel Prize 
in Physiology or Medicine in 2012 for the discovery of induced pluripotent stem cells (iPS 
cells). As the name suggests this is a method by which adult cells can be induced to become 
stem like cells. In 1962 Dr. Gurdon performed an experiment where he took nuclei from the 
differentiated intestinal cells of tadpoles and transplanted them into the anucleate egg cells of a 
donor Xenopus laevis. Many of these eggs then gave rise to functional feeding tadpoles. Thus 
he concluded that the nucleus of differentiated cells have all the information in them to 
differentiate into other types of differentiated cells (90). Since then many scientist have 
demonstrated that cells can be reprogrammed by nuclear transplantation or cells and nuclear 
fusion  (91). But the proteins inducing these changes remained a mystery until in 2006 Dr. 
Shinya Yamanaka published a ground breaking paper where they found four specific factors 
required to reprogram adult differentiated cells (mouse fibroblasts) into undifferentiated stem 
cells (pluripotent cells), which can then be differentiated into various lineages and even into a 
complete organism. These four factors are Oct-4, Sox-2, Klf-4 and c-Myc (92). These 
pluripotent cells when injected into the blastocysts of a pseudopregnant mouse could give rise 
to chimeras. They also demonstrated that these cells could contribute to the formation of 
chimeras.  They further published a second paper in 2007 where they demonstrated this was 
possible with primary human cells as well. Human dermal fibroblasts (HDF), neonatal 
fibroblasts (BJ cells) and human fibroblast-like synoviocytes (HFLS) can be reprogrammed 
with the same four factors and induced to pluripotency (93). In the same year another group in 
the lab of James A. Thomson reported a similar phenomenon. They screened through initial 14 
factors and found that over expression of Oct4, Sox2, Nanog and Lin28 could reprogram 
human heamtopoeitic CD45+ cells to induced pluripotent stem cells (94). They also performed 
similar reprogramming assays with the primary human fibroblasts IMR90 (fetal fibroblasts) 
and postnatal fibroblasts (CRL-2097). Both of these group demonstrated that the iPS cells 
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generated by these methods were similar to human ES cells in their genetic profile. They 
express the stem cell markers, Oct-4, Sox-2, Nanog, Rex-1, Lin28, Klf-4 and other genes 
similar to human ES cells. They also expressed stage specific embryonic antigen-3 (SSEA-3) 
and 4 (SSEA-4) and Tra-1-60 and Tra-1-81, markers of human ES cells (93, 94). They had 
similar methylation pattern on promoters of certain genes (93, 94). They exhibited active 
telomerase enzyme and high rate of proliferation similar to human ES cells. They also 
differentiated into three germ layers when a teratoma assay was performed with these cells 
(93, 94). Since then there has been an exponential increase in the knowledge base of factors 
which could make differentiated cells pluripotent.  
Since then iPS cells have been made from various cells types like pancreatic β cells, 
stomach and liver cells, neural stem cells, melanocytes, mature B cells, adipocytes and 
keratinocytes (95-99). This demonstrates the intrinsic capability of differentiated cells to revert 
back to a stem like state that can then be induced to differentiate into various other lineages.  
Many other researchers have published the use of other downstream targets of these 
transcription factors in an attempt to delineate the pathway of reprogramming, as this process 
seems to be largely stochastic. Also the main problem with the use of c-Myc and Klf-4 is that, 
these are known oncogenes and thus their use in vivo is of major concern. A few such 
downstream target genes, which have been successful in reprogramming cells in combination 
are UTF1, Esrrb, Sall4 and Dppa2 (94). The overexpression of these genes have also been 
shown to be good predictors of reprogrammed cells. These factors can replace Klf-4 and c-
Myc. Also the use of retroviral vectors (Yamanaka’s group) or lentiviral vectors (James 
Thomson’s group) are not suitable delivery methods as they have been shown to be oncogenic. 
Thus other groups have tried to design viral free vectors like plasmids {Chou,  #542)or mini-
circle DNAs (100), non-integrative episomal vectors (101) and excisable viral vectors. The use 
of transient overexpression plasmids has also been reported. The other ways of avoiding viral 
vectors are introducing the mRNA for the reprogramming factors or the purified proteins 
themselves (102). This was successfully done, but resulted in even lower efficiencies. Also 
there was a problem in selecting the right host for the protein production and the isolation 
process, as this requires strong chemicals, which could contaminate the proteins and cause 
toxicity during reprogramming. Transfection of cells with mRNA is a better method, but 
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entails a lot of time and effort. The cells have to transduced with mRNA for 17 days. Also the 
mRNAs may cause strong immune responses in human cells (103).  
The method of iPS cells generation from differentiated cells has also been reported to 
be very inefficient (.001%). In an attempt to overcome such inefficiencies the use histone 
modifying enzymes, 5-azacytidine (AZA) and three HDAC inhibitors including 
suberoylanilide hydroxamic acid, trichostatin A, valproic acid (VPA) (104-106). Most of these 
are small molecule inhibitors that prevents the DNA from being methylated keeping it in a 
more open state like that found in ES cells. This has increased the reprogramming efficiency to 
1%. In order to increase efficiencies secondary iPS cells have also been made from iPScs 
derived differentiated cells. This improves the efficiency of reprogramming from .01% to 
about 5% {Maherali, 2008 #641}.  
 
1.8.2. Application of iPS cells and associated problems 
When James Thomson first isolated human ES cells in 1998, researchers thought this 
could be another ‘magic bullet’. Human ES cells were thought to be able to differentiate into 
multiple cell types. Therefore multiple incurable diseases like degenerative diseases of the 
nervous system and muscle could be cured. Although this proved to be true, but there are 
multiple problems associated with this strategy. First is the challenge to obtain enough adult 
stem cells from patients. Since adult stem cells are very few in numbers and are very hard to 
obtain the next choice is to obtain stem cells from normal human embryos. Second is immune 
rejection of tissues generated from these cells as they are not matched to the recipient’s tissue 
or cell type.  Thus in 2006 with the derivation of successful iPS cells from mouse fibroblasts 
ushered a new era of hope in stem cell therapy.  This meant that differentiated cells could be 
isolated from patients induced to become iPS cells and differentiated into the required tissue 
type in vitro or vivo. These could then be transplanted back to the patients without risk of 
immune rejection. Unfortunately the iPS cells that have been derived until now have been 
shown to be different in the genetic and epigenetic make up from the normally occurring ES 
cells. Therefore further research is necessary to derive iPS cells which would mimic the ES 
cells better. Inspite of this, iPS cells are being investigated for their potential to differentiate. 
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Various cell types have been obtained from these iPS cells like neruronal cells, hematopoieitic 
cells, pancreatic β cells capable of secreting insulin, cardiomyocytes, epidermal cells and many 
others (107-110). 
Although there are concerns with transplantation of the differentiated tissues from iPS 
cells, this has paved way for better disease modeling in vitro. Human primary cell lines are 
mortal and are hard to culture. Also the immortalized human cell lines have their own 
mutations and are not suitable to be studied for disease specific cell culture models. Therefore 
patient specific iPS cells are now being generated to study the effects of various mutations in 
specific tissue type obtained from these iPS cells. These cells lines may be maintained for 
indefinite periods of time with only disease specific mutation and minimum other alterations. 
Examples of the iPS cells made from patient specific tissues are familial dysautonomia , long 
QT syndrome (111), Parkinson’s disease (112), Huntington’s disease (113), Down’s syndrome 
(114),  Fanconi anemia (115), Sickle-cell anemia (116), beta-thalassemia (117), Type I 
diabetes(118), SCID or leaky SCID (119), cystic fibrosis (120), retinitis pigmentosa  and many 
others. Some of these diseases do not have appropriate mouse models and many of the existing 
mouse models do not recapitulate the human disease symptoms. Therefore now with the help 
of disease specific iPS cells and the tissue derived from them, these diseases can be better 
studied.  
The other important aspect of iPS cell generated tissue is that they can be used for drug 
testing. This will allow for screening of drugs in these cells. Many drugs exhibit cardiotoxicity. 
Cardiomyoctes can be derived from iPS cells and screened for such toxic effects.  
 
1.8.3. Role of p53 in iPS cell  
Several proteins have been shown to have an inhibitory effect on reprogramming of 
adult cells. As murine fibroblasts are passaged they lose their ability to be reprogrammed. On 
the other hand if p53 is silenced, then cells which show lack of reprogramming can be 
reprogrammed (121, 122). Telomerase deficient cells usually cannot be reprogrammed, but 
silencing of p53 allows these cells to be reprogrammed. Immortalized cell lines are more 
amenable to reprogramming than primary cells and with higher efficiencies (about 1%) (121, 
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123, 124). This provided researchers with a clue that senescence may be the roadblock to 
reprogramming. Many factors affecting cellular senescence like p16
Ink4a
, p19 
Arf
 , p21, JmjD3 
and p53, have been shown to suppress reprogramming (121, 125-127). There is an increase in 
p53 levels with overexpression of the Yamanaka factors in the cells. This leads to the increase 
in expression of p53 target genes and p53 mediated growth arrest and apoptosis. Therefore 
induction of p53 expression is critical in inhibiting the reprogramming process through its 
mediator p21.  
Interestingly cells have been shown to be partially reprogrammed by transient 
downregulation of p53. These cells are called Gene suppression plastic cells (GSPCs). 
Researchers observed that when p53 is downregulated with the help of lentiviral shRNA in 
fibroblasts from Oct4-GFP mice, these cells expressed GFP suggesting expression of Oct4. 
They also downregulated p53 in normal human keratinocytes and found that these cells 
phenotypically looked like human ES or iPS cells. They expressed alkaline phosphatase and 
could be passaged for more than five times and still retained AP staining. These cells could 
also form neuronal cells when cultured in neuron specific media. When injected into SCID 
mice these cells gave rise to partially differentiated teratomas showing structures of ectodermal 
origin. Thus scientists concluded that these cells could not be reprogrammed to a state more 
undifferentiated than the primitive ectoderm. These cells could also form neurons in vitro and 
ex vivo when transplanted into brain slices from mice. They gave rise to nestin positive cells 
(128).  
 
1.9. Role of the p63 isoforms in tumorigenesis –lessons learnt from mouse models 
Eighty percent of all tumors are epithelial in origin. p63 is one of the predominant proteins 
expressed in the epithelial tissues specifically in the basal layer (73). Therefore its role in 
tumor suppression and epithelial tissue homoeostasis is not surprising. Although it took 
researchers several years to realize that apart from playing a big part in development, p63 is 
also involved in the suppression of tumorigenesis. In 2002 Flores et. al. showed that cells and 
tissues lacking p63 could not induce apoptosis efficiently. There was a defect in the 
transactivation of some of the target genes like PERP, BAX and NOXA. This was found to be 
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due to the inability of p53 to bind to these target genes in the absence of p63 (129). In 2005, 
Flores et al. further investigate the tumor suppressive role of p63 by crossing the p63 
heterozygous mice to the p53
 +/-
(130). These mice had a shorter lifespan in comparison to the 
p53
 +/-
 mice. Median survival was 7 months for the double mutants in comparison to 10 
months in the p53
 +/-
 mice. Ten percent of the p63
 +/-
 mice develop squamous cell carcinomas 
and 20% of the mice developed histiocytic carcinomas by 12 months. The mutant mice for p63 
and p53 showed a high rate of transitional carcinomas (20%) and mammary adenocarcinoma 
(10%). Tumors from p63
 +/-
 mice displayed loss of heterozygosity, a hallmark of tumors 
suppressors. Interestingly 50% of the p63
 +/-
; p53
 +/-
 mice developed metastatic diseases like 
squamous cell carcinomas that metastasized to the lung and the heart and also osteosarcomas 
and rhabdomyosarcomas metastatic to liver and the lung. Seven out of eight of the 
osteosarcomas were found to be metastatic in the p63
 +/-
; p53
 +/-
 mice compared to only 1 out 8 
in the p53
 +/-
 mice (130). These mice also developed myelogenous leukemia. These results 
suggest that p63 plays a tumor suppressive role in various epithelial tissues (130).  Since then 
several papers have been published on the function of the p63 isoforms and their role in tumor 
suppression (65, 131).  TAp63 has been shown to be the main isoform capable of inducing 
apoptosis and cell cycle arrest in a similar manner to p53. The TAp63γ and TAp63β isoforms 
are structurally the closest to p53. They are also induced after stress and behave like p53 in 
many aspects. TAp63 can transactivate apoptotic, cell cycle arrest and senescence targets like 
BAX, PUMA, NOXA, PERP, p21, (129, 132). Recently mutant p53 was shown to bind to p63 
and sequester it from binding to SMAD proteins and inhibit its suppression on metastasis 
(133).  ΔNp63 on the other hand have been shown to be oncogenic (45, 46). It’s over 
expression in human cancer implicated it as an oncogene, although the data from human 
tumors is plagued with misinterpretations due to lack of specific antibodies towards these two 
isoforms. In tissue culture studies ΔNp63 has also been found to behave as an oncogene. 
ΔNp63 has also been shown to behave as a dominant negative regulator of p53 and TAp63. 
ΔNp63 also behaves as an oncogene by its dominant negative interaction with p53 and TAp63. 
The ΔNp63 protein has been shown to bind to these proteins and inhibit them from binding to 
their target promoters. An alternative model also suggests ΔNp63 binding to the target thereby 
inhibiting p53 and TAp63 from binding to it. Either way it inhibits the transactivation of 
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apoptotic and senescence targets in this manner. Therefore, in humans, its over expression may 
be enough to sequester p53 and TAp63 causing loss of apoptosis (77). Interestingly ΔNp63 
have been shown to be able to transactivate genes involved in DNA repair mechanism 
suggesting that it too may have tumor suppressive ability (134). ΔNp63 has also been shown to 
be able to induce p21 and GADD45 (89).  
 
1.10. MicroRNAs 
1.10.1. MicroRNA Gene Transcription 
MicroRNAs were first discovered in 1993 in the laboratory of Dr. Victor Ambros as 
small non-coding RNAs important in the regulation of molting in C.elegans (135) . Since then 
they have been shown to regulate almost all biological processes. This was the first 
demonstration that what was thought to be ‘junk’ DNA in eukaryotes was in reality a very 
important component of cellular RNA make-up. MicroRNAs are a group of small 17-22 
nucleotide RNAs which regulate gene expression post-transcriptionally (136). Their role has 
been most studied in the repression of protein expression in context of both development and 
diseases. MicroRNAs are often transcribed from their own transcriptome which are mainly 
present in the intergenic regions (137). Recently they also have been shown to be present in 
protein coding region of the DNA or the non-coding intronic areas of the genome. They are 
transcribed by both Polymerase II and Polymerase III enzymes (137, 138). Many of the 
microRNAas are present in close proximity to one another forming a polycistronic RNA unit. 
These usually give rise to a polycistronic pimary transcript (139). The intergenic microRNAs 
have their own promoter from where they are transcribed.  On the other hand the intronic 
microRNAs may be under the control of the promoter site of their host mRNA. 
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Figure 3: Canonical microRNA biogenesis pathway 
The microRNAs are transcribed by RNA polymerase II/III. They form hairpin loop structures 
which are 2-3Kb in length. They are called primary microRNAs (PRI-MICRORNA). They get 
cleaved by DGCR8/DROSHA complex in the nucleus to form the precursor microRNAs 
(PRE-MICRORNA) 70-90 nucleotide in length. They are then transported to the cytoplasm by 
Exportin V, where are they cleaved by the Dicer complex to form the single stranded mature 
microRNA (MATURE MICRORNA). They are then loaded onto the RISC complex and 
guided to their target mRNAs (140).  
Modified and reproduced with permission from the copyright clearance center, Many roads to 
maturity: microRNA biogenesis pathways and their regulation, Nat Cell Biol. 2009 
Mar;11(3):228-34. doi: 10.1038/ncb0309-228 
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1.10.2. MicroRNA biogenesis pathway 
           MicroRNAs are transcribed as primary microRNA or pri-miR in the nucleus by 
polymerase II and polymerase III (137) (137, 138, 141). These usually have 7-
methylguanosine cap and a poly-A tail. These transcripts are several kilobases long and carry a 
hairpin loop structure (142). This primary transcript is then cleaved by the microprocessor 
complex in the nucleus made up of Drosha and the DiGeorge’s syndrome critical region gene 
8 (DGCR8) (142, 143). The Drosha protein is a 160KDa protein, has two tandem Rnase III 
domain and a double stranded RNA binding domain (dsRBD)(142). The DGCR8 protein is 
120KDa. This protein has tandem double stranded RNA binding domain. These domains have 
been shown to be critical in binding to the primary microRNAs and also in recognizing the 
primary miR transcripts. The Drosha nuclease cannot cleave the primary transcript in the 
absence of DGCR8.  The precursor miR or pre-miR is a 70-90 nucleotide double stranded 
RNA molecule that has hairpin-loop structure. It also has a 2-nt 3’ overhang (142, 143). This 
pre-miR gets exported from the nucleus to the cytoplasm by the nuclear transporter exportin V 
enzyme (144). In the cytoplasm the hairpin loop structure is removed the nuclease called Dicer 
(Rnase III nuclease protein) in coordination with its other partners, HIV-1 transactivation 
response (TAR) RNA-binding protein (TRBP), PACT and argonaute protein family (Ago1/2) 
(145, 146). Dicer recognizes the 3’ overhang in the precursor miR. This produces a miR-miR* 
duplex with 3’ overhangs on both ends. Once the hairpin loop is cleaved by Dicer only one 
strand (guide strand) is loaded onto the AGO protein to form the RISC complex (mi-RISC) 
(145, 146). Although recent literature has also shown that both the guide strand and passenger 
strand (miR*) may both be loaded onto to the RISC complex and mediate gene-silencing. 
These microRNAs are called mature miRs. They are 17-19 nucleotides in length. 
 
1.10.3. Mode of action of microRNAs  
These small RNAs bind primarily to the 3’UTR of mRNAs and regulate their silencing 
in several ways (145). Although recently it has been shown that they can also bind to the 5’ 
end of mRNAs and regulate their expression level (147). The 2-8 nucleotide sequence in the 
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microRNA are known as the ‘seed’ sequence. This sequence determines which mRNA will be 
targeted by which microRNAs based on the complementarity between the ‘seed’ region and 
the 3’UTR of the mRNA (148). In animal cells the downregulation of mRNAs by microRNAs 
is achieved by mRNA deadenylation and degradation, translational arrest or sometimes by 
mRNA cleavage (149). In most cases the complementarity between the mRNA and microRNA 
is imperfect leading to a hindrance in translation, but not degradation (150). Usually the 
mismatches are in the middle of the duplex complex (151).  
 
1.10.4. Role of p53 in the regulation of microRNA biogenesis 
Recently p53 has been shown to play a role in the regulation of the microRNA 
biogenesis pathway. First in 2007 Lin He et al found that p53 can regulate the promoter of the 
miR-34 family of microRNAs (152). In the same year David Corney et al found that p53 
regulates proliferation and adhesion in p53-dependant cell growth by the regulation of miR-
34b and miR-34c . This regulation was later shown by many to be important in inhibition of 
tumorigenesis, metastasis and the induction of apoptosis. Later in 2009 p53 was found to 
interact with the p68 helicase protein (153). This protein forms a complex with the 
Drosha/DGCR8 complex in the nucleus and has been shown to be important in the proper 
processing of the pri-miRs to the pre-miRs (154). p53 has since been shown to be very 
important in the regulation of several other microRNAs by directly binding to their promoters 
(miR-15a/b, miR-106a,miR-23a, miR-17-5p, miR-25, miR-103) , or by regulating them 
indirectly through their processing in the nucleus from pri-miRs to pre-miRs (miR-103, miR-
107, miR-145, miR-182, miR-203) (155, 156).  
 
1.10.5. DGCR8 knock-out mouse phenotype and its role in pluripotency 
The DGCR-8 knock-out mouse was created by targeting exon-3 of the DGCR8 gene. 
This exon next to the exon-4 which codes for the WW domain is required for the proper 
processing by microRNAs. Deletion of this exon causes a frame-shift and creation several 
premature stop codons. The ES cells generated by this method were slow growing and 
drastically defective in differentiation. They retained the expression of some of the 
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pluripotency related proteins like Oct-4, Sox-2, Nanog and Rex-1 inspite of treatment with 
retinoic acid. When injected into nude mice, they formed very undifferentiated teratomas with 
some glandular structures. The ES cells were profiled for microRNA expression. There was a 
global reduction in precursor and mature microRNAs in these cells (157). This indicated that 
loss of DGCR8 leads to a defect in proper differentiation although not a complete loss of 
differentiation.   
 
1.10.6. Dicer knock-out mouse phenotype 
Dicer1 knock-out mice were created by targeting exon-21 in the Dicer gene. This gave 
rise to ES cells, which lacked Dicer. But when injected into blastocysts of pseudopregnant 
mice no Dicer null mice were obtained. On further investigation it was found that the Dicer 
mutant embryos die at E7.5. These embryos showed a decrease in the expression of Oct-4 
suggesting premature differentiation of the blastocysts in these mice leading to trophoblast 
differentiation in these embryos driving lethality (158).  
  
1.10.7. Conditional knock-out mouse model for Dicer/DGCR8 specifically in the skin 
demonstrate a similar phenotype  
The Dicer and DGCR8 conditional knock-mice (cko) were crossed with mice carrying 
the K14-Cre ER transgene. The resultant mice had depleted Dicer and DGCR8 in their 
epithelium. Both types of mice were born. But they die at p5 mainly due to dehydration. Their 
skin showed defects in morphogenesis although all the epidermal layers (basal, spinous, 
granular and stratum corneum) are present. The pups had very thin skin and evaginated hair 
follicles. Interestingly the microRNA make-up of the Dicer cko skin and the DGCR8 cko skin 
were distinct. Most of the abundantly present skin microRNAs were not expressed in the skin 
from both these animals, whereas there were some microRNAs like miR-320 and miR-484 
which were present only in the DGCR8 knock-out animals, but not in the Dicer knock-out 
animals. Also miR-21 showed a very high expression in both the cko mice (159). 
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1.10.8. Role of microRNA in iPS cell generation 
MicroRNAs have been reported to drive or assist in reprogramming. Most of these 
microRNAs have been selected in the basis of their high expression in human ES or mouse ES 
cells. The miR-302/miR-367 has been shown to be a potent microRNA combination in 
induction of pluripotency. These microRNAs when overexpressed in mouse and human 
fibroblast along with treatment of these cells with valproic acid (Hdac2 inhibitor) induces 
pluripotency (160). These cells express all markers of stem cells and can form chimeras. 
Another group of microRNA hsa-miR-370 cluster which is homologous to the mouse miR-290 
cluster has been shown to be able to induce pluripotency with only three factors (Oct4, Sox2, 
Klf4) in mouse cells. Many microRNAs have been shown to be downregulated by c-Myc, like 
miR-21 and miR-29a (161).  This event occurs early in reprogramming. These microRNAs are 
called embryonic stem cell cycle specific microRNAs (ESCC). Certain microRNA have been 
shown to directly inhibit p53 or p21. miR-138 repress p53 expression in mouse cells. 
MicroRNA clusters 17-92, 106b-25, 106a-363 and 302-367 shares similar seed sequences with 
ESCC. Therefore these microRNAs are also instrumental in the regulation of cell cycle. As 
mentioned before down regulation of p53 and p21 is an important event in the reprogramming 
process and increases efficiency of reprogramming.  MicroRNA like miR-130b, miR-301b and 
miR-721 targets the transcription factor Meox2. This affects MET and may affect senescence. 
Most of these microRNAs work in co-ordination with the Yamanaka factors. Except miR-302, 
miR-367, miR-369and miR-200. Overexpression of miR-302 and miR-367 by a lentiviral 
system was shown to induce pluripotency in both human and mouse cells(160). Also another 
group showed that cells could be reprogrammed by the transient transfection fo miR-200c, 
miR-302 cluster and miR-369 (162).  
 
1.10.9. Role of microRNAs in tumorigenesis and metastasis 
Since their first implication in CLL patients, microRNAs have been shown to be 
intimately involved in tumorigenesis and metastasis. In 2002 Dr. George Calin demonstrated 
for the first time demonstrated that miR-15 and miR-16-1 locus is at the break point of the 
 27 
 
BCR/ABL. In 60% of the chronic lymphocytic leukemia (CLL) patients there was a loss of 
miR-15 and miR-16-1 (163).    MicroRNAs have been shown to be important in tumor 
suppression and also suppression of metastasis (153). Recently they have been shown to be 
important in oncogenesis as well. miR-34 family have been shown to be a target of p53 and 
has been important in inducing tumorigenesis and apoptosis (152). The main targets of this 
family are Bcl-2, Cyclin D2, Cyclin E1, c-Myc, MET, E2F3, N-Myc, Sirt-1 and other targets 
(164, 165). All these proteins are important in the regulation apoptosis, cell cycle, senescence 
and invasion and migration. Therefore miR-34 inhibits all of these processes, which promote 
tumorigenesis and metastasis. In many tumor type miR-34a, miR-34b/c expression is reduced 
or lost mainly by CpG island methylation of its promoter (166).  miR-17-miR-92 cluster 
reduces the tumorigenic levels of E2F1 in lymphomas. There is a global downregulation of 
microRNAs in several tumors. The let-7 family of microRNAs repress KRAS, NRAS and high 
mobility group A2 and MYC in lung cancers. miR-15a-miR-16-1 cluster downregulates BCL-
2 and cyclinD1 in chronic lymphocytic leukemias, mantle cell lymphomas and prostate cancer. 
miR-126, miR-335 and miR-206 were found to be downregulated in metastatic breast cancer 
(167). Their restoration of these microRNAs in breast cancer cells decreased the number of 
metastases. Their suppression of SOX-4 mediates their ability to reduce metastasis (168). miR-
335 have also been shown to reduce expression of tenascin, which is a predominant protein in 
the microenvironment of many solid tumors (168).  Loss of miR-126 has been shown to 
increase proliferation but not metastasis in breast cancer, whereas in lung cancer it acts by 
suppressing motility (168).  Mir-200 family has been shown to be a major repressor of EMT. 
They inhibit the main inducers of metastasis Zeb-1, and Zeb-2, by repressing E-cadherin (169, 
170). miR-205 represses prostate cancer by the downregulation of protein kinase C. miR-203 
has also been to suppress specifically bone metastasis by suppressing Zeb-2, surviving, bmi 
and bone specific metastatic factor Runx2. miR-146 has been shown to play tumor suppressive 
roles in breast cancer (inhibits EGFR), prostate cancer and (targets Rock 1) and glioblastoma 
(targets Notch1). Many of these microRNAs have been downregulated in tumors by the 
hypermethylation of their promoter or the promoter of the genes locus where they reside. 
MicroRNAs also play roles in the induction of tumors. miR-155 has been shown to be 
overexpressed in several solid tumors and leukeaemias and lymphomas . miR-21 in 
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overexpressed in several tumor types, like pancreatic, gastric, head and neck, breast,lung, 
lymphomas and glioblastomas. miR-21 regulates PTEN, SERPINB5, TIMP3 and other targets. 
PTEN is a tumor suppressor and down regulation of PTEN causes increased tumorigenesis 
(171). miR-26 has been shown to be both tumor suppressive and oncogenic in lymphomas, 
hepatocellular carcinomas and thyroid carcinoma (172). Overexpression of miR-9 and miR-10 
has been implicated in breast cancers (173). miR-9 targets E-cadherin directly inducing an 
EMT response thereby increasing the invasiveness of tumors. miR-9 has also been shown to be 
secreted by cancer cells to recruit endothelial cells and increase angiogenesis through the JAK-
STAT pathway (174). It has been shown that miR-10b can inhibit HOXD10 thereby inducing 
the expression of RHOC (173). This leads to an increased invasion in breast cancers. 
  
1.10.10. Expression of Dicer in cancers 
MicroRNAs have been shown to be downregulated in various types of cancers. Infact 
recently the global loss of microRNAs is emerging as a hallmark of cancer. Various 
mechanisms of loss of microRNAs have been described. One of the common one being CpG 
methylation of the microRNA promoter or the gene promoter where the microRNA is located 
(253). Apart from this other mechanisms like mutations in the proteins responsible for the 
processing of microRNAs are also thought to be major contributors to this loss. The proteins 
like TARBP2, XPO5 (ExportinV) and DICER1 have been shown to be mutated in various 
types of cancers (124). Truncating mutations in TARBP2 also causes impaired processing of 
microRNAs by Dicer. This type of abnormality has been shown to be present in the hereditary 
and sporadic carcinomas with microsatellite instability (MSI). In case of DICER1, 
heterozygous germline truncating mutation of DICER1 has been shown in pleuropulmonary 
blastoma-inherited cancer syndrome and hypomorphic somatic mutations have been found to 
be present in non-epithelial ovarian tumors. Interestingly heterozygous deletion of Dicer is 
further deleterious than the homozygous deletion. This was also demonstrated by Kumar et al 
in a mouse model for lung cancer. They showed that when Dicer
fl/fl 
and Dicer
fl/+
 mice were 
crossed to Kras
G12D
 mice (lung cancer model), the resulting mice treated intranasally with 
adenoviral –Cre, develop aggressive lung tumors. Curiously the Dicerfl/+;KrasG12D mice have a 
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more aggressive tumor phenotype and a reduced survival curve than the Dicer
fl/fl
;Kras
G12D .
 
This suggests that Dicer is a haplo-insufficient tumor suppressor (145). 
                         The p63 field is filled with contradictory data on the role of p63 in 
development, stem cell biology and tumorigenesis. The primary reason for this is the lack of 
isoform specific-knockout mouse models. There has been a lot of work on the isoforms in 
vitro, which has further led to more contradictory findings on these isoforms. The generation 
of the isoform specific knock-out mouse models allows us to study the different mode of 
action of the p63 isoforms. Although they originate from the same gene, their functions are 
distinct from one another. Therefore my thesis work focuses on dissecting the roles of these 
isoforms in vivo in stem cell biology, tumorigenesis and metastasis. The common theme of my 
work focuses on the role of p63 in regulation of the microRNA biogenesis pathway. For the 
first time I show that p63 can regulate the microRNA biogenesis pathway thereby regulating 
various biological processes. 
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2.   Chapter 2: Materials and Methods 
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2.1. Genotyping of TAp63 and ΔNp63 conditional knock-out mice 
Genomic DNA was analyzed by PCR  amplification to detect the wild-type, TAp63flox, 
and TAp63KO alleles using the following primers and annealing temperatures: 1) for wild-
type: wt-F, 5' - ACTGGTGAGCTTGTAGAATCGG - 3' and wt-R, 5  -
ACTGAGCATATAGGCCTAGCAC, annealing temp: 60  C, 2) for TAp63flox: fl-F, 5  - 
CCACATAGCCATATCTGCC - 3  and fl-R, 5  - TCGCCATAACTTCGTATAGC - 3 , 
annealing temp: 60  C, and 3) for TAp63KO: fl-F and wt-R, annealing temp: 60  C. Primers 
used to genotype for the CRE gene are as follows: Cre-F, 5  -
TGGGCGGCATGGTGCAAGTT - 3  and Cre-R, 5  - CGGTGCTAACCAGCGTTTTC - 3 , 
annealing temp: 60  C. The PCR products were electrophoresed on a 1.2  agarose gel. 
Genomic DNA from tail biopsies was also genotyped by Southern blot analysis by digesting 
genomic DNA with AflII. 
Genomic DNA from tail biopsies was genotyped by Southern blot analysis by 
digesting genomic DNA with BglI or by PCR using the following primers and annealing 
temperatures: 1) for wild-type: wt-F, 5'- ACAGTCCTCTGCTTTCAGC-3' and wt-R (fl-R), 5'- 
CACACAGCA CTGGCCTTGC -3’, annealing temp: 62°C, 2) for ∆Np63flox: fl-F, 5' – 
TTAGGTGGA TCCCTAGGAAGAG - 3' and fl-R (wt-R), 5' – 
CACACAGCACTGGCCTTGC - 3 , annealing temp: 62°C, and 3) for ∆Np63KO: ko-F, 5’- 
TACAGCTCCTGGAGGATC CCATGC-3’ and wt-R, annealing temp: 62°C. Primers used to 
genotype for the CRE gene are as follows: Cre-F, 5' –TGGGCGGCATGGTGCAAGTT - 3' 
and Cre-R, 5' – CGGTGCTAACCAGCGTTTTC - 3', annealing temp: 60° C. The PCR 
products were electrophoresed on a 1% agarose gel.  
 
2.2. Generation of  ΔNp63  Conditional Knockout Mice 
The cre-loxP strategy was used to generate the  ΔNp63  conditional knockout allele ( 
ΔNp63 fl). Genomic p63 DNA from intron 3 to intron 3’ was amplified from BAC clone DNA 
(BAC RP23-186N8, Children's Hospital Oakland Research Institute). LoxP sites flanking exon 
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3’ of p63 and neomycin (neo) gene flanked by frt sites inserted in intron 3’ were cloned into 
pL253.(175) Mouse embryonic stem cells (ESCs) were analyzed by Southern blot analysis for 
proper targeting of the  ΔNp63  allele. Chimeras resulting from ESC clones injected into 
C57BL/6 blastocysts were mated with C57BL/6 albino females and genotyped as described 
below. Mice with germ line transmission of the targeted allele (conditional, flox neo allele, fn) 
were crossed to the FLPeR mice to delete the neo cassette (176).  Resulting progeny were 
intercrossed with Zp3-Cre (C57BL/6) (177)transgenic mice. ΔNp63fl/+; Zp3-Cre females were 
mated with C57BL/6 males to generate ΔNp63 +/- mice. The ΔNp63 +/- mice were intercrossed 
to generate ΔNp63 -/- mice.   All procedures were approved by the IACUC at U.T. M.D. 
Anderson Cancer Center. 
 
2.3. Quantitative Real time RT-PCR 
RNA was isolated from keratinocytes or MEFs using the RNeasy kit (Qiagen) followed 
by quantitative real time PCR for TAp63 and ΔNp63 using the StepOnePlus real-time PCR 
system (Applied Biosystems) and iScriptTM One-Step RT-PCR Kit with SYBR Green (Bio-
Rad) following the manufacturer's protocol. The following primers were used: 1) for ΔNp63: 
forward, 5’-CAAAACCCTGGAAGCAGAAA-3’ and reverse, 5’-
GAGGAGCCGTTCTGAATCTG-3’and 2) for TAp63: forward 5’-
GTGTATGAACCTTCCGAAAA-3’ and reverse, 5’- GAGGAGCCGTTCTGAATCTG-3’. 
GAPDH was used as internal control: forward 5’- TCACCACCATGGAGAAGGC-3’ and 
reverse 5’-GCTAAGCAGTTGGTGGTGCA-3’. 
 
2.4. Generation of mice and tumor analysis  
TAp63 mutant mice were intercrossed with p53 mutant mice to generate compound 
mutant TAp63/p53 mice on an enriched C57BL/6 background ((C57BL/6 95%) and (129/SvJ 
55%)). ΔNp63 mutant mice were crossed to p53 mutant mice to generate ΔNp63/p53 
compound mutant mice on an enriched C57BL/6 background. For analysis of tumor formation 
and metastatic disease, 30 mice of each genotype were aged for 2.5 years. Moribund mice 
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were killed, following the approved guidelines of the IACUC at the University of Texas M. D. 
Anderson Cancer Center and analyzed histologically by haematoxylin/eosin (H&E) staining as 
described previously8. Tumor-free survival of mice was plotted with PRISM5 software 
(GraphPad).  
 
2.5. Histology and immunostaining of E18.5 embryos 
Pregnant females at day 18.5 of gestation were injected three times at 1hour intervals 
with BrdU (100 mg / gram of total body weight). Embryos were extracted 1 hour later and 
fixed in 10% formalin at room temperature for 18 hours.  Fixed embryos were embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for microscopic analysis. 
For immunofluorescence (IF), paraffin-embedded sections were dewaxed in xylene and 
rehydrated using decreasing concentrations of ethanol. Sections were subjected to antigen 
unmasking in citrate buffer unmasking solution (Vector Laboratory) followed by incubation 
with blocking solution, and 18 hour incubation at 4
o
C with the following primary antibodies:  
K5 (1:1000) (Abcam), K14 (1:500) (LifeSpan BioSciences), K10 (1:1000) (Covance), K1 
(1:500) (gift from Dennis Roop), K18 (1:200) (Sigma), and filaggrin (1:1000) (Abcam). 
Visualization was performed using an anti-rabbit secondary antibody conjugated to Texas-red 
(1:5000) (Jackson ImmunoResearch Laboratories), an anti-guinea pig secondary antibody 
conjugated to FITC (1:1000, Jackson ImmunoResearch Laboratories), or an anti-chicken 
secondary antibody conjugated to Alexa 488 (1:1000) (Molecular Probes) followed by 
counterstaining with DAPI (Vector Laboratory). Incorporation of BrdU was analyzed using 
the BrdU detection kit II (Roche). For BrdU analysis by IF, an anti-rabbit secondary antibody 
conjugated to Texas Red was used with the BrdU detection kit II (Roche).   For 
immunohistochemistry (IHC), paraffin-embedded sections were prepared as described above 
and incubated with K8 primary antibody (1:80) (University of Iowa) or DGCR8 primary 
antibody (1:100)(Abcam). Visualization was performed using the Vectastain Elite ABC and 
DAB Peroxidase Substrate Kits (Vector Laboratory).  
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2.6. Keratinocyte cells – proliferation assay 
1 X 10
3
  ΔNp63 fl/fl and  ΔNp63 D/D epidermal cells were plated on mitomycin c 
(Roche)-treated J2 3T3 feeder cells in F media as described (67, 72, 178, 179). Colonies 
cultured for 7 days were trypsinized, counted, and plated at limiting dilution 10 cells, 100 
cells, and 1000 cells per 6 cm dish.  At each passage, dishes were fixed in 10% formalin for 30 
min and stained with 2% rhodamine B (Sigma). Some dishes were treated with 10 mM BrdU, 
fixed in 70% ethanol for 30 minutes, denatured with 0.01N NaOH, and double immunostained 
with anti-cytokeratin 5 (Abcam) (1:1000) and BrdU-FITC conjugated antibody (GeneTex, 
Inc.). To detect and visualize cytokeratin 5 staining, Texas Red-conjugated goat anti-rabbit 
secondary antibodies were used (Jackson ImmunoResearch) (1:500).  
 
2.7. Migration and invasion assay 
MEFs, keratinocytes or mouse and human tumor cell lines were resuspended in 500 ml 
of DMEM with 10% FBS and penicillin/streptomycin (5X10
4
 cells) and added to the top of 
each chamber containing BD BioCoat cell culture inserts (354578; BD Biosciences) or 
Matrigel Invasion Chamber (354480;BD Biosciences). Non-invasive cells were removed from 
the upper chamber. Cells remaining on the membrane were fixed, stained with Diff-Quik 
(DadeBehring, Inc.), and counted with a Zeiss AxioObserver A1 inverted microscope. 
 
2.8. Mouse and human tumor cell lines  
Tumors were excised from p53 and TAp63 mutant mice and from  ΔNp63  mutant mice 
at the time of necropsy. Half of the tumor was fixed in 10% formalin and analyzed 
histologically by H&E staining. The other half of the tumor was minced and treated for 20 min 
with 0.25% trypsin EDTA solution at 37°C. Cells were suspended in DMEM medium 
containing 10% fetal bovine serum (FBS) and 13penicillin/streptomycin. Human primary and 
metastatic squamous cell carcinomas (cell lines 10A, 10B, 17A, 17B, 22A and 22B) were 
cultured similarly. 
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2.9. Immunocytochemistry 
            Cells were fixed on chamber slides for 30 min at room temperature (25°C) with 4% 
paraformaldehyde in PBS and incubated in blocking buffer (8% FBS, 0.3% Triton X-100 in 
PBS) for 30 min at room temperature as described previously. Samples were incubated 
overnight in anti-cH2AX(dilution 1:100; Upstate Biotechnology, Inc.) at 4°C under humidified 
conditions, followed by incubation for 1 h with secondary antibodies (goat anti-mouse Texas 
Red, dilution 1:500; Jackson ImmunoResearch Laboratories) at room temperature.49,6-
Diamidino-2-phenylindole (DAPI; Pierce Biotechnology) was used as a nuclear counterstain. 
Photomicrographs were taken with a Zeiss AxioObserver A1 inverted fluorescence 
microscope. 
 
2.10. Immunofluorescence and immunohistochemistry of tumors 
Paraffin-embedded sections of tumors were prepared as described previously8. Tissue 
microarrays containing primary and metastatic HNSCCa (HN242), lung adenocarcinomas and 
squamous cell carcinomas (LC1005) and mammary adenocarcinomas (BR480) were obtained 
from US Biomax. For detection of Dicer, PCNA and cleaved caspase 3 sections were 
incubated overnight with anti-Dicer (dilution 1:100; Abcam), anti-PCNA (dilution 1:200, Cell 
Signaling) and anti-cleaved caspase-3 (dilution1:200, Cell Signaling) at 4 uC in a humidified 
chamber followed by incubation for 1 h with goat anti-mouse-fluorescein isothiocyanate 
(dilution 1:500; Jackson ImmunoResearch Laboratories) at room temperature for 
immunofluorescence or using the Vectastain universal ABC Kit (Vector Labs), followed by 
the DAB kit (Vector Labs) for immunohistochemistry. For detection of TAp63, sections were 
incubated with anti-TAp63 (dilution 1:100; gift from C.Prives) followed by detection for 
immunohistochemistry as described above. For detection of γH2AX in frozen tumor sections, 
tumours were fixed in 4% paraformaldehyde, frozen in OCT medium (Tissue Tek) and 
detected by incubation in anti-γH2AX (dilution 1:100; Upstate Biotechnology, Inc.) followed 
by incubation for 1 h with goat anti-mouse Texas Red (dilution 1:500; Jackson 
ImmunoResearch Laboratories) at room temperature. DAPI (Pierce Biotechnology) was used 
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as a nuclear counterstain for immunofluorescence or haematoxylin (Vector) for 
immunohistochemistry. Photomicrographs were taken with a Ziess Axioplan2 imaging 
fluorescence microscope. 
 
2.11. Human HNSCCs and lung adenocarcinomas 
  Total RNA was isolated from 25 human HNSCCs and 19 lung adenocarcinomas of 
various grades (well differentiated (grade I), moderately differentiated (grade II) and poorly 
differentiated and invasive (grade III)) for qRT-PCRusing primers for TAp63, Dicer and miR-
130b as described below. SA-b-gal staining. SA-b-gal staining was performed on frozen 
sections of tumors as described previously. 
 
2.12. Quantitative Real time PCR 
Total RNA was isolated from mouse MEFs, human squamous cell carcinomas and cell 
lines, or mouse tumors and tumour cell lines by using TRIzol LS Reagent (Invitrogen). qRT-
PCR was performed with a StepOnePlus real-time PCR system (Applied Biosystems), a 
SuperScript First-Strand Synthesis System(Invitrogen) and PowerSYBRGreen PCRMasterMix 
(AppliedBiosystems) in accordance with the manufacturers’ protocols. The following primers 
were used: human TAp63(132), human ΔNp63(132, 180) and murine or human Dicer. Murine 
or human glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. Average 
cycle threshold (Ct) values were calculated from triplicate reactions of three biological 
replicates. 
 
2.13. Cytogenetics 
Tumor cells at 70% confluence were treated for 3 h with 0.02 mg ml colcemid and 
prepared as described previously19. Images were captured and processed with MetaMorph 
Premier (Molecular Devices) using a Nikon Eclipse E400 microscope. 
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2.14. Northern blot analysis 
Total RNA was fractionated on a denaturing 15% polyacrylamide gel containing 8M 
urea, and transferred to Hybond-N1 membrane (Amersham Biosciences) by a semi-dry gel 
transfer method. Membranes were hybridized with end-labelled [c-32P]ATP miRCURY LNA 
detection probes (Exiqon) in ULTRA hyb-Oligo Hybridization Buffer (Ambion) at 37°C. 
Membranes were washed twice for 5 min in 23SSC, 0.1% SDS at 37 °C followed by a 
prolonged wash for 15 min at 25 uC, and then exposed to X-ray film overnight.  
 
2.15. miRNA TaqMan assays 
Applied Biosystems TaqMan miRNA assays were used to detect and quantify mature 
miRNAs using looped-primer real-time PCR. Total RNA samples were prepared from tumor 
cell lines and MEFs with TRIzol LS Reagent (Invitrogen). Total RNA (1 mg) was used to 
synthesize complementary DNA with the Two-Step TaqMan MicroRNA Assay kit (Applied 
Biosystems) in accordance with the protocol. qRT-PCR was performed with the Step One Real 
Time PCR System, TaqMan PCR master mix, and TaqMan primers for the specific miRNAs 
(Applied Biosystems). Each sample was run in triplicate. Ct values for miRNAs were 
calculated and normalized to Ct values for RNU6B. 
 
2.16. MicroRNA overexpression 
MicroRNA mimics were bought from Qiagen (miScript). NHEK-shΔNp63 and NHEK-
shDGCR8 cells were transfected with either control or microRNA mimics for let-7, miR-141 
and miR-203 (20um) in 6-well dish. Media was changed next day and cells were allowed to 
grow for the next 4 days in keratinocyte specific media. At 2 days and 4 days cells were 
collected lysed and microRNA Taqman assay was performed and western blot analysis was 
performed. 
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2.17. ChIP assay 
ChIP was performed with nuclear extracts from wild-type and p632/2;ArfG/G 
keratinocytes as described previously. qRT-PCRwas performed with the following primer 
sequences specific for p63-binding sites:murineDicer,21433,5’- 
AGGCTGGCCTTGATCTGTGA-3’ (forward) and 21333, 5’- 
CACATCCTCGGCTGTCTTTCA-3’ (reverse);mmu-miR-34a,1367, 5’-
TAGCCAAACAGCCACCATCTT-3’ (forward) and 1457, 5’-CCCCAGCCCTCCACAAG-
3’(reverse); and mmu-miR-130b, 2850, 5’-CACGTGAGTAACTGGTCTGGGATA-3’ 
(forward) and 2763, 5’-TCCTAACAGATTCTCCTGCCTAGAA-3’(reverse). Primer 
sequences for non-specific binding sites were as follows: murine Dicer promoter, 22560, 5’-
CGAACCCAGAGAGTCCACAAG-3’ (forward) and 22499, 5’-
CCCCATCCCCGACACTTAC-3’ (reverse); mmu-miR-34a promoter, 1732, 5’-
AAGCGGGTTTCAAGTGCATCTCAG-3’ (forward) and 1796, 5’-TC 
AGGCTACTAAACCAGTTGCCCT-3’ (reverse); and mmu-miR-130b promoter, 21431, 5’-
AAATGTCCCATCCTGGAGGAGCAA-3’ (forward) and 21323, 5’-
TCACCAAATTAGCGAGGGCTCTGA-39 (reverse). Primers for the p53-binding site for 
miR-34a were used as described previously23. 
Wild type keratinocytes and ΔNp63 -/- epidermal cells were grown to near confluence 
on J2-3T3m feeder cells in F media as described previously (72, 179). Feeder cells were 
removed with 0.02% EDTA 24 hours prior to collecting keratinocytes for chromatin 
extraction. Cellular proteins were crosslinked to DNA using 1% formaldehyde and chromatin 
was prepared as described earlier (72, 129, 179). p63 ChIP analysis was performed using a 
pan-p63 antibody (4A4, Abcam) as described previously. Each ChIP was performed in 
triplicate using keratinocytes from three embryos of each genotype.  Q-RT–PCR was 
performed by using primers specific for the indicated regions of the DGCR8 promoter:  Site1 
(-3393) - forward 5’-AGTCACCTTGGTGCC TCTCATAG-3’ and (-3348) -reverse 5’-
AAACAGGTGGCAAGGCTTCTT-3’, Site2 (-1459) - forward 5’-
CATTTTTTTCTGTGGATCTTTTGGT-3’ and (-1397) - reverse 5’-CACAGGGCAGGC 
AGATCAG-3’, and nonspecific site (-3893) - forward 5’-
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CAAATCAAAATCTGCATCCATAGG -3’ and (-3833) - reverse 5’-
GCCCTCCTGCCTGTAAACCT-3’.   
Wild-type MEFs and ΔNp63 -/- MEFs were grown in 10% FBS, DMEM. Cellular protein was 
cross-linked. ChIP was performed using antibody for total p63. qRT-PCR was performed with 
primers directed towards the TAp63 promoter region: forward 5’-
GCTATAAATGTTTCCATGTGATGGATTGC-3’ and reverse 5’-
TGCAGACTTAGCTATGGTCTCTTG-3’.  
 
2.18. Lentiviral infection 
Lentivirus-based vectors (2 mg) containing shRNAs (SBI System Biosciences) for 
mmu-miR-34a, mmu-miR-126, mmu-miR-130b or scramble sequence (as control) and tagged 
with green fluorescent protein (GFP) or pDESTmycDICER28 were transfected into 293T cells 
along with 2 mg of each vector required for lentivirus packaging (pCMV-VSVG, pRSV-REV 
or pMDLg/pRRE) using Fugene HD (Roche) in accordance with the manufacturer’s protocol. 
After transfection of 293T cells, supernatants containing the lentivirus were collected, filtered 
and added to target MEF or tumour cells for 24 h in the presence of 8 mgml21 Polybrene. At 
24 h after infection, puromycin was added to the media at 3 mgml21 for 7 days. Infection 
efficiency of the cells was calculated by dividing the number of GFP-expressing cells by the 
total number of cells, with the use of a Zeiss AxioObserver A1 inverted fluorescence 
microscope. The infection efficiency was calculated to be 100% in all experiments. Infected 
cells were analysed by TaqMan assay to determine the level of miRNA silencing. These cells 
were further analysed by migration and invasion assays. All experiments were performed in 
triplicate. Retroviral infection (pSuper mouse Dicer1). Wild-type and TAp632/2 MEFs 
(10
6
)were infected with pSupermouse Dicer1 (Addgene) as described previously(181). 
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2.19. Adenovirus-Cre infection  
TAp63
fl/fl
MEFs (10
6
)were plated on 10-cmdishes and infected with 53103 Ad-Cre–GFP 
(Vector Development Laboratory) particles per cell. Infection efficiency was calculated on the 
basis of expression of GFP and found to be 98%. To verify recombination, qRT-PCR was 
performed for TAp63 mRNA. 
 
2.20. Cloning of dgcr8-luciferase reporter genes 
To generate the dgcr8 S luciferase construct, DNA was amplified from wild type 
mouse genomic DNA (C57BL/6) using primers containing the p63 binding site shown by 
ChIP and 5’ XhoI and 3’ BglII cloning restriction enzyme sites: 1. forward - DGCR8- Luc F: 
XhoI 5’-CCGCTCGAGGCTTCTAGTTGTCTATTCC-3’ and 2.  reverse - DGCR8- Luc R: 
BglII 5'- GGA AGATCTGCTCACCAGATAGCTTGGA -3'.  PCR amplicons were digested 
with XhoI and BglII and ligated into pGL3 basic luciferase reporter vector (Promega). The 
QuickChange® Multi Site-Directed Mutagenesis kit was used to generate dgcr8 Sm using the 
dgcr8 S luciferase construct as a template and the following primers: 1. 5'-
ATGCCTGTCTAAAGTCACTTTTGTGCCTCTCATAGGCCTG-3', 2. 5'-
GCATGTATCTCCTAAGAAGCTTTTCCACCTGTTTACAACACCAG-3', and 3. 5'-
TGGTGCCTCTCATAGGCCTGTTTTTATCTCCTAAGAAGCCTTGC-3'. 
 
2.21. Dual luciferase reporter assay 
Luciferase assays were performed with p532/2;p632/2MEFs as described previously.  
Briefly, p53
 -/-
;p63
 -/-
 MEFs (129) were plated on 6-well plates (3.5 x 10
5
 cells per well). 
Twelve hours after plating, the MEFs were transiently transfected using Fugene HD (Roche) 
with 1 μg of dgcr8 S or dgcr8 Sm, 0.5 μg of Renilla luciferase plasmid (transfection control), 
and 0.5 μg plasmids encoding the p63 isoforms [TAp63α, TAp63β, TAp63γ, ΔNp63α, ΔNp63β, 
or ΔNp63γ or 0.5 μg of empty vector (pcDNA3)]. After 24 hr, cells were harvested and 
luciferase activity was measured using the Dual-Luciferase Reporter Assay system (Promega) 
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and a Veritas microplate luminometer (Turner BioSystems). Each experiment was performed 
in triplicate. To generate the luciferase reporter genes pGL3-Dicer, pGL3-miR-130b and 
pGL3-miR-34a, the DNA fragment containing the p63-binding site identified by ChIP was 
amplified from C57BL/6 genomic DNA by PCR with the following primers containing 5’ 
NheI and 3’ BglII cloning restriction enzyme sites: DICER1, 5’-GCTAGCATGTGCCAGG 
GCTTTGGCATGTA-3’ (forward) and 5’-AGATCTTCCTGGAACTTGCTCTGTACACCA-
3’ (reverse); mmu-miR-34a, 5’-GCTAGCTGGAGTGTGAGCACTTCTGGCTAA-3’ 
(forward) and 5’-AGATCTTGGACATTCAGGTGAGGGTCTTGT-3’ (reverse); and mmu-
miR-130b, 5’-GCTAGCATGGTTAAAGATGGAGCCGAGGGA-3’ (forward) and 5’ 
AGATCTTCTCCTGCCTAGAAGAGCAGAACT-3’ (reverse). 
 
2.22. Western Blot 
Total lysates were generated from wild-type and TAp63
 -/-
 MEFs infected with vector 
or Dicer overexpression plasmid. Western blot was performed on a 7.5% SDS PAGE gel 
Total cell lysates were generated from mouse ES, mouse iPS
Yam
, keratinocytes or skin from 
E18.5 day embryos.  50 μg of protein were electrophoresed on a 10  SDS PAGE and 
transferred to PVDF membrane as described previously (72, 179). Blots were probed with 
anti-ΔNp63 (1:1000) (BioLegend), K5 (1:1000) (Abcam), K10 (1:1000) (Covance), filaggrin 
(1:1000) (Abcam), DGCR8 (1:200) (Abcam), Oct4 (1:1000) (Santa Cruz), Sox2 (1:500) (Santa 
Cruz), Nanog (1:1000)(Abcam), or p53 (1:1000)(Vector Labs) at 4
o
C for 18 hours followed by 
incubation for one hour at room temperature with the appropriate secondary antibodies 
conjugated to horseradish peroxidase (1:5000)(Jackson Lab). Actin (Sigma 1:5000) was used 
as a loading control. Detection was performed using the ECL Plus Kit (Amersham) following 
the manufacturer’s protocol and x-ray autoradiography. 
 
2.23. Normal Human Epidermal Keratinocytes (NHEK) culture and infection 
NHEKs (Lonza) were cultured in serum free media containing supplements according 
to the manufacture’s protocol (Lonza). NHEKs were infected with pGIPZ lentiviral vectors 
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with shRNAs for human p63 and DGCR8 (Open Biosystems). Cells were selected for 48 hours 
with puromycin (2 g/ml). Selected cells were subsequently used for the generation of 
embryoid bodies. 
 
2.24. Cell Culture 
Wild type, Np63 -/-, Np63fl/fl keratinocytes were isolated from E18.5 day embryos as 
described previously (72, 179). Cells were plated on J2-3T3m feeder cells and cultured in F 
media (Sigma) supplemented with 0.4 mg/ml hydrocortisone, 24 ng/ml adenine, 8.4 ng/ml 
cholera toxin, 5 mg/ml insulin, 13 ng/ml 3,3,5-triiodo-L-thyronine, and 10 ng/ml EGF as 
described earlier (72, 178, 179).  Mouse ES cells or iPS
Yam 
(S3) cells (gift from Dr. Austin 
Cooney, Baylor College of Medicine) (182) were cultured on mitomycin treated feeder cells in 
the presence of ES cell media containing Knockout™ D-MEM(Invitrogen), 20% ESC 
screened FBS (Hyclone), 200mM L-glutamine (Gibco), 100ug/ml penicillin/streptomycin 
(Gibco), 0.1mM β-mercaptoethanol(Sigma) and 10ng/ml recombinant mouse Leukemia 
inhibitory Factor (LIF, Gibco). Human iPS
Yam
 cells (a gift from Dr. Brian Davis, MD 
Anderson Cancer Center) were maintained on hESC qualified Matrigel (BD Biosciences) 
following manufacturer’s protocol in mTeSR1(Stemcell Technologies) media.  
 
2.25. Immunofluorescence – Cell culture 
Mouse iPS
Yam
, mouse ES, and Np63 -/- epidermal cells were cultured in 24 well dishes 
on feeder cells. These cells were fixed in 4% paraformaldehyde for 30 minutes and incubated 
with the following antibodies: SSEA-1(1:200 Developmental Studies Hybridoma Bank), Oct4 
(1:100 Santa Cruz), Nanog (1:100 Abcam) for 18 hours at 4°C. Visualization was performed 
using an anti-mouse secondary antibody conjugated to Texas-red (1:5000) (Jackson 
ImmunoResearch Laboratories), or an anti-rabbit secondary antibody conjugated to FITC 
(1:1000, Jackson ImmunoResearch Laboratories) for one hour, followed by counterstaining 
with DAPI (Vector Laboratory). Human iPS cells were fixed in 4% paraformaldehyde for 30 
minutes at room temperature and incubated with SEEA-4 (1:200 Developmental Studies 
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Hybridoma Bank), Tra-1-60 (1:200 Millipore), Oct4 (1:100 Santa Cruz), Sox2 (1:100 Santa 
Cruz), Nanog (1:100 Abcam) for 18 hours at 4°C. Secondary antibodies were used as 
mentioned above and DAPI was used for visualization. Cells were rinsed in PBS and 
photomicrographs were taken with a Zeiss AxioObserver A1 inverted fluorescence 
microscope.  
 
2.26. Small RNA Sequencing and Analysis 
For small RNA library construction, RNA samples were prepared using the DGE-
Small RNA Sample Prep Kit (Illumina, San Diego, CA) as described previously (183, 184). A 
total of two Solexa-ready small RNA templates were analyzed on an Illumina GA-IIx Genome 
Analyzer at University of Houston. Cluster generation was performed and clusters were 
sequenced. Initial sequence process and analysis was followed as described previously(183, 
184). Small RNA-Seq sequencing data was uploaded and processed using the Genboree Small 
RNA Toolset (http://genboree.org). The Illumina adapter was trimmed, and reads with length 
between 11 and 30, a copy number of at least 4, and finishing in monomers with length less 
than 10, were selected for further processing, similar to the processing described previously 
(183, 184). The reads were mapped to the mouse genome and build UCSC mm9 (NCBI 37) 
using Pash 3.0(185). Reads mapping up to 100 locations were selected for further analysis. 
The miRNA definitions from miRBase (186-189) were used to construct a known miRNA 
profile for each sample; the abundance of the known miRNAs were normalized as a fraction of 
the usable reads. For each species, a combined profile of all samples was computed; miRNA 
abundance was mean-centered and z-score transformed for each miRNA individually. 
Principal component analysis was performed using the implementation within the R statistical 
analysis system. Hierarchical clustering of samples was performed by first computing the 
symmetrical sample distance matrix using the Pearson correlation between microRNA profiles 
as a metric. Supervised sample analysis was performed using the t-test statistics, and heatmaps 
were generated using the heatmap.2 package in R. 
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2.27. RNA Sequencing and Analysis 
Approximately 5 μg of polyA+ RNA was used to construct RNA-Seq libraries using 
the standard Illumina protocol. Mouse and human mRNA sequencing yielded 30-40million 
read pairs for each sample. The mouse mRNA-Seq reads were mapped using TopHat (190) 
onto the mouse genome and build UCSC mm9 (NCBI 37) and the RefSeq mouse genes. The 
human mRNA-Seq reads were mapped using TopHat onto the human genome and build 
UCSC hg19 (NCBI 37) and the RefSeq human genes. Gene expression and gene expression 
differences were computed using Cufflinks (190). For each species, a combined profile of all 
samples was computed; miRNA abundance was mean-centered and z-score transformed for 
each miRNA individually. Principal component analysis was executed using the 
implementation within the R statistical analysis system. Hierarchical clustering of samples was 
executed by first computing the symmetrical sample distance matrix using the Pearson 
correlation between mRNA profiles as a metric, supervised sample analysis was performed 
using the t-test statistics, and heatmaps were generated using the heatmap.2 package in R. For 
gene signatures, we further explored gene enrichment using DAVID and the GSEA 
implementation at the Molecular Signature Database (MSigD) (191). 
 
2.28. Multi-species analysis of smRNA-Seq and RNA-Seq data 
To integrate the smRNA-seq datasets between mouse and human, first we selected the  
conserved microRNAs between mouse and human; next, we combined the z-score transformed 
miRNA abundance obtained from the human and the mouse cell types. For integrated mRNA-
seq analysis, the z-score transformed mRNA abundance datasets for mouse and human were 
combined by selecting only the conserved miRNAs. For each resulting dataset, principal 
component analysis and hierarchical clustering using the Pearson correlation coefficient metric 
were carried out using the implementations available within the R statistical analysis system. 
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2.29. Generation of an inducible DGCR8 lentiviral vector 
A tetracycline inducible DGCR8 lentiviral vector was generated by cloning a PCR 
amplified product from pFLAG/HA-DGCR8 (192). Primers used to amplify the DGCR8 
cDNA were as follows: FOR –GGATCCCATGGAGACAGATGAGAGC, REV -
GAATTCGGTGCACAGGGGCTCAC . The resulting PCR product was cloned into the 
EcoRI sites in the pLVX-Tight-Puro vector (Clontech).   
 
2.30. Southern Blot Analysis of mouse ∆Np63
 -/-
 epidermal cells and iPS
Yam 
cells 
Genomic DNA was extracted from mouse iPS cells generated using the Yamanaka 
factors (miPS
Yam) and ∆Np63 -/- epidermal cells, digested with EcoRI, and separated on a 0.7% 
agarose gel.  Hybridization was performed as described previously (72) using a probe for Klf4 
amplified from miPS
Yam
 DNA using forward primer 5’-GCAGCCACCTGGCGAGTCTGA-3’ 
and reverse primer 5’-GAGCCCTCCACCTGTGTTGCT-3’. 
 
2.31. Calculation of Timing and Efficiency of Reprogramming  
1 x 10
5
 normal human epidermal keratinocytes (NHEK) were plated on 6 cm dishes 
coated with 0.1% gelatin and infected for 48 hours with the following lentiviruses: shTRP63-
pGIPz (Open BioSystems), shDGCR8-pGIPz (Open BioSystems), or OKSIM  (Addgene) 
(182). On day 3, ES cell media was added to the cells.  The cells were fixed with 4% 
paraformaldehyde on day 6, 8, and 14 to determine the timing of reprogramming by 
immunofluorescence staining with Oct-4 (Santa Cruz; 1:100), Tra-1-60 (Millipore; 1:200) or 
Nanog (1:100; Abcam) antibodies. DAPI (Vector Laboratory) was used as counterstain. To 
determine percentage of reprogramming efficiency the cells were fixed at days 8 and 14 and 
visualized by immunofluorescence using the antibodies listed above. Photomicrographs were 
taken with a Zeiss AxioObserver A1 inverted fluorescence microscope at 10x magnification.  
Percent efficiency was calculated by counting Tra-1-60 positive colonies, dividing by 1 x 10
5
 
cells, and multiplying by 100.  
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2.32. Teratoma Formation Assay 
∆Np63 -/- epidermal cells were infected with the tet-inducible DGCR8 vector and the 
pTet-On Advanced vector (Clontech) as described previously (193).  Severe combined 
immunodeficiency disease (SCID) mice were injected subcutaneously in the dorsal flank with 
a wild-type mouse ES cells or Np63 -/- epidermal cells transduced with the tet-inducible 
DGCR8 vector as described previously (92).   Mice were administered 2 mg/mL doxycycline 
in the drinking water to induce expression of DGCR8, 3 weeks post injection after palpable 
tumors had formed.  Another group of mice were administered water without doxycycline as 
controls for the same amount of time.  Tumors were harvested 6 weeks after injection and 
fixed in 10% formalin.  Paraffin embedded cross-sections were analyzed by hematoxylin and 
eosin staining and IHC using antibody for DGCR8 (1:250)(Abcam). Visualization was 
performed using the Vectastain Elite ABC and DAB Peroxidase Substrate Kits (Vector 
Laboratory). For immunofluorescence (IF), paraffin-embedded sections were rehydrated in 
xylene and decreasing concentrations of ethanol. Sections were subjected to antigen 
unmasking in citrate buffer unmasking solution (Vector Laboratory) followed by incubation 
with blocking solution, and 18 hour incubation at 4
o
C with the following primary antibodies:  
Nestin (1:50  Millipore), AFP (1:100 Santa Cruz), Brachyury (1:50 Santa Cruz). Visualization 
was performed using an anti-mouse secondary antibody conjugated to Texas-red (1:5000) 
(Jackson ImmunoResearch Laboratories), an anti-rabbit secondary antibody conjugated to 
FITC (1:1000, Jackson ImmunoResearch Laboratories) or an anti-goat secondary antibody 
conjugated to Texas-red (1:1000, R&D Systems) for one hour, followed by counterstaining 
and mounting in Vectashield with DAPI (Vector Laboratory). Teratomas from normal human 
epidermal keratinocytes (NHEK) transduced with shNp63 cells were performed by Applied 
StemCell,Inc. NHEK-shNp63 and NHEK-shDGCR8 cells were grown on feeders in ES cells 
media. 1 x 10
6
 cells were injected into the testes or the kidney capsule of SCID mice.    
Tumors were then fixed in 10% formalin, embedded in paraffin, cross-sectioned, and analyzed 
by H&E. Immunofluorescence was performed on paraffin embedded sections following 
rehydration and antigen retrieval (Vector Laboratories) as mentioned earlier. The slides were 
blocked for an hour in blocking solution (Vector Laboratories) and incubated for 18 hours at 
4
o
C with the following primary antibodies: AFP (1:100, Santa Cruz), brachyury (1:50, Santa 
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Cruz), K5, (1:200, Abcam), E-cadherin, (1:100, Abcam). Visualization was performed using 
anti-mouse Texas red or FITC (1:1000, Vector Laboratories), anti-rabbit Texas red or FITC 
(1:5000, Vector Laboratories) and anti-goat Texas red antibody (1:1000, R&D Systems). 
Counterstaining and mounting was performed using Vectashield with DAPI (Vector 
Laboratory). 
 
2.33. Generation and analysis of chimeric mice 
ΔNp63 -/- cells (12-18 cells) expressing pLenti-GFP (Vector Development Laboratory, 
Baylor College of Medicine) or iPS
Yam
 (S3) cells (12-18 cells) expressing eGFP (194) were 
injected into albino B6 blastocysts and implanted in CD-1 pseudopregnant mice. Embryos at 
E18.5 were analyzed for GFP expression using a Zeiss SteREO Lumar, V12 microscope, with 
fluorescent and bright field capability. Non-chimeric E18.5 day embryos were used as negative 
controls. The embryos were fixed in 10% formalin, embedded in paraffin, and 
immunofluorescence was performed on cross-sections using an anti-GFP antibody. 
 
2.34. Raft culture 
Human immortalized keratinocytes (BC-1-Ep/SL) were grown as described previously. 
Skin raft culture was performed as described previously (195). Collagen was mixed with 
human fibroblasts was layered onto an insert of a well. The collagen was allowed to solidify. 
Keratinocytes were plated onto this collagen plug and cultured in a submerged culture for 3-4 
days. The insert is lifted and placed on a support grid with media in the bottom chamber for 14 
days. The raft is then fixed in 10% formalin and stained (195). 
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3. Chapter 3: TAp63 suppresses metastasis through coordinate regulation of Dicer 
and miRNAs 
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3.1. Introduction 
MicroRNAs have been shown to be very important in the regulation of metastasis. 
Several microRNAs like miR-126, miR-10b, miR-34a, miR200 –family play critical role in the 
regulation of mammary, lung, prostate, ovarian, colorectal and other types of cancer metastasis 
and in EMT (initiation of metastasis)(196-204). In many cancers the expression of these 
microRNAs are lost(205-207). Recently p53 was found to transcriptionally regulate miR-34a 
(164, 165). Also p53 has been shown to regulate the microRNA biogenesis pathway by 
binding to p68 and p72 thereby affecting pre-miR biogenesis(154, 208). Drosha is a critical 
component in the cleavage of  the primary microRNAs in the nucleus along with DGCR8 that 
processes them  into precursor microRNAs (141, 209).  p68 and p72 have been shown to be 
associated with Drosha/DGCR8 microprocessor complex in the nucleus (210). The loss of 
these proteins cause a downregulation in the processing of pri-miR to pre-miR by thirty five 
percent.  
p63 being a p53 family member has been shown to be important in development, 
senescence and tumorigenesis (65, 74, 79). There are conflicting data on whether it is a tumor 
suppressor or an oncogene primarily due to the presence of the two isoforms of p63, which 
play significantly different roles. TAp63 has been shown to be important in the regulation of 
the stem cell compartment and ΔNp63 has been shown to be important in development (72, 74, 
211). In the context of tumorigenesis their roles have not yet been clearly delineated. Most of 
the in vitro cell culture based assays indicate TAp63 to be a tumor suppressor (211)and ΔNp63 
to be an oncogene (212). p63 protein has also been shown to be highly expressed in various 
types of human tumors (50). However the roles of these isoforms have never been tested in 
vivo. The construction of the total p63 knock-out only added more confusion to the field. This 
mouse lacks both the isoforms of p63 and has severe developmental defects (29). Owing to the 
lack of epithelium formation these mice die postnatally a few hours after birth from 
dehydration and desiccation.  
Thus it became imperative to generate mouse models, which lack these individual 
isoforms of p63. Because these two isoforms of p63 have their own promoters and 
transcription start sites, it was possible to generate the TAp63 knock-out mouse model which 
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retained the expression of the ΔNp63 isoforms (65). The TAp63 knock-out mice showed skin 
defects. It demonstrates skin erosions, blisters, ulcerations and wound healing defect, all 
indications of a premature ageing phenotype (72). These mice are highly tumor prone and 
develop metastatic carcinomas. In this chapter we investigate the role of TAp63 in 
tumorigenesis and metastasis. We show that TAp63 regulates microRNA expression by the 
transcriptional regulation of Dicer. TAp63 also regulates miR-130b by transcriptional 
activation of their promoter sites. We show both these regulations to be important in mouse 
carcinomas and human lung adenocarcinoma, mammary adenocarcinoma and head and neck 
squamous cells carcinoma metastasis. In humans high grade tumors lose TAp63/Dicer/miR-
130b. We also show that introducing TAp63, Dicer and miR-130b in murine and human 
metastatic cells and tumor cell lines reduces the metastatic potential of these cells and cell 
lines.     
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3.2. Results 
3.2.1. TAp63 mutant mice develop highly metastatic tumors 
To delineate the role of TAp63 in tumorigenesis and to determine whether it behaves 
like a tumor suppressor or an oncogene, a cohort of mice was generated with 30 mice for 
TAp63
 -/-
, 30 for TAp63
 +/-
 and 30 for wild-type and aged them for 2.5 years analyzing them for 
spontaneous tumors. Both these cohorts developed highly metastatic tumors and had a reduced 
life span when compared to the wild-type cohort (Figure 4A). The TAp63
 -/-
 mice died at a 
median age of 23 months and the TAp63
 +/-
 mice died at a median age of 17 months (Figure 
4A). These mice developed highly metastatic sarcomas and carcinomas to the lung, liver, bone 
and even to the brain, a rare occurrence in tumor mouse models.   Shown is an example of a 
TAp63
 -/-
 mouse with a highly metastatic mammary adenocarcinoma (Figure 4B) which 
metastasized to the lung (Figure 4C), liver (Figure 4D) and brain (Figure 4E). Interestingly 
10% of the TAp63
 -/-
 mice develop mammary adenocarcinomas, which metastasize to the brain.    
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Figure 4: TAp63
 -/-
 mice develop metastatic tumors 
A) Tumor free survival curves of wild-type (WT), TAp63
 +/-
 and TAp63
 -/-
 mice; n= 30 and 
p≤0.05. B) Mammary adenocarcinoma in a TAp63 -/- mouse. C) Metastatic mammary 
adenocarcinoma to the lung (LU),(D) liver (LI) and (E) brain (BR). Bar in panel E denotes 
100um.  
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.2. Histological analysis of the tumors from TAp63
 -/-
 and TAp63
 +/-
 mice demonstrate a 
diverse profile 
Since p63 has been shown to be important in the maintenance of the integrity of the 
epithelium (72), it was not surprising to find that the TAp63
 -/-
 and the TAp63
 +/-
 mice 
developed a high percentage of carcinomas (animals analyzed, n=30 from each cohort). They 
also developed sarcomas and lymphomas. 46% of the TAp63
 -/-
 mice developed various types 
of carcinomas of the lung, mammary gland, liver and transitional cell (Figure 5). 26% of the 
mice developed sarcomas of various types including osteosarcoma, histiocytic sarcoma and 
rhabdomyosarcoma (Figure 5 and Table 1).  A very small percentage (5%) developed 
lymphoma. Similar percentage of the TAp63
 +/-
 mice developed similar types of carcinomas 
and sarcomas.  A greater number of mice (10%) developed lymphomas. Paradoxically a higher 
number of the TAp63
 -/-
 mice lived tumor free (about 24%) compared with the TAp63
 +/-
 mice 
(15%) (Figure 5 and Table 1). 
 
 
 
 
 
 
 
 54 
 
                      
Figure 5: Tumor spectrum of TAp63 mutant mice 
Percentage of carcinomas (blue), sarcomas (red) and lymphomas (green) in the TAp63
 -/-
 and 
the TAp63
 +/-
 mice. Black bar denotes percentage of mice without tumors; n=30. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.3. TAp63 is a haploinsufficient tumor suppressor 
Interestingly we found that the TAp63
 +/-
 mice had a higher incidence of metastatic 
tumors. Both the TAp63
 -/-
 and TAp63
 +/-
 developed equal percentage of metastatic carcinomas 
(73% and 80% respectively) but a higher percentage of the sarcomas metastasized in TAp63
 +/-
 
mice (100%) compared to the TAp63
 -/-
 (60%) (Figure 6A). Additionally the proportion of 
mice with multiple tumors was greater in the TAp63
 -/-
 cohort (50%) compared to the TAp63
 -/-
 
cohort (12%) (Figure 6B). In agreement to their tumor make-up the TAp63
 +/-
 mice also had a 
shorter life span suggesting that TAp63 acts as a haploinsufficient tumor suppressor. We 
analyzed the sarcomas (n=10) and carcinomas (n=10) from these mice and found that they did 
not present loss of heterozygosity for TAp63 and retained the wild-type allele (Figure 6C). 
These data taken together suggests that TAp63 is a haploinsufficient tumor suppressor gene 
and heterozygous loss of TAp63 is more deleterious than complete loss of this gene.   
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Figure 6:TAp63 is a haploinsufficient tumor suppressor 
A) Percentage of mice with metastatic sarcomas and carcinomas of the indicated genotypes; 
n=30. B) Percentage of mice with multiple malignancies. C) Loss of heterozygosity in 
sarcomas (S) and carcinomas (C) from the mice of the indicated genotypes;n=10. Asterisk 
indicates statistical significance, p value ≤0.05.                   
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.4. TAp63/p53 double mutant mice have a tumor profile that is distinct from the p53 
mutant mice  
The p53
 -/-
 and p53
 +/-
 mice were shown to develop non-metastatic tumors . In human 
tumors both p53 and p63 has been shown to be mutated many a times (130). Also mutant p53 
can act in a dominant negative manner over p63 by binding to and inactivating p63 (213). To 
understand the co-operation between p53 and p63 in tumors we generated six cohorts of mice, 
30 each: TAp63
 -/-
;p53
 +/-
, TAp63
 +/-
;p53
 +/-
, TAp63
 -/-
;p53
 -/-
 and TAp63
 +/-
;p53
 -/-
. Cohorts of 
p53
 +/-
 and p53
 -/-
 mice were also generated as controls. These mice were aged for 2.5 years and 
analyzed for spontaneous tumors (Table1). The TAp63/p53 compound mutant mice developed 
high numbers of metastatic tumors in contrast to the p53 mutant (p53
 +/-
 and p53
 -/-
) mice 
which did not display any metastases (Figure 7A-F and Table 1). While 80% of the p53
 +/-
 
mice developed sarcomas and 20% of these mice developed lymphoma, only 55% of TAp63
 -/-
;p53
 +/-
 mice developed sarcomas and 11% developed thymic lymphoma (Figure 7G). 
However 60% of the TAp63
 -/-
;p53
 +/-
 mice developed carcinomas, including lung 
adenocarcinoma (15%) and mammary adenocarcinomas (10%), squamous cell carcinomas 
(SCC) (15%), and transitional carcinoma (10%) (Figure 7G). Although the TAp63
 +/-
;p53
 +/-
 
mice has a similar tumor spectrum to the TAp63
 -/-
;p53
 +/-
 mice , the sarcomas form these mice 
were significantly more invasive and metastatic (88%) than those in the TAp63
 -/-
;p53
 +/-
 cohort 
(14%). In contrast, the carcinomas in the TAp63
 -/-
;p53
 +/-
 cohort were more metastatic (44%) 
than those in the TAp63
 +/-
;p53
 +/-
 cohort (29%) (Figure 7H).  
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Figure 7:TAp63/p53 double mutant mice have a distinct tumor profile from the p53 
mutant mice 
A & B) Metastatic rhabdomyosarcoma C) Metastatic squamous cell carcinoma of the skin 
(SCC) metastasized to the lung, (LU) (D & F) and lymph nodes (E) of a TAp63
 -/-
;p53
 +/-
 
mouse. G) Percentage of mice of the indicated genotypes with carcinomas (blue), sarcomas 
(red), lymphomas (green). Yellow bar indicates percentage of mice without tumors; n=30. H) 
Percentage of mice of the indicated genotypes with multiple metastatic carcinomas (blue) and 
sarcomas (red); n=30. Asterisks indicate significance, pvalue ≤0.05. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.5. TAp63 does not undergo LOH in the TAp63/p53 double mutant mice tumors 
We examined the TAp63/p53 double mutant sarcomas and carcinomas for the loss of 
heterozygosity in TAp63 and p53 in order to determine whether they lose their wild-type allele. 
We examined sarcomas (n=10) and carcinomas (n=10) from the TAp63
 +/-
;p53
 +/-
 mice and 
found that they retain the wild-type allele of TAp63 (Figure 8A). We also examined the same 
tumors and TAp63
 -/-
;p53
 +/-
 tumors for the loss of the p53 wild-type allele. We found that 1 out 
of 10 sarcomas exhibit loss of the p53 wild-type allele in the TAp63
 +/-
;p53
 +/-
 tumors. A 
somewhat higher percentage of tumors from the TAp63
 -/-
;p53
 +/-
 sarcomas (1 out of 8) and 
carcinomas (1 out of 8) lost the p53 wild-type allele. This indicates that there is an increase in 
selection pressure to lose the p53 allele in the complete absence of TAp63 (Figure 8B).  
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Figure 8: TAp63 does not undergo LOH in TAp63/p53 double mutant tumors 
A) PCR analysis for the loss of TAp63 from the tumors of the indicated genotype (n=10). B) 
PCR analysis for LOH of p53 in these tumors (n=10). 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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Table 1: Tumor landscape of the TAp63/p53 mutant mice 
 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.6. Loss of TAp63 is tumor protective in some tissues 
We found that the TAp63
 -/-
 mice age early in life. Ageing has been shown to be tumor 
protective in certain tissues. Age-related senescence has been shown to have tissue-specific 
tumor suppressive potential. We wanted to investigate this phenomenon in the TAp63/p53 
double mutant mice. Multiple TAp63
 -/-
;p53
 +/-
 mice developed carcinomas and sarcomas 
simultaneously in various tissues. The osteosarcomas from a number of TAp63
 -/-
;p53
 +/-
 mice 
were non-metastatic (Figure 9A). On the contrary the carcinomas from the same TAp63
 -/-
;p53
 
+/-
 and TAp63
 +/-
;p53
 +/-
 mice were highly metastatic (Figure 9B-D).  
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Figure 9: Loss of TAp63 is tumor protective in some tissues 
A) Non-metastatic osteosarcoma from TAp63 -/-;p53 +/- mouse. B) Metastatic lung 
adenocarcinoma (LA) from a TAp63
 -/-
;p53
 +/-
 mouse that has metastasized to the kidney (KI) 
(C) and small intestine (SI) (D). 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.7. Carcinomas are the more malignant of the tumor types in the TAp63 mutant and 
TAp63/p53 double mutant mice 
To test whether the arrest in metastasis of the osteosarcomas was due to the expression 
of senescence markers in these tumors, we wanted to test the expression of SA-β-galactosidase 
in these tumors and also perform real time PCR for some known senescence markers like 
PML, p16
Ink4a
 and p19
Arf
. Interestingly the osteosarcomas and rhabdomyosarcoma from the 
TAp63
 -/-
;p53
 +/-
 mice were found to be highly senescent but not the same tumor types from the 
TAp63
 +/-
;p53
 +/- 
(Figure 10A-C). All the carcinomas from the TAp63
 -/-
;p53
 +/-
 and TAp63
 +/-
;p53
 +/-
 mice were found to be negative for the validated senescence markers (Figure 10D). 
This suggests that the loss TAp63 has variable effect on the tumor phenotype in different 
tissues. These findings were also in accordance with the aggressiveness and metastatic 
capacity of these tumors. 
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Figure 10: Tumors lacking TAp63 exhibit senescence 
A & B) SA-β-gal staining of sarcomas of the indicated genotypes. C) Quantitation of the SA-
β-gal positive sarcomas from the indicated genotypes expressed in percentage;n=6. D) 
Quantitative real-time PCR for PML, p16
Ink4a
 and p19
Arf
 in the indicated tumors (n=6) of each 
genotype. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.8. Genomic instability empowers the carcinomas to overcome senescence and 
metastasize in the absence of TAp63 
Genomic instability from the TAp63
 -/-
 mouse tissues have been demonstrated to be 
high (72). In order to determine whether the tumors from the TAp63
 -/-
;p53
 +/-
 mice displayed a 
similar level of genomic instability, and whether this correlated with their metastatic potential, 
γ-H2AX (Figure 11D-F) staining and metaphase spreads (Figure 11A-C) were performed on 
tumors from these mice. The TAp63
 -/-
 carcinomas were indeed found to express high levels of 
γ-H2AX, chromosomal aberrations and polyploidy (Figure 11A-C). This suggests that tumors 
lacking TAp63 specifically of epithelial origin, acquire additional changes in order to 
overcome the senescence pathway and promote metastasis. In sarcomas decreased levels of 
TAp63 can induce senescence and make these tumors non-metastatic. 
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Figure 11: Loss of TAp63 leads to high levels of genomic instability in tumors 
 
A) Percentage of TAp63
 -/-
 and TAp63
 +/-
 tumors with chromosomal aberrations determined by 
metaphase spread ;n=6 of each genotype. Frag/DM, fragmented, double –minute chromosome. 
B & C) Representative images of metaphase spreads of the indicated genotypes. Colored 
arrows indicate aberration; ring (red) , double-minute (blue). D) Percentage of γ-H2AX 
positive cells from carcinomas of the indicated genotypes. E) Representative image of lung 
adenocarcinomas stained for γ-H2AX from the mice of the indicated genotypes. 200X 
magnification; insets shown are 400X magnification. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.9. The TAp63
 -/-
 cells and tumor cell lines are more invasive 
Since the TAp63 mutant tumors in mice exhibited such aggressiveness, we wanted to 
investigate the loss of TAp63 in inducing metastasis in tumors, MEFs and other cell lines.  We 
found that the mouse embryonic fibroblasts derived from the TAp63
 -/-
 mice showed 1.8 fold 
increased invasion in a Boyden chamber assay (Figure 12A). In order to determine whether 
this was true for human tumors, we went on to probe the migratory and invasive capacity of 
the tumor cell lines generated from the primary head and neck squamous cell carcinomas 
(10A, 17A, 22A) and the matched metastases (10B, 17B, 22B) from the same patient (214). 
Interestingly the TAp63 mRNA levels were found to be low in all the metastatic cell lines 
when compared to the cell line generated from the primary tumors (Figure 12B). In Boyden 
chamber assay the cell lines with low levels of TAp63 were more invasive compared to the cell 
lines which retained TAp63 (Figure 12C). The cell lines 22A and 22B had low levels of 
TAp63 and demonstrated comparably high levels of invasion  (Figure 12C). This suggests that 
TAp63 is an important regulator of invasion in vitro and metastasis in vivo. 
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Figure 12: TAp63
 -/-
 primary cells and cell lines are highly invasive 
A) Percentage of invasive wild-type (n=3) and TAp63
 -/-
 (n=3) MEFs subjected to Boyden 
chamber assay. B) Real-time PCR of TAp63 mRNA levels in the human head and neck 
squamous cells carcinoma cell lines (n=5) of the indicated types. C) Percentage of invasive 
cells of the indicated head and neck squamous cell carcinoma cell lines in Boyden chamber 
assay. Asterisk indicate significance, p≤0.05. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.10. Dicer mutant mice exhibit similarities to the TAp63 mutant mice 
In many human cancers there is a heterozygous deletion of Dicer (180). In most tumors 
only a single allele of Dicer is lost (180). Our recent findings that TAp63
 +/-
 tumors are more 
aggressive than those from TAp63
 -/-
 mice are reminiscent of the recently reported phenotype 
of Dicer conditional knock-out  (Dicer1
fl/+) 
mice intercrossed to the Kras
LSL-G12D 
lung cancer 
model. Dicer1
fl/+;
Kras
LSL-G12D 
mice displayed a more aggressive tumor phenotype and 
shortened lifespan as compared to the Dicer1
fl/fl
;Kras
LSL-G12D 
mice following treatment with 
Adenovirus-Cre, indicating that Dicer is a haploinsufficient tumor suppressor (180, 215), 
similar to what we observed for TAp63
 -/-
 mice on an enriched C57/B6 background, where we 
have observed that 35% of TAp63
 -/-
 embryos die between E6.5 and E8.5dpc. 
 
3.2.11. Dicer mRNA level is low in TAp63 mutant human and murine cells, tumors and 
cell lines  
Given the similarities between TAp63 mutant mice and Dicer mutant mice, we wanted 
to investigate whether the TAp63 mutant tumors have lower expression of Dicer. Dicer levels 
were significantly low in the TAp63 and TAp63/p53 mutant murine tumors compared to TAp63
 
+/-
 and p53
 -/-
 tumors (Figure 13A). Dicer mRNA level was analyzed in the cell lines derived 
from osteosarcomas, lung and mammary adenocarcinomas deficient for TAp63 (n=6 of each 
cell line) (Figure 13A). We also immunostained carcinomas from TAp63
 +/-
 and TAp63
 -/-
 mice 
(n=10 for each genotype) and found that highly metastatic tumors lose expression of Dicer 
(Figure 13D-I). To determine whether Dicer was specifically low in the absence of TAp63, we 
analyzed primary cells (MEFs) deficient for TAp63 and compared mRNA expression level of 
Dicer to wild-type MEFs. We found Dicer levels were significantly low in the TAp63
 -/-
 MEFs 
(about 50folds) suggesting loss of TAp63 leads to a loss of Dicer mRNA levels (Figure 13B). 
We also tested Dicer levels in the human HNSCC cell lines with predetermined TAp63 levels 
and found that Dicer was lost in the more metastatic cell lines (10B, 17B) compared to their 
primary tumor cell line (10A, 17B) (Figure 13C). The cell lines with low levels of TAp63 
(22A and 22B) also had low levels of Dicer (Figure 13C). These data indicate that Dicer 
levels are low in metastatic human lesions of HNSCC comparable to the loss of TAp63 in 
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these metastatic tumors. This also suggests a critical role of TAp63 in the regulation of Dicer 
levels. Interestingly Dicer levels have been shown to be low in various human cancers.  
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Figure 13: Dicer levels are low in TAp63 mutant tumors 
A) Quantitative real-time PCR analysis of Dicer mRNA levels in murine tumors of the 
indicated genotypes; n=3. B) Quantitative real-time PCR analysis of Dicer mRNA levels in 
primary MEFs of the indicated genotypes; n=3. C) Quantitative real-time PCR analysis of 
Dicer mRNA levels in human primary and matched metastatic tumor cell lines of the indicated 
types; n=5. D-I) Dicer immunofluorescence staining of lung adenocarcinomas, hepatocellular 
carcinomas and squamous cell carcinomas of the indicated genotypes. 200X magnification. 
Asterisk indicate significance. p≤0.05. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.12. Low levels of Dicer expression in human metastatic tumors correlate with TAp63 
expression levels 
TAp63 level and Dicer level was determined in human tumors of various grades with 
the help of immunohistochemistry for Dicer and TAp63. We found that the more the advanced 
metastatic tumors had a greater loss of TAp63 and in turn Dicer (Figure 14A-D and Table 2). 
This was true for all the tumor types tested including head and neck squamous cell carcinoma 
(n=46), mammary adenocarcinoma (n=43) and lung adenocarcinomas (n=92). The higher 
grades of tumors, which were more metastatic, lost TAp63 expression and Dicer expression.  
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Table 2: TAp63 and Dicer expression in human tumors 
 
Figure 14: Low levels of Dicer expression in human metastatic tumors correlate with 
TAp63 expression levels 
 A & B) TAp63 and Dicer immunostaining of human HNSCC (Grade I) and C & D) (Grade 
III) tumors. Arrows indicate positive cells for TAp63. Magnification 200x. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.13. TAp63 transcriptionally regulates the Dicer promoter  
These data together suggests TAp63’s role in the transcriptional regulation of Dicer. 
Since TAp63 is a transcription factor and shares its concensus site homology with p53 we first 
scrutinized the Dicer promoter for TAp63 binding site and found a binding site (p63BS) 1446 
nucleotides upstream of the Dicer transcriptional start site (Table 3). We found several 
binding sites in accordance with the consensus binding sequence. We performed a chromatin 
immunoprecipitation assay using an antibody towards p63 using lysates from wild-type and 
p63
 -/-
;Arf 
G/G
 keratinocytes. We found that p63 bound to the Dicer promoter  (Figure 15A). 
We used a non-specific sequence located 2560 nucleotides upstream of the start site where no 
p63 binding was detected (Figure 15A). We further verified whether TAp63 transactivated the 
Dicer-luciferase reporter gene promoter with a luciferase assay. We constructed a luciferase 
reporter gene containing the p63 binding site on the Dicer promoter. We found that all 
isoforms of TAp63 α, β and γ could transcriptionally activate the Dicer promoter (Figure 
15C). On the contrary p53 could not bind to and activate the Dicer promoter. This indicates 
that p63 and not p53 is a specific transcriptional activator of the Dicer (Figure 15B).  
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Table 3: p63/p53 response element on Dicer promoter 
 
 
 
 
 
 78 
 
Figure 15: TAp63 transcriptionally regulates Dicer by directly binding to its promoter 
A) Quantitative real-time PCR of ChIP assay using keratinocytes from wild-type and p63
 -/-
;ArfG/G cells. P63 binding site is indicated by p63BS and non-specific binding site by NSBS 
on the Dicer promoter, n=3. B) Quantitative real-time PCR of ChIP assay using keratinocytes 
from wild-type and 53
 -/-
 cells at the p63 binding site. C) Luciferase assay for the Dicer, n=5, 
V, pcDNA3 vector. D) Table demonstrating the p63 binding site on the Dicer promoter.  
Asterisk indicates significance. p≤0.05. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.14. Loss of Dicer expression in MEFs causes increased invasion  
To understand the contribution of Dicer in the invasiveness of the TAp63
 -/-
 cells we re-
expressed Dicer with an overexpresion plasmid  (pDESTmycDICER) (216) in the TAp63
 -/-
 
MEFs (Figure 16A). To test any changes in their invasiveness, these cells were then assayed 
for invasion by a Boyden chamber assay. These cells demonstrated a significant decrease in 
their invasive potential compared to their TAp63
 -/-
 control without Dicer expression (Figure 
15B). Conversely when wild-type cells are treated with a short-hairpin for Dicer (pSuper-
Dicer1) (181) (Figure 16A) they show increased invasion in a Boyden chamber assay 
compared to the wild-type control. This indicates that Dicer affects the invasive capacity of 
cells similar to TAp63 (Figure 16C). 
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Figure 16: Loss of Dicer expression in MEFs causes increased invasion 
A) Western blot analysis of MEFs overexpressing Dicer and ablation of Dicer infected with 
the indicated vectors. B) Percent invasion of MEFs overexpressing Dicer and MEFs treated 
with shRNA for Dicer (C) Asterisk indicate significance. p≤0.05. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.15. TAp63 regulates metastasis through the regulation of Dicer in cells and cell lines 
To determine whether TAp63 regulates metastasis through the transcriptional 
regulation of Dicer, we re-expressed TAp63γ in the TAp63 deficient MEFs (Figure 17A) and 
the more metastatic HNSCC cell lines (10B and 17B) (Figure 17D). The TAp63 γ isoform was 
re-expressed in these cells and cell lines and subjected to invasion assay by a Boyden chamber. 
These cells became less invasive and comparable to wild-type cells (Figure 17C & 17F). 
When we measured Dicer levels in these cells and cell lines, we found that Dicer expression 
was as high as the wild-type MEFs on expression of TAp63 γ (Figure 17B & 17E).  
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Figure 17: TAp63 regulates metastasis through the regulation of Dicer in cells and cell 
lines 
A) Quantitative real-time PCR for TAp63 in MEFs of the indicated genotype with vector 
control (V) or TAp63γ. B) Quantitative real-time PCR for Dicer in MEFs of the indicated 
genotype with vector (V) or TAp63γ. C) Percentage of invasive MEFs treated with vector 
control or overexpressing TAp63γ; n=3. D) Quantitative real-time PCR for TAp63γ and E) 
Dicer, after overexpression of control vector (V) or TAp63g in the HNSCC cell lines of the 
indicated genotypes. F) Percentage of invasion of the cells infected with vector (V) or TAp63γ. 
Error bars indicate s.e.m. Asterisks indicate statistical significance, p≤0. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.16. Loss of TAp63 and Dicer expression increases the metastatic potential of the non-
metastatic cells 
To understand whether downregulation of TAp63 with a short hairpin RNA could 
ablate the expression of Dicer as seen in the mouse and human tumors, we treated the wild-
type MEFs (TAp63
fl/fl
) with either adenovirus-GFP as control or adenovirus-Cre and acutely 
ablated TAp63 (TAp63
Δ/Δ
) (Figure 18A). In these cells Dicer was concomitantly down 
regulated and resulted in increased invasion when subjected to Boyden chamber assay. This 
indicates that modulation of TAp63 in turn affects Dicer levels and invasion (Figure 18B-C). 
Therefore loss of TAp63 is an important factor in the invasiveness of primary cells, tumor cell 
line and tumors. Taken these data into consideration, TAp63 is important in the regulation of 
Dicer in the suppression of metastasis. 
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Figure 18: Loss of TAp63 and Dicer expression increases the metastatic potential of the 
non-metastatic cells 
A) Quantitative real time PCR analysis for TAp63 in MEFs infected with adenovirus-GFP 
(TAp63
fl/fl
) and adenovirus-Cre (TAp63 
Δ/Δ
). B) Quantitative real time PCR analysis for 
Dicer in MEFs infected with adenovirus-GFP (TAp63
fl/fl
) and adenovirus-Cre (TAp63 
Δ/Δ
). 
C) Invasion assay of MEFs infected with Adenocirus-GFP or Adenovirus-Cre; n=3. Error 
bars indicate s.e.m. Asterisks indicate statistical significance, p≤0.05.  
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.17. TAp63
 -/-
 MEFs express low levels of mature microRNAs 
Since Dicer is one of the key enzymes in the cleavage of precursor microRNAs to 
mature microRNAs, we investigated whether all the mature microRNA species in the TAp63
 -/-
 
MEFs were expressed at low levels. Interestingly we found several microRNAs, miR-10b, 
miR-34a, miR-130b, miR-200b and miR-200c, that were expressed at significantly low levels 
in these cells by Northern blot analysis (Figure 19). All of these microRNAs have been shown 
to play roles in lung and mammary adenocarcinoma metastasis. In most of these tumors these 
microRNAs were downregulated (152, 196, 204, 217). 
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Figure 19: TAp63
 -/-
 MEFs express low levels of mature microRNAs 
 Northern blot analysis in wild-type (
 +/+
) and TAp63
 -/-
 (
 -/-
) MEFs for the indicated mature 
microRNAs. 5S rRNA is used as a loading control.  
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.18. Modulation of TAp63 effects the expression of mature microRNA 
To determine whether modulating the levels of TAp63 could affect the expression of 
mature microRNA, we expressed TAp63γ in the TAp63 -/- MEFs and acutely ablated TAp63 in 
the TAp63
fl/fl
 MEFs with the help of adenovirus-Cre infection (TAp63
Δ/Δ
). Northern blot was 
performed for miR-10b and miR-130b with probes against mature microRNAs. This probe 
detects the precursor microRNA species as well. As expected we observed a loss of mature 
miR-10b in the TAp63
 -/-
 and the TAp63
Δ/Δ 
MEFs, but no effects on the precursor levels of this 
microRNA (Figure 20A). Surprisingly we found a loss of miR-130b precursor expression in 
the TAp63
 -/-
 and the TAp63
Δ/Δ
 MEFs suggesting that TAp63 possibly regulates its transcription 
at the primary microRNA stage and therefore loss of TAp63 causes a loss in the precursor 
microRNA expression (Figure 20B). Re-expression of TAp63γ isoform in the TAp63 -/- MEFs 
rescued the loss of expression of mature and precursor microRNAs suggesting that TAp63 not 
only regulates the expression of mature microRNAs through the regulation of Dicer but may 
indeed regulate microRNA transcription. 
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A) Northern blot analysis of miR-10b or (B) miR-130b using MEFs expressing vector (V) or 
TAp63γ, TAp63fl/fl (fl/fl) and TAp63Δ/Δ (Δ/Δ). 5SrRNA is used as loading control. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
  
Figure 20: Modulation of TAp63 effects the expression of mature microRNA 
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3.2.19. TAp63
 -/-
 cells and tumors express low level of miR-130b compared to p53
 -/-
 cells 
We performed a Taqman reverse transcriptase assay to determine the expression levels 
of miR-130b and miR-34a in wild-type, TAp63
 -/-
 and p53
 -/-
 MEFs (Figure 21A), murine 
tumors (Figure 21B) and HNSCC (Figure 21C). Interestingly we found that miR-130b was 
expressed at lower levels in the TAp63 mutated cells and tumors in comparison to the p53
 -/-
 
cells and murine tumors (Figure 21A-B). miR-130b was found to be expressed at lower levels 
in the metatstatic HNSCC (10B and 17B), which express low levels of TAp63 as shown 
earlier, compared to their primary matched tumors (10A and 17A) (Figure 21C). Since p53 
has been shown to be a transcriptional regulator of miR-34a, we hypothesized that TAp63 
could be the transcriptional regulator of miR-130b and miR-34a. 
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Figure 21: TAp63
 -/-
 cells and tumors express low level of miR-130b compared to p53
 -/-
 
cells 
A-C) Quantitative reverse transcriptase Taqman assay for miR-130b and miR-34a in TAp63
 -/-
, 
p53
 -/-
 and wild-type MEFs (A), murine tumors and cell lines (B) and (C). D) Quantitative   
reverse transcriptase Taqman assay for miR-130b and miR-34a of the indicated human tumor 
cell lines as specified earlier; n=5. Error bars indicate s.e.m. Asterisk indicate statistical 
significance, p≤0.05.  
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
  
 91 
 
3.2.20. Expression level of mature miR-130b correlates with TAp63 and Dicer expression 
in human cancers 
We wanted to determine whether TAp63 is an effecter of miR-130b. We analyzed the 
levels of mature miR-130b in the panel of primary and metastatic head and neck squamous cell 
carcinomas and lung adenocarcinomas. The level of miR-130b correspond with the level of 
expression of TAp63 and Dicer in these tumors. The more metastatic tumors (Grade II and 
Grade III) have a loss in TAp63, Dicer and miR-130b expression (Table 4). 
 
Table 4: TAp63, Dicer and miR-130b expression in human tumors 
Tumor Type HNSCC (n=25) Lung Ad (n=19) 
Tumor Grade  I  
(n=12) 
II 
(n=5) 
III 
(n=8) 
I 
(n=11) 
II 
(n=5) 
III 
(n=3) 
TAp63/Dicer   LOW 83% 100% 100% 82% 80% 100% 
TAp63/miR-130b   LOW 42% 60% 38% 9% 60% 67% 
TAp63/Dicer/miR-130b LOW 42% 60% 38% 9% 60% 67% 
 
Percentage of head and neck squamous cell carcinomas HNSCC), and lung adenocarcinomas 
(Lung Ad) of various grades :I denotes well-differentiated, II denotes moderately differentiated 
and III denotes poorly differentiated.  
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.21. TAp63 transcriptionally regulates the activation of miR-130b promoter site 
To further elucidate the role of TAp63 in the transcriptional regulation of miR-130b and 
miR-34a, we searched the upstream region of miR-130b for a p53/p63 consensus binding site. 
Putative p63 binding sites were identified by analyzing 1000 nucleotides upstream of each 
microRNA and 500 base pairs downstream of the transcriptional start site (Table 5). We 
performed chromatin immunoprecipitation for these sites and found a specific site for p63 
binding at 786 nucleotides upstream of the miR-130b transcription start site (Figure 22A). We 
also found a binding site of p63 on the miR-34a promoter besides the published p53 binding 
site at 432 bases downstream of the transcription start site (Figure 22B). We also performed 
ChIP analysis for p63 binding at the published p53 binding site, but found that although p53 
binds to this site, p63 does not (Figure 22D). Interestingly we found that p53 did not bind to 
the miR-130b binding site (Figure 22C). To determine whether p63 can transactivate the miR-
130b and miR-34a promoters, we cloned these sites into a luciferase reporter vector and 
performed a luciferase assay. We found that while all the isoforms of TAp63 indeed 
transactivate the miR-130b promoter site, they do not transactivate the miR-34a promoter 
binding site (Figure 22E-F). 
  
 93 
 
 
Table 5: p63/p53 response elements 
Element Location Sequence MM/Spacer 
miR-34a +432 to+461 gggCTTGctg      gctgtttaca             cttCTTGtgg 6 / 10 
miR-130b -786 to -763 gccCTAGttc         tgct                     cttCTAGgca            7 / 14 
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Figure 22: TAp63 transcriptionally regulates the activation of miR-130b promoter site 
A & B) Chromatin immunoprecipitation assay for p63 binding (p63BS) at the miR-130b and 
miR-34a promoter sites using p63 antibody. Quantitative real time PCR was performed to 
quantify the binding potential. C & D) Chromatin immunoprecipitation assay for p53 binding 
(p63BS) at the miR-130b and miR-34a promoter sites using p53 antibody. Quantitative real 
time PCR was performed to quantify the binding potential. Published p53 binding site at miR-
34a promoter site was used as positive control. Non-specific binding site (NSBS) was used as 
negative control. E & F) Luciferase assay for miR-130b and miR-34a promoter binding site 
with MEFs transfected with the indicated vectors, (n=3). Error bars indicate s.e.m. Asterisk 
indicate statistical significance, p≤0.05.  
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.22. TAp63 regulates metastasis by the regulation of miR-130b 
To further address whether TAp63 could regulate metastasis by the regulation of miR-
130b, we overexpressed and downregulated TAp63 in the TAp63
 -/-
 MEFs and TAp63
fl/fl 
MEFs 
as specified earlier. miR-130b levels were infact dependant on the TAp63 status and increased 
upon TAp63 upregulation in the TAp63
 -/-
 MEFs (Figure 23A), while ablated in the TAp63
Δ/Δ
 
MEFs (Figure 23B). This clearly indicates that miR-130b is a direct target of TAp63.  
  
 96 
 
 
 
                                       
Figure 23: Modulating TAp63 levels correlate with the level of miR-130b 
A) Quantitative real time Taqman PCR assay determining miR-130b levels in MEFs of 
indicated genotypes transfected with either vector (v) or TAp63γ overepxression plasmid B) 
Quantitative real time Taqman PCR assay determining miR-130b levels in MEFs infected with 
Adenoviral-GFP (TAp63
fl/fl
) or Adenoviral-Cre (TAp63 
Δ/Δ
). Experiments done in triplicate. 
Error bars indicate s.e.m. Asterisk indicated statistical significance, p≤0.05. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.23. Loss of miR-130b causes increase in invasion 
Further to test whether this regulation was relevant to the metastatic phenotype seen in  
the tumors, we assessed the ability of the wild-type and TAp63
 -/-
 MEFs to migrate and invade 
after downregulation of miR-130b. With the help of a lentiviral shRNA, we downregulated the 
expression of miR-130b in wild-type cells and tested their invasion and migration by Boyden 
chamber assay. Taqman quantitative real-time PCR was performed to quantify the levels of 
miR-130b. miR-130b level was 50% lower in these cells compared to the wild-type (Figure 
24A) . When assayed for migration and invasion in the Boyden chamber assay, these cells 
about 1.5 fold increase in their invasiveness compared to the wild-type vector only control 
cells (Figure 24B). This suggests loss of miR-130b alone can increase invasion of cells 
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Figure 24: Loss of miR-130b causes an increase in invasion 
A) MEFs treated with lentiviral scramble control (sc) or lentiviral shRNA for miR-130b 
(sh130b). B) Invasion assay with wild-type cells treated with scramble, miR-130b shRNA 
treated MEFs and TAp63
 -/-
 MEFs. Experiments done in triplicate. Error bars indicate s.e.m. 
Asterisk indicated statistical significance, p≤0.05. 
Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.2.24. Dicer and miR-130b coordinately regulate invasion and migration 
To further analyze if there was a co-operation between Dicer and miR-130b in the 
induction of the invasive phenotype of cells and whether expressing both miR-130b and Dicer 
in TAp63
 -/-
 cells could reduce their invasion potential to wild-type levels, we modulated the 
levels of miR-130b and Dicer alone or in combination in TAp63
 -/-
 MEFs (Figure 25A-B). 
These cells were assayed for invasion migration with the Boyden chamber as before. We 
found that overexpression of miR-130b in these did not have an effect on their invasion 
potential possibly due to the low levels of Dicer present in these cells and therefore a lack of 
proper miRNA processing (Figure 25C). So we overexpressed both Dicer and miR-130b in 
these cells and assayed for their invasion potential. We found that when expressed in 
combination (Dicer and miR-130b) the level of invasion is even lower than when Dicer is 
expressed alone similar to wild-type levels (Figure 25C). This indicates a co-ordination 
between Dicer and miR-130b in the suppression of metastasis. Also TAp63 plays an important 
role in the suppression of metastasis by the co-ordinate regulation of Dicer and miR-130b. 
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Figure 25: Dicer and miR-130b coordinately regulate invasion and migration 
A & B) Quantitative real time PCR for Dicer and miR-130b in MEFs of the indicated 
genotypes expressing vector only (V), miR-130b (130b), Dicer (D) and miR-130b and Dicer 
together (130b+D). C) Invasion Assay with MEFs of the indicated genotypes expressing 
vector only (V), miR-130b, Dicer or both together. Experiments done in triplicate. Error bars 
indicate s.e.m. Asterisk indicated statistical significance, p≤0.05. 
 Reproduced with permission from the copyright clearance center, TAp63 suppresses 
metastasis through coordinate regulation of Dicer and miRNAs, Nature. 2010 Oct 
21;467(7318):986-90. doi: 10.1038/nature09459. 
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3.3. Discussion 
We have shown that TAp63 can regulate metastasis by the transcriptional regulation of 
individual microRNA (miR-130b) and Dicer and that this regulation is important in the 
suppression of metastasis in many tissues. The regulation of Dicer by TAp63 has global 
biological implications. MicroRNAs are involved in regulation of an array of different 
processes like cancer, differentiation (218-222), stem cell biology (223, 224), DNA damage 
response (225, 226), apoptosis (227, 228), senescence (229), regulation of other microRNAs 
(230),  and  also in diseases like diabetes (230), inflammatory diseases (231, 232) and many 
others . Dicer has been implicated in the processing of other small RNAs like siRNAs (233), 
Alu RNA and 7SL RNAs (Dicer-Dependent Biogenesis of Small RNAs Derived from 7SL 
RNA). Dicer has also been shown to play a role in the regulation of apoptosis in 
Caenorhabditis elegans. This seems to be an independent mechanism of Dicer that does not 
involve processing of microRNA. Dicer is processed by the caspase CED-3 in the worms 
giving rise to a C-terminal fragment with deoxyribonuclease activity. It can then digest the 
DNA and promote apoptosis (234). In primates since the Dicer protein function is conserved 
to a certain extent, this could potentially be a possible mechanism promoting apoptosis (234).   
Therefore TAp63 may play a role in all of these processes. TAp63 is a stress response protein 
similar to p53 in certain aspects of its mode of action. This would also suggest that there may 
be differences in Dicer regulation by TAp63 in an unstressed situation compared to a stressed 
scenario. This interaction will also need to be evaluated. Finally the feedback loop between 
Dicer, microRNAs and TAp63 will be an interesting aspect of this interaction as microRNAs 
have been also been shown in turn to regulate Dicer like let-7 (234) and p63 like miR-203 
(234-236). Taken these together it will be intriguing to find the interplay between these 
proteins and the microRNAs and ultimately their effects on the various biological processes. 
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4. Chapter 4: Induced multipotency in adult keratinocytes through down regulation 
of Np63 or DGCR8 
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4.1. Introduction 
 The factors required to reprogram adult somatic cells to induced pluripotent stem (iPS) 
cells is an area of intense research.  The introduction of defined factors, such as Oct4, Sox2, 
Klf4, and c-myc, gives rise to the efficient reprogramming of fibroblasts to iPS cells (92).   
Cells deficient for p53 also show enhanced ability for reprogramming with the addition of 
Oct4 and Sox2 only (127, 237-240).  Unfortunately, overexpression of oncogenes or down 
regulation of tumor suppressor genes while leading to the generation of cells that are 
pluripotent, can also lead to the production of tumorigenic cells (238).  Consequently, an 
alternative method for creating iPS cells or cells with stem-like properties from somatic cells is 
desirable.  Here, we show that one such method is through the down regulation of the p53 
family member, ΔNp63, or through downregulation of its transcriptional target, DGCR8, in 
adult keratinocytes.   
Both miRNAs and the p53 family member, p63, have been implicated in processes that 
control stem cell proliferation and cell fate determination (30, 66, 67, 72, 241).  As 
demonstrated using genetically engineered mice, p63 is critical for the development and 
maintenance of stratified epithelial tissues (30, 66). Mice lacking p63 cannot form skin, have 
craniofacial and skeletal defects and die within hours after birth. These defects are partially 
due to the functions of p63 as a transcriptional regulator of genes involved in multiple 
processes in skin development including epithelial stem cell proliferation, differentiation, and 
adhesion (67, 75, 242-244).  While it is clear that p63 plays a crucial role in epidermal 
morphogenesis, its roles as an essential gene in stem cell proliferation and/or differentiation 
are still not well understood.  The controversial roles of p63 in epidermal development are due, 
at least in part, to the complexity of the gene and existence of multiple isoforms (245).  There 
are two major isoforms, those with a transactivation domain (TAp63) that structurally resemble 
p53 and those lacking this domain (ΔNp63); however, ΔNp63 also transcriptionally regulates 
unique target genes shown to be involved in limb and epidermal morphogenesis (75, 246).    
To determine the roles of these isoforms in skin development and maintenance, we and 
others have constructed isoform specific conditional knock out alleles of p63. Using the TAp63 
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conditional knock out mouse, we generated TAp63
 -/-
 mice and found that they age 
prematurely, develop blisters, and display wound-healing defects, which result from 
hyperproliferation of dermal stem cells resulting in premature senescence and depletion of 
these cells that are necessary for wound repair (72). While we found that TAp63 plays a critical 
role in maintaining adult stem cells, it is dispensable for epidermal morphogenesis.  This data 
along with work from other labs indicates that ΔNp63 is the critical isoform in the 
development of epithelial tissues (67, 72, 75, 247). 
To further study the role of ΔNp63 in skin development, we generated ΔNp63 
conditional knock out mice (ΔNp63fl/fl), allowing for deletion of ΔNp63 and retention of the 
TAp63 isoforms in any tissue of interest.  We then generated ΔNp63 knock out mice by 
intercrossing the ΔNp63 conditional knock out mice to germline specific cre transgenic mice 
(Zp3cre).  Surprisingly, in contrast to the skin of p63
 -/- 
mice, the ΔNp63 -/- mice developed a 
hyperproliferative, disorganized epidermis that expressed some markers of terminal 
differentiation similar to the phenotype observed in another mouse model deficient for ΔNp63 
(ΔNp63gfp/gfp) (247) or with in vivo siRNA knock down of ΔNp63α (75).  The ΔNp63gfp/gfp mice 
are born with a fragile epidermis that has accelerated differentiation in some areas of the 
epidermis and expression of K8 and K18 in other areas (247).  The mice expressing an siRNA 
to knock down ΔNp63α exhibited skin that is hyperproliferative and cells within the basal 
layer fail to exit the cell cycle (75).  These observations are similar to the phenotypes observed 
in our allele of the ΔNp63 -/- mice, which have areas of terminal differentiation in the 
epidermis, expression of K8 and K18, and hyperproliferative skin.    
We however have gone a step further and characterized the hyperproliferative skin of 
the ΔNp63 -/- mice.  Epidermal cells derived from the epidermis of ΔNp63 -/- mice had the 
ability to hyperproliferate and phenotypically resembled embryonic and induced pluripotent 
stem cells. Indeed, using a genome wide analysis, we found that epidermal cells deficient for 
ΔNp63 express Oct4, Sox2, Nanog, and other genes associated with pluripotency, suggesting 
that ΔNp63 is critical for silencing of these factors to induce terminal differentiation.  The 
DGCR8
 -/- 
embryonic stem cells (ESCs) were found previously to display a hyperproliferative 
defect by failure of silencing pluripotency genes (157), and the phenotype of the epidermis of 
ΔNp63 -/- mice is similar to the DGCR8 and Dicer conditional knockout mice with DGCR8 and 
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Dicer ablated in the skin (159, 194, 248).  Additionally, we previously identified TAp63 as a 
transcriptional activator of Dicer and hypothesized that ΔNp63 may similarly regulate 
enzymes required for microRNA biogenesis.  Indeed, we found that ΔNp63 transcriptionally 
activates DGCR8 and in turn regulates a unique miRNA signature critical for reprogramming. 
Murine ΔNp63 deficient epidermal cells had the capacity to hyperproliferate at late passages, 
expressed a miRNA signature that is similar to that of mouse embryonic and iPS cells, and 
could be differentiated into multiple cell fates in vitro and in vivo.  Additionally, ΔNp63 
deficient epidermal cells can be forced into a keratinocyte cell fate by re-expression of 
DGCR8.  We recapitulated this stem cell phenotype in normal human epidermal keratinocytes 
(NHEKs) by deletion of ΔNp63 or DGCR8.  Our data indicate that down regulation of ΔNp63 
or DGCR8 in cells derived from the epidermis are reprogrammed into stem cells that can be 
differentiated into multiple cell types.  
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4.2. Results 
4.2.1. Generation of a ΔNp63 conditional knock-out mouse model 
To delineate the role of ΔNp63 in vivo we generated a ΔNp63 conditional knock-out 
mouse model using the Cre-loxP system. This allows for tissue specific deletion of the ΔNp63 
isoform when crossed to a transgenic tissue specific Cre mouse and retention of the TAp63 
isoform. LoxP sites were inserted flanking exon 3’ (Figure 26A). This exon contains the 
transcriptional start site of the ΔNp63 protein. Southern blotting analysis was performed to 
confirm proper targeting (Figure 26B). 
 To understand the role that ΔNp63 plays in skin development, we crossed the ΔNp63 
conditional knock-out mice to FLPeR transgenic mouse to exclude the neomycin cassette ref. 
These mice were then crossed to the female germline-specific cre transgenic mice (Zp3-Cre) to 
generate the ΔNp63 +/- mice. These mice were intercrossed to obtain the ΔNp63  -/- mice. We 
found that these mice are born in proper Mendelian ratios, but die a few hours after birth. 
Genotyping PCR determined the genotypes of the mice (Figure 26C). Quantitative real-time 
PCR was performed on RNA derived from E9.5 embryos and from the skin of E18.5dpc 
embryos (Figure 26D). We further verified the absence of ΔNp63 RNA and protein from 
embryo and the skin of the embryos while retaining wild-type levels of TAp63 mRNA (Figure 
26 E-F). 
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Figure 26: Generation of a conditional ΔNp63 knock-out mouse model 
A) The ΔNp63 targeting vector was generated by inserting loxP sites (triangles) flanking exon 
3’and a neomycin cassette (neo) flanked by frt sites (squares). Location of primers used for 
genotyping is indicated by arrows. The targeted region of the allele is depicted by a dashed 
yellow line. Flox neo (fn) mice were crossed to the FLPeR mice expressing the flp 
recombinase to delete the neo cassette in vivo and to generate the flox (fl) allele. The knock 
out (KO) allele is shown after cre recombination. B) Southern analysis of genomic DNA from: 
ΔNp63fn/+, ΔNp63fn/fn, ΔNp63 +/+ and ΔNp63 -/- mice. C) PCR analysis of genomic DNA 
from: ΔNp63fl/+, ΔNp63fl/fl, ΔNp63 +/+ and ΔNp63 -/- mice. D) Quantitative (q) RT PCR analysis 
of ΔNp63 mRNA from E9.5 and E18.5 wild-type and ΔNp63 -/- embryos. Asterisks indicate 
statistical significance,(p<0.001). E) Western blot analysis for ΔNp63 using epidermal cells 
derived from wild-type and ΔNp63 -/- embryos (E18.5) (left panel) and p53 -/-;p63 -/- MEFs 
expressing ΔNp63α and ΔNp63β cDNAs. Actin was used as a loading control. F) qRT-PCR 
analysis of TAp63 mRNA from E9.5 and E18.5 wild-type and ΔNp63 -/- embryos. qRT-PCR 
values are normalized to GAPDH. 
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4.2.2. Phenotype of the ΔNp63 mutant mice 
The ΔNp63 -/- mice had phenotypic resemblance to the p63 -/- mice and the ΔNp63gfp/gfp 
mice. The mice lacked limbs and had cleft lip and palate (Figure. 27D). These mice develop a 
rudimentary fragile epidermis, which lacks proper adhesion to the dermis (Figure 27C). 
Therefore during birth this epidermal layer easily detaches. The death of the ΔNp63 -/- mice is 
mainly due to dehydration and desiccation from the loss of an intact epidermal layer. 
Microscopic analysis of the epidermis from E18.5dpc embryos by hematoxylin and eosin 
staining demonstrated partial stratification of the epidermis with clusters of basal epidermal 
cells that were apparent in patches over 20%-30% of the embryo (Figure 27C). On the 
contrary the wild-type embryos have a perfectly stratified epithelium (Figure 27A) and the 
total p63
 -/-
 embryos are completely denuded (Figure 27D). Interestingly the ΔNp63 +/- 
embryos seemed to have excessive epidermal folding (Figure 27B). On analysis of the skin 
from the ΔNp63 +/- embryos displayed an expanded basal epidermal layer. 
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Figure 27: Phenotype of the ΔNp63 mutant mice 
Embryos at day E18.5 of the following genotypes: A) wild-type, (B) ΔNp63 +/-, (C) ΔNp63 -/-  
and (D)  p63
 -/-
 . Arrows in panel (B) indicate extra folds of skin and in panel (C) indicate non-
adherent skin. E-H) Hematoxylin and eosin (H&E) stained cross sections of the skin of E18.5 
embryos of the indicated genotypes.  
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4.2.3. ΔNp63 
-/-
 mouse epidermis displays defects in terminal differentiation 
Since the ΔNp63 +/- and ΔNp63 -/- embryos had expanded disorganized epidermis, we 
hypothesized that loss of ΔNp63 could lead to a loss of proper differentiation in the epidermal 
layer from these mice. In an attempt to characterize the differentiation potential of the 
epidermal cells, we immunostained the epidermis from the ΔNp63 +/- and ΔNp63 -/- embryos 
and compared them to the epidermis from wild-type and p63
 -/-
 embryos (Figure 28A-B’). We 
performed immunofluorescence staining with markers for epidermal differentiation assessing 
the expression of keratin 5(K5) and keratin 14(K14) for the basal layer, keratin 10(K10) and 
keratin 1(K1) for the spinous layer and filaggrin (Fila) in the granular layer (Figure 28A-T). 
All marker of terminal differentiation was expressed in the wild-type embryos (Figure 
28A,E,I,M) while all these marker expression was absent in the p63
 -/-
 embryos (Figure 
28D,H,L,P), which does not possess any epidermis. Curiously both ΔNp63 -/- and ΔNp63 +/- 
epidermis expressed all the markers for terminal differentiation (Figure 28B,F,J,N & 
28C,G,K,O). In the ΔNp63 +/- mice, there was an expansion in the expression of these markers 
almost giving an impression that the layers were several cell layers thick and merged into the 
next more differentiated layer (Figure 28B,F,J,N). There was inappropriate expression of 
these markers in the epidermis from the ΔNp63 -/- embryos as well (Figure 28C,G,K,O). K5 
and K14 markers expression was found in multiple layers of the epidermis in contrast to the 
wild-type embryos where the expression of these markers were restricted to the basal layer 
(Figure 28A,E). The ΔNp63 -/- embryos also expressed K10 and Filaggrin in several patches 
throughout the epidermis (Figure 28G,K). Expression of these markers were present only 5%-
10% of the embryos suggesting a failure to terminally differentiate in the absence of ΔNp63. 
Given the apparent disorganization of the epidermis from the ΔNp63 mutant mice, we 
investigated whether cells in the epidermis expressed multiple differentiation markers 
simultaneously. We performed double immunostaining for an early basal marker like K14 and 
a later spinous marker like K10 (Figure 28Q-T). Surprisingly we found that in the ΔNp63 +/- 
and ΔNp63 -/- embryos there was a high percentage cells demonstrating overlapping expression 
of the differentiation markers (Figure 28B’-C’). This indicates that ΔNp63 is required for 
proper differentiation of the epidermis.  
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Because of the appearance of the basaloid cells in the skin from the ΔNp63 +/- and 
ΔNp63 -/- embryos, we investigated the expression of keratin 8(K8) and keratin 18(K18) 
markers of the simple epithelia. While we found very few positive cells in the wild-type skin 
(Figure 28U&Y), skin from the ΔNp63 +/- (Figure 28V&Z) and ΔNp63 -/- (Figure W&A) 
embryos had many areas of positive cells expressed in layers above the basal epithelium. The 
p63
 -/-
 embryos did not have any positively stained cells (Figure 28X&B’). 
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Figure 28: ΔNp63 mutant mice exhibit epidermal abnormalities and defects in terminal 
differentiation 
A-B’) Immunofluorescence (IF) or immunohistochemistry (IHC) of skin from day E18.5 
embryos of the indicated genotypes.  Antibodies used are as follows: (A-D) keratin 5 (K5), (E-
H) keratin 10 (K10), (I-L) keratin 1 (K1), (M-P) filaggrin (Fila), (Q-T) keratin 14 (K14) 
(green) and K10 (red), (U-X) keratin 8 (K8), and (Y-B’) keratin 18 (K18).  DAPI was used as 
a counterstain for IF and hematoxylin was used for IHC.  Magnification 400X.  Black 
arrowheads indicate examples of K8 positive cells in the basal layer (U). White arrowheads 
indicate examples of K18 positive cells in the basal layer (Y). Yellow arrows indicate 
examples of K8 or K18 positive cells in the spinous layer (V, W, Z, & A’).  C’-H’) Double 
immunofluorescence using skin from E18.5 day embryos of the indicated genotypes. 
Magnification 400X. Asterisks indicate statistical significance, (p<0.001).  The dashed lines 
denote the dermal/epidermal interface. 
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4.2.4. Loss of ΔNp63 results in hyperproliferation of the epidermis  
The presence of an expanded epidermis in ΔNp63 mutant mice suggested that cells 
within this tissue are hyperproliferative. To determine whether there was an over proliferation 
of epidermal cells in the skin of ΔNp63 +/- and ΔNp63 -/- embryos, we injected pregnant ΔNp63 
+/-
 female mice carrying wild-type, ΔNp63 +/- and ΔNp63 -/-embryos with bromodeoxyuridine 
(BrdU) to mark cells in S-phase of the cell cycle. By performing double immunofluorescence 
for BrdU and K5 (Figures 29A-C) or BrdU and K10 (Figures 29D-F), we found that the skin 
of E18.5 dpc ΔNp63 +/- and ΔNp63 -/- embryos have hyperproliferative and expanded basal and 
spinous layers as evidenced by the simultaneous expression of K5 and BrdU (Figures 29G) 
and K10 and BrdU (Figures 29H), respectively. 
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Figure 29: Loss of ΔNp63 results in hyperproliferation of the epidermis 
A-F) Immunofluorescence staining for anti-keratin 5, keratin 10 and bromodeoxyuridine. 
Antibodies used are as follows: (A-C) keratin 5 (K5, red) and bromodeoxyuridine (BrdU, 
green) and (D-F) keratin 10 (K10) (red) and bromodeoxyuridine (BrdU, green).  DAPI was 
used as a counterstain. A-C) White arrowheads indicate examples of BrdU positive cells in the 
basal layer. E&F) Yellow arrows indicate examples of BrdU positive cells in the K10 
expressing spinous layer G) Percentage of K5 positive cells expressing BrdU.  H) Percentage 
of K10 positive cells expressing BrdU.  Asterisks indicate statistical significance, (p<0.001).  
The dashed lines denote the dermal/epidermal interface. 
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4.2.5. ΔNp63 deficient epidermal cells can self-renew 
Due to presence of an expanded basal layer and the expression of K8 and K18, which 
are one of the earliest embryonic genes expressed in both mouse ES cells and human ES cells, 
we investigated whether these cells can self-renew. ΔNp63fl/fl (wild-type) and ΔNp63Δ/Δ 
(ΔNp63 deficient) epidermal cells were serially passaged and stained with rhodamine B to 
score for the morphology of epidermal clones (Figure 30A). We scored for the shape, size, 
and number of clones formed by each genotype. Large, round clones are indicative of a more 
stem-like morphology. Indeed, the number of large, round clones was greater in ΔNp63 
deficient epidermal cells. To quantify the proliferative capacity of these clones, we labeled 
wild-type and ΔNp63 -/- clones with BrdU after serial passaging (passages 1 through 5). We 
then performed double immunofluorescence using anti-BrdU and anti-K5 antibodies (Figure 
30B). Colonies of wild-type epidermal cells were initially proliferative (passage 1) but by 
passage 5 greater than 75% of these colonies incorporated very little BrdU (Figures 30B & 
C), indicating an inability to self-renew beyond passage 5. In contrast, colonies derived from 
ΔNp63Δ/Δ epidermal cells incorporated high levels of BrdU even at passage 5 (Figures 30B & 
C), indicating the ability to self-renew. 
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Figure 30: ΔNp63 deficient epidermal cells can self-renew 
A) Epidermal colonies from wild-type and ΔNp63 deficient epidermal cells (Δ/Δ) cultured on 
J2 3T3 feeder layers and stained with rhodamine B.  Passages 1 (P1), 3 (P3), and 5 (P5) are 
shown.  B) Immunostaining for BrdU (green) and K5 (red) in passage 3 and 5 wild-type 
(ΔNp63fl/fl) and ΔNp63 Δ/Δ epidermal cells.  DAPI (blue) was used as a counterstain. White bar 
indicates 100 µm.  C) Quantification of BrdU incorporation in colonies after 8 days in culture.  
Passages 1, 3, and 5 are shown.  Experiments performed in triplicate.  Asterisks indicate 
statistical significance (p-value <0.001).  
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4.2.6. ΔNp63 deficient epidermal cells express high levels of factors associated with 
induced pluripotency 
Based on the remarkable ability of the ΔNp63 -/- and ΔNp63Δ/Δ cells to proliferate over 
several serial passages and also based on the stem cell like morphology, we performed 
immunofluorescence staining for Oct-4, Nanog and stage specific embryonic antigen 1(SSEA-
1). Indeed we found that ΔNp63 -/- epidermal cells express Oct-4, Nanog and SSEA 1 at levels 
comparable to mouse induced pluripotent stem cells (miPS
Yam
) generated by introduction of 
the Yamanaka factors while wild-type keratinocytes (WT-KC) do not express these markers 
(Figure 31). These data indicate that ΔNp63 -/- epidermal cells express factors associated with 
induced pluripotency. 
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Figure 31: ΔNp63 deficient epidermal cells express high levels of factors associated with 
induced pluripotency 
 Immunofluorescence (IF) performed with the indicated antibodies on mouse iPS cells 
(iPS
Yam
), ΔNp63 -/- epidermal cells, or wild-type keratinocytes (WT-KC) using the indicated 
antibodies.  DAPI (blue) was used as a counterstain. Magnification 400X. Experiments were 
done in triplicate.  
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4.2.7. DGCR8 expression is low in ΔNp63 mutant cells and ΔNp63 
-/-
 epidermis 
Previously we have shown that TAp63 transcriptionally regulates Dicer, which is a 
critical regulator of the microRNA biogenesis pathway. To investigate whether ΔNp63 too 
plays a role in the regulation of the microRNA biogenesis pathway, we determined the mRNA 
levels of the three main important proteins in the microRNA pathway, Drosha, DGCR8 and 
Dicer (Figure 32A). We found DGCR8 level was specifically downregulated in the ΔNp63 -/- 
epidermal cells compared to wild-type keratinocytes (Figure 32A-B). Interestingly we found 
the expression of DGCR8 to be unaffected in the TAp63
 -/-
 epidermal cells (Figure 32B).  
We went on to test whether the epidermis from the ΔNp63 -/- embryos demonstrate a 
lack of DGCR8 protein expression. We performed immunostaining for DGCR8 in the 
epidermal tissue of the ΔNp63 -/- and wild-type embryos and found the expression of DGCR8 
to be absent in the epidermis of ΔNp63 -/- embryos (Figure 32C). In the wild-type embryos 
DGCR8 expression was high in the basal layer of the epidermis and in the hair follicles. 
 qRT-PCR and western blot analysis with anti ΔNp63 or DGCR8 antibody with RNA 
and protein lysates from wild-type, ΔNp63 +/- and ΔNp63 -/- epidermal cells showed low 
expression level of ΔNp63 and DGCR8 in the ΔNp63 +/- and ΔNp63 -/- cells (Figure 32D-F). 
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Figure 32: DGCR8 expression is low in ΔNp63 mutant cells and ΔNp63 
-/-
 epidermis 
 A) qRT-PCR for Dicer, DGCR8 and Drosha using total RNA from wild-type (WT) and 
ΔNp63 -/- (ΔN -/-) epidermal cells. B) qRT-PCR for DGCR8 using total RNA from wild-type 
(WT), ΔNp63 -/- (ΔN -/-) and TAp63 -/- epidermal cells. C) Immunohistochemistry using an 
antibody for DGCR8 on skin samples from day E18.5 wild-type and ∆Np63 -/- mouse embryos. 
D) qRT-PCR for ΔNp63 in wild-type, ΔNp63 +/- and ΔNp63 -/- RNA from epidermal cells. E) 
qRT-PCR for DGCR8 wild-type, ΔNp63 +/-  and ΔNp63 -/-  RNA from epidermal cells. F) 
Western blot analysis with anti DGCR8 antibody with protein lysates from wild-type, ΔNp63 
+/-
 and ΔNp63 -/- epidermal cells. Each bar represents the average of the fold activation of three 
independent experiments. The asterisks indicate statistical significance (p-value <0.001). 
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4.2.8. ΔNp63 transcriptionally activates the DGCR8 promoter 
To determine whether DGCR8 is a direct transcriptional target of ΔNp63, we 
performed chromatin immunoprecipitation (ChIP) analysis using p63 antibodies and primers 
specific for two putative p53/p63 binding sites that we identified within intron 1 of the DGCR8 
promoter (Figure 33B). We found that p63 robustly binds to one of these sites (site 1) (Figure 
33A). We also tested the ability of p53 to bind to site 1 and could not detect any significant 
binding, indicating that DGCR8 is a unique p63 target gene.  
To determine whether p63 isoforms can transactivate a DGCR8-luciferase reporter 
gene, we cloned the site bound to p63 in the ChIP assay (site 1) into a vector containing the 
luciferase reporter gene. We co-transfected the DGCR8-luciferase reporter gene (dgcr8 S-luc) 
(Figure 33C) and each p63 isoform individually (TAp63α, β, γ or ΔNp63 α, β, γ) into p53 -/-
;p63
 -/-
 mouse embryonic fibroblasts (MEFs). Only the ΔNp63 isoforms could transactivate the 
reporter gene with ΔNp63α and β exhibiting the highest transactivation activity (Figure 33C). 
To determine whether the cloned p63 binding site is critical for transactivation of the DGCR8-
luciferase reporter gene, we mutated the p63 consensus site from (ctgCATGtat ctcctaaga 
agcCTTGcca) to (ctgTTTTtat ctcctaaga agcTTTTcca) using site-directed mutagenesis (Figure 
33C). None of the p63 isoforms transactivated the mutant DGCR8 reporter gene (dgcr8 Sm-
luc) (Figure 33C), indicating that ΔNp63 transcriptional activates DGCR8 by binding to site 1.  
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Figure 33: ΔNp63 transcriptionally activates the DGCR8 promoter 
A) qRT-PCR of ChIP assay using wild-type (WT) and ΔNp63 -/- (ΔN -/-) epidermal cells and 
indicating p63-binding site (site 1) or no binding of p63 to site 2 or non-specific binding site 
(NSBS).  B) Schematic showing DGCR8-site 1 (dgcr8 S) and DGCR8- mutant of site 1 (dgcr8 
Sm) luciferase reporter genes. C) Luciferase assay for DGCR8 in p53
 -/-
;p63
 -/-
 MEFs 
transfected with the indicated p63 isoforms and the indicated luciferase reporter gene. Each 
bar represents the average of the fold activation of three independent experiments. The 
asterisks indicate statistical significance (p-value <0.001).  
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4.2.9. ΔNp63 represses Oct-4, Sox-2 and Nanog through transcriptional regulation of 
DGCR8 
DGCR8 has been shown to be a critical repressor of Oct-4, Sox-2 and Nanog 
expression, which are critical factors in the maintenance of pluripotency.  To determine 
whether the ΔNp63 -/- epidermal cells regulate expression of Oct-4, Sox-2 and Nanog through 
DGCR8, we performed immunoblotting using lysates from mouse induced pluripotent cells, 
reprogrammed with the Yamanaka factors (miPS
Yam
), mouse embryonic stem cells (mES), 
wild-type keratinocytes (WT-KC) and ΔNp63 -/- cells infected with doxycyline inducible 
DGCR8 construct, with or without the induction of DGCR8 (Figure 34). We found significant 
levels of expression of Sox-2 and Nanog in the ΔNp63 -/-, somewhat higher than the expression 
level in miPS cells and lower than the expression in mES cells. Expression of DGCR8 in the 
ΔNp63 -/- cells reduced the expression of Sox-2 and Nanog in these cells.  Oct-4 expression 
level was much lower in the ΔNp63 -/- epidermal cells compared to mES and miPSYam cells. 
The expression of Oct-4 was also reduced on expressing DGCR8. This data indicates that 
ΔNp63 -/- epidermal cells express markers of pluripotency, which are under the regulation of 
DGCR8. This suggests the differentiation defects seen in these cells is possibly due to the lack 
of expression of DGCR8 in these cells, which maintains the cells in an undifferentiated state 
(Figure 34). 
Because cells deficient for p53 have been shown to have an enhanced ability to be 
reprogrammed, we investigated whether these cells have lower levels of p53. We found that 
p53 expression in these cells remains undisturbed and the expression is comparable to wild-
type cells, mES and miPS
Yam
 cells (Figure 34). This suggests that the expression of these 
pluripotency markers is not dependent on the p53 status. We also assayed for the ΔNp63 
expression and found ΔNp63 to be robustly expressed in the wild-type cells, but not in mES 
and miPS
Yam
 cells indicating that pluripotent stem cells do not express ΔNp63 and further that 
ΔNp63 is required for terminal differentiation.  
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Figure 34: ΔNp63 represses Oct-4, Sox-2 and Nanog through transcriptional regulation 
of DGCR8 
 Western blot analysis of mouse embryonic stem cells (mES), mouse induced pluripotent stem  
cells (miPS
Yam
), wild type mouse keratinocytes (WT-KC) and ΔNp63 -/- epidermal cells 
infected with doxycycline inducible DGCR8 treated with doxyccyline (+) or without 
doxycycline (-) using the indicated antibodies. Arrow indicates Oct4 specific band. Asterisk 
indicates non-specific band.  Upper Oct4 blot is a longer exposure of the one immediately 
below it.  Actin was used as loading control. 
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4.2.10. ΔNp63 
-/-
 epidermal cells, iPS cells and mouse ES cells have a similar microRNA 
and mRNA signature 
Because we found that ∆Np63 transcriptionally activates DGCR8, we determined the 
expression of miRNAs and mRNAs in the ∆Np63 -/- epidermal cells using miRNA-Seq and 
RNA-Seq experiments.  Importantly, there are critical microRNAs that have been shown to 
reprogram cells, such as miR-302 (249).  To determine the miRNA signature of the ∆Np63 -/- 
epidermal cells, we performed miRNA-Seq experiments on RNA isolated from ∆Np63 -/- 
epidermal cells and compared them to wild-type keratinocytes, iPS
Yam
, and mouse ES cells 
(Figure 35).  Using Pearson’s Correlation Analysis, we found that the  
∆Np63 -/- epidermal cells clustered with mouse iPSYam and ES cells (Figure 35 and Appendix 
1).  We then identified an iPS signature, which included mouse iPS
Yam, ES, and ∆Np63 -/- 
epidermal cells (Figure 36 and Appendix 2) using supervised hierarchical clustering. We also 
performed mRNA-seq analysis with the same set of RNA from the same cell lines (Figure 37 
and Appendix 11 ) We next performed miRNA-RNA functional pair analysis (Figure 36 and 
Appendix 3 and 4) using our miRNA-Seq and RNA-Seq data (184).  Among the significantly 
upregulated miRNAs in ∆Np63 -/- epidermal cells, iPSYam and ES cells were miR-290, miR-
295, and miR-302, miRNAs that have been found to be critical for reprogramming (191) or 
upregulated in iPS cells reprogrammed with the Yamanaka factors (250)  (Figure 36 and 
Appendix 2).  In addition, we found a number of miRNAs that were significantly down 
regulated in the ∆Np63 -/- epidermal cells, iPSYam and ES cells including miR-200a, miR-200b, 
miR-200c, miR-141, miR-203, miR-205, and miR-15b (Figure 36 and Appendix 2).  We also 
found a set of eighteen miRNAs using miRNA-mRNA pair analysis (184) that were most 
significantly up or down regulated in the ΔNp63 -/- epidermal cells that also matched the 
expression pattern of miRNAs in mouse ES and mouse iPS
Yam
 cells (Table 6. and Appendix 
3 and 4). Lastly, we performed Gene Ontology using the miRNA-mRNA pairs and DAVID 
software (Figure 38 and Appendix 5).  We identified genes involved in multiple pathways 
including proliferation, differentiation, and development (Figure 38). 
 To determine whether these microRNAs are regulated in ∆Np63 -/- epidermal cells 
through DGCR8, we expressed DGCR8 in ∆Np63 -/- epidermal cells cultured in keratinocyte 
media (Figure 36).  Importantly, we found that the miRNA signature from these cells 
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clustered with that of wild-type keratinocytes (Figure 35 & 36 and Appendices 1 & 2) 
indicating that the critical miRNAs for pluripotency in these cells is controlled through 
DGCR8.  
 There were also a number of miRNAs that were differentially regulated in ∆Np63 -/- 
epidermal cells that were distinct from the published ES and iPS miRNA profiles indicating 
that ΔNp63 -/- epidermal cells have a unique miRNA signature that poises them for 
pluripotency (Figure 35, Figure 39 and Appendices 1 & 10). 
 RNA-Seq using RNA isolated from wild-type mouse keratinocytes, ∆Np63 -/- 
epidermal cells, miPS
Yam
 and mES cells revealed that the gene expression signature of the 
∆Np63 -/- epidermal cells most closely resembled the miPSYam and mES cells (Figure 37 and 
Appendix 11).   These data suggest that factors other than high expression of Oct4, Sox2, and 
Nanog are critical for reprogramming in cells deficient for ∆Np63. 
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Figure 35: Pearson’s Correlation Analysis from miRNA-Seq 
Pearson’s Correlation Analysis from miRNA-Seq performed using cells of the following 
genotypes: wild-type mouse keratinocytes (Keratinocytes 1, 2), mouse ΔNp63 -/- epidermal 
cells (ΔNp63 -/- 1, 2, 3), mouse ΔNp63 -/- epidermal cells expressing DGCR8 (ΔNp63 -/-1 and 2 
+ DGCR8)  mouse iPS cells generated from fibroblasts using the Yamanaka factors (miPS
Yam
), 
and mouse embryonic stem cells (mES).    
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Figure 36: Heat map showing supervised hierarchical clustering from mouse miRNA seq 
Heat map showing supervised hierarchical clustering of the samples shown in (Figure 35). 
Low miRNA expression is indicated in green and high expression in red for both (Figure 35) 
and (Figure 36).  Boxes marked in black indicate miRNAs that were most significantly up- or 
down- regulated in the ∆Np63/iPS cell signature.  The signature that was found to be most 
highly significant is boxed in black.  
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Figure 37:  Unsupervised and supervised clustering for mRNA-seq mouse 
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Table 6: miRNA-mRNA functional pair analysis 
 
miRNA-mRNA functional pair analysis using the samples shown in (A).   
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Figure 38: Gene Ontology using DAVID software 
Gene Ontology using DAVID software of the miRNA-mRNA functional pair analysis shown 
in (Table 6). 
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Figure 39: Supervised miR-seq clustering with the data from Figure 35 showing 
differences between  ΔNp63 
 -/-
 and miPSYam. 
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4.2.11. ΔNp63 deficient epidermal cells can be differentiated into multiple cell fates in 
vitro  
High levels of Oct4, Sox2, and Nanog in ΔNp63 -/- and ΔNp63Δ/ Δ epidermal cells and 
their apparent morphology suggested that these cells are pluripotent. To determine whether the 
epidermal cells deficient for ΔNp63 are pluripotent and could differentiate into different cell 
fates, we cultured ΔNp63Δ/Δ cells under conditions permissive for keratinocyte or neuronal 
differentiation. Because differentiation of ΔNp63 deficient epidermal cells is dependent on 
expression of DGCR8, we cultured ΔNp63Δ/Δ epidermal cells expressing DGCR8 in 
keratinocyte differentiation media and found that cells exhibited a differentiated morphology 
(compare Figures 40A &B) and expressed markers of keratinocyte differentiation, similar to 
levels expressed in wild-type keratinocytes (Figure 40D).  
When we cultured ΔNp63Δ/Δ epidermal cells expressing DGCR8 in neuroectodermal 
media, these cells displayed a neuronal morphology (Figure 40C). Importantly, these cells 
expressed nestin and NeuN, markers of neuronal differentiation (Figure 40E).  
Furthermore when the ΔNp63Δ/Δ cells and ΔNp63 -/- epidermal cells with or without 
the expression of DGCR8, were cultured under conditions permissive for embryoid body 
formation, they all formed embryoid body like structure (Figure 41A-D). On validation of the  
differentiation marker expression for ectoderm-nestin, mesoderm-brachyury and endoderm-
alpha-feto protein (AFP) , we found that the embryoid bodies expressing DGCR8 had a higher 
level of expression of these differentiation markers, compared to the ΔNp63 deficient 
embryoid bodies which did not express DGCR8. Embryoid bodies from mES cells were used 
as positive control for these marker expressions (Figure 41E-G). 
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Figure 38: ΔNp63 deficient epidermal cells are pluripotent 
A-D) ΔNp63 deficient epidermal cells (Δ/Δwith or without DGCR8 (pDGCR8) cultured under 
the following conditions: (A) keratinocyte media (Low Ca
2+
), (B) keratinocyte differentiation 
media (High Ca
2+
), and (C) neuroectodermal media. D) Western blot analysis of epidermal 
cells cultured in keratinocyte differentiation media of the indicated genotypes with 
(+pDGCR8) or without (-pDGCR8) DGCR8 and using the antibodies shown.  Actin was used 
as a loading control.  E) qRT-PCR for nestin and NeuN using total RNA from epidermal cells 
of the indicated genotypes cultured in neuroectodermal media. Magnification at 200x. 
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Figure 39:  ΔNp63  deficient cells can form embryoid bodies 
A-D) Embryoid bodies from cells of the indicated genotypes: A) Embryoid body from mouse 
embryonic stem cells. B) Cell clump from murine keratinocytes. C) ΔNp63  -/- cells infected 
with lentiviral DGCR8 with (+DGCR8) or without doxycycline (-DGCR8) form embryoid 
bodies D)  ΔNp63 d/d cells infected with lentiviral DGCR8 with or without DGCR8 form 
embryoid bodies. E-G) qRT-PCR for AFP from the embryoid bodies from mouse ES cells,  
ΔNp63  -/- cells and  ΔNp63 d/d infected with lentiviral DGCR8 treated with (+DGCR8) or 
without (-DGCR8) doxycycline. Experiments were done in triplicates. The asterisks indicate 
statistical significance (p-value <0.001).  
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4.2.11. ΔNp63 deficient epidermal cells are pluripotent and can differentiate into multiple 
cell fates in vivo 
  Our data thus far indicates that epidermal cells lacking ΔNp63 have characteristics of 
induced pluripotent stem (iPS) cells. To further determine whether ΔNp63 -/-epidermal cells are 
iPS cells, we asked whether cells lacking ΔNp63 could form teratomas after injection into 
mice.  Indeed, we found that ΔNp63 -/- epidermal cells can form poorly differentiated teratomas 
in mice and express markers of the ectoderm, mesoderm, and endoderm (Figure 42B,E,H). 
Moreover, we found that these ΔNp63 -/- teratomas express low levels of mesoderm -brachyury 
(Figure 42K), ectoderm-nestin (Figure 42N), and AFP (Figure 42Q). Because we found that 
the terminal differentiation of ΔNp63 -/- epidermal cells depends on the expression of DGCR8 
(Figure 34), we transduced ΔNp63 -/-epidermal cells with a tetracycline inducible DGCR8 
vector. These cells were injected into mice, were allowed to form tumors for four weeks, and 
fed doxycycline for two weeks. The ΔNp63 -/-epidermal cells expressing DGCR8 form well-
differentiated teratomas (Figure 42B-H) that express markers of the mesoderm (Figure 42L), 
ectoderm (Figure 42O), and endoderm (Figure 42R). Expression and structures apparent in 
ΔNp63 -/- epidermal cells expressing DGCR8 is similar to that of wild-type mES cells (Figure 
42A-P). These data indicate that ΔNp63 -/-epidermal cells are iPS cells that can be 
reprogrammed into multiple cell fates.  
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Figure 40: ΔNp63 deficient epidermal cells can form teratomas 
A-C) Immunohistochemistry (IHC) using an antibody for DGCR8 on teratomas of the 
indicated genotypes. (200X magnification) and insets (400X magnification).  Arrows in insets 
point to examples of positive cells.   D-I) Hematoxylin and eosin (H&E) stained cross sections 
of teratomas derived from wild-type mouse embryonic stem cells (D & G), ∆Np63 -/- 
epidermal cells (E & H), and ∆Np63 -/- epidermal cells expressing DGCR8 (F & I). (J-R) 
Immunofluorescence (IF) of teratomas of the indicated genotypes using the indicated 
antibodies. DAPI (blue) was used as counterstains. Magnification 200X 
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4.2.12. Generation of chimeric mouse embryos from  ΔNp63 
 -/-
 epidermal cells 
We next asked whether ΔNp63 -/- epidermal cells could contribute to tissues of the 
developing mouse. To determine this, we performed blastocyst injections using iPS
Yam 
expressing GFP and ΔNp63 -/- epidermal cells expressing GFP. Indeed we found that ΔNp63 -/- 
epidermal cells expressing GFP form high contribution chimeras (Figure 43C,D,H,I) 
comparable to what is seen with iPS cells created using the Yamanaka factors expressing GFP 
(Figure 43A,B,F,G). Cross sections through multiple tissues of chimeras generated from both 
iPS cell types revealed similar chimeric contribution (Figure 43K-N) as detected by anti-GFP 
immunostaining. The epidermis from the ΔNp63 -/- chimeric mice resembled the epidermis of 
ΔNp63 -/- and ΔNp63 +/- mice (Figure 44A-C). They showed hyperproliferation of K5 positive 
cells in the basal layer (Figure 44D-F). The epidermis also demonstrated overexpression of 
K8 and K18 positive cells similar to ΔNp63 -/- and ΔNp63 +/- mice epidermis (Figure 44G-L). 
We also performed a southern blot to eliminate the possibility of contamination of the ΔNp63 -
/-
 epidermal cells with the miPS
Yam   
cells with a probe targeted towards the Klf4 exon (Figure 
44M). The southern blot conclusively indicates that the ΔNp63 -/-cells are not contaminated. 
The chimeras generated from the ΔNp63 -/-epidermal cells exhibited post-natal lethality due to 
their similarity in phenotype to the ΔNp63 -/-mice. Like the ΔNp63 -/-mice, these chimeras also 
died few hours after birth due to the lack of proper skin formation from dehydration and 
desiccation.  Table. 7. summarizes the number of chimeras generated from the ΔNp63 -/-
epidermal cells and the control miPS cells generated by the Yamanaka factor infection of 
mouse fibroblasts. 
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Figure 41: Generation of chimeric mouse embryos from ΔNp63 
-/-
 epidermal cells 
A-E) Brightfield images of chimeric embryos at day 13.5 (E13.5) generated from mouse 
induced pluripotent stem cells expressing the Yamanaka factors and GFP (iPS
Yam
) (A&B) or 
ΔNp63 deficient epidermal cells expressing GFP (ΔNp63 -/-) (C&D).  (E)  E13.5 embryos from 
wild-type, non-chimeric mice.  F-J)  Fluorescent images of E13.5 chimeric embryos with GFP 
expressing tissues derived from the Yamanaka miPS cells (F & G) or ΔNp63 -/- epidermal cells 
(H&I).  J)  E13.5 embryos from wild-type, non-chimeric mice.  K-N) Immunofluorescence for 
GFP (green) in the brain (K) and gut (L) of E13.5 embryos generated from Yamanaka miPS 
cells expressing GFP (Yamanaka Factors) or in the brain (M) and gut (N) of E13.5 embryos 
generated from ΔNp63 -/- epidermal cells.  DAPI (blue) was used as counterstain.  
Magnification 200X 
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Figure 42: Analysis of ∆Np63 
 -/-
chimeras 
A-C) Hematoxylin and Eosin (H&E) stained cross sections of the epidermis from E18.5 
embryos of wild-type mice and ∆Np63 -/- chimeric mice.  D-L) Immunofluorescence (IF) or 
immunohistochemistry (IHC) of cross sections from wild-type and ∆Np63 -/- chimeras at day 
E18.5 stained with the indicated antibodies (200X magnification).  M) Southern blot analysis 
using genomic DNA extracted from mouse iPS cells reprogrammed with the Yamanaka 
factors (iPS
Yam) and ∆Np63 -/- epidermal cells.   A probe for Klf4 was used to indicate 
endogenous (endo) and exogenous (exo) Klf4 DNA.  
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Table 7: Embryos generated from iPS cells 
 
iPS cells # of blastocysts # of embryos @ E13.5 # of GFP +ve 
ΔNp63-/- 1 17 4 2 
ΔNp63-/- 2 12 3 1 
ΔNp63-/- 3 14 0 N/A 
ΔNp63-/- 4 15 1 0 
ΔNp63-/- 5 15 4 2 
ΔNp63-/- 6 20 0 N/A 
ΔNp63-/- 7 21 0 N/A 
iPS
Yam
 -1 14 0 N/A 
iPS
Yam
 -2 12 2 1 
iPS
Yam
 -3 16 9 4 
iPS
Yam
 -4 16 9 3 
iPS
Yam
 -5 21 6 2 
iPS
Yam
 -6 21 7 3 
 
ΔNp63-/-: epidermal cells derived from ΔNp63-/- mice 
iPS 
Yam 
:  mouse fibroblasts reprogrammed with Yamanaka factors 
E13.5:  embryonic day 13.5 
N/A: not applicable 
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4.2.13. Normal human epidermal keratinocytes can be induced to pluripotency by 
knockdown of ΔNp63 
To determine whether knockdown of ΔNp63 or DGCR8 could induce pluripotency in 
human epidermal keratinocytes. We knocked down ΔNp63 or DGCR8 in normal human 
epidermal keratinocytes (NHEKs) (Figure 45A & B). NHEKs with knock down of ΔNp63 or 
DGCR8 changed morphology (Figure 45 E & F). We started to notice small packed Tra-1-60 
positive colonies at 6 days in the shΔNp63 or shDGCR8   Colonies from NHEKs with knock 
down of ΔNp63 or DGCR8 appeared more packed than colonies formed from NHEKs (Figure 
45A) and more similar to human iPS colonies (hiPS) (Figure 45D). NHEKs with knock down 
of ΔNp63 (Figure 46A-E) or DGCR8 (Figure 46F-J) also expressed SSEA-4, Tra-1-60, Oct4, 
Sox2, and Nanog similar to the expression in hiPS cells (Figures K-O) while NHEKs alone do 
not express these markers of pluripotency (Figure P-T).  
Western blotting was performed on these cells with antibodies towards either ΔNp63 or 
DGCR8 to determine whether the lentiviral silencing was still maintained (Figure U&V). 
ΔNp63 and DGCR8 were still found to be down regulated. qRT-PCR was performed to verify 
levels of Oct-4, Sox-2 and Nanog in the NHEK-shΔNp63 (Figure W-Y) and NHEK-
shDGCR8 cells (Figure Z-B’). Levels of Oct-4 and Sox-2 and Nanog were found to high but 
varied in the different cell lines, suggesting that the reprogramming occurs at different levels 
in these different cell lines.  
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Figure 43: Reprogramming of NHEK cells by down regulation of ΔNp63 or DGCR8 
A-B) Western blot analysis of downregulation of ΔNp63 or DGCR8 in the NHEK cells. Actin 
was used as a loading control C-H) Phenotypes of the colonies of cells of the indicated 
genotypes. Magnification 400x. I) A cartoon representing the timing of reprogramming of the 
NHEK cells after knock down of ΔNp63 or DGCR8.  
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Figure 44: Characterization of NHEK-shΔNp63/DGCR8 cells 
A-T) Immunofluorescence (IF) using normal human epidermal keratinocytes (NHEK) infected 
with lentiviral shRNA for ΔNp63 (NHEK-shΔNp63) (A-E) or DGCR8 (NHEK-shDGCR8) (F-
J), fibroblasts infected with the Yamanaka Factors (Human iPS) (K-O), and NHEK cells and 
the indicated antibodies.  DAPI (blue) was used as counterstain. Arrows indicate examples of 
positive nuclei.  Magnification, 200X. 
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4.2.14. NHEK-ShΔNp63 /shDGCR8 cells can form teratomas 
We next asked whether these cells could form teratomas in SCID mice. Indeed, we 
found that these cells form differentiated teratomas with structures representing the endoderm 
(Figure 47A&E), mesoderm (Figure 47 B,C & F,G), and ectoderm (Figure 47D&H). 
Additional immunofluorescence for marker analysis revealed robust expression of AFP, 
brachyury, E-cadherin, and keratin 5 (Figure 47I-P) comparable to the expression in human 
iPS cells generated using the Yamanaka factors (Figure 47Q-T). Taken together, these data 
indicate human keratinocytes can be reprogrammed to different cells fates by knock down of 
ΔNp63.  
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Figure 45: NHEK-shΔNp63 /shDGCR8 cells can form teratomas 
A-H) Micrographs of hematoxylin and eosin stained cross-sections from teratomas generated 
using NHEK-shΔNp63 and NHEK-shDGCR8 cells indicating the structural diversity of the 
three embryonic layers as indicated.  Magnification, 200X. I-T) IF performed on cross-
sections of teratomas derived from NHEK-shΔNp63 cells (I-L), NHEK-shDGCR8 cells (M-P) 
or human iPS cells (Q-T) using the indicated antibodies.  DAPI (blue) was used as 
counterstain. Magnification, 200X.   
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4.2.15. ∆Np63 deficient mouse and human epidermal cells have a similar miRNA signature 
to mouse and human iPS cells reprogrammed with the Yamanaka factors 
 We performed microRNA-Seq using RNA isolated from NHEKs with knock down of 
ΔNp63 or DGCR8 (Figure 48A-C and Appendices 5,6 and 7). Interestingly, we found that the 
microRNA expression signature of these cells clustered with ΔNp63 -/-epidermal cells, 
miPSYam , and mES cells indicating that pluripotency can be induced by acute knock down of 
ΔNp63 or DGCR8 in human keratinocytes (Figure 48A and 48B and Appendices 5 and 6). 
Additionally, NHEKs with knock down of ΔNp63 or DGCR8 had a nearly identical micoRNA 
expression signature, indicating that cells deficient for ΔNp63 regulate the same genes in 
differentiation and stem cell specification as DGCR8 (Figure 48C and Appendix 7).  
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Figure 46: MicroRNA-seq data analysis in mouse and humans    
A-C) Bioinformatic analysis of a human to mouse comparison of microRNA-Seq data of the 
following genotypes: mouse embryonic stem cells (mES), mouse iPS cells generated from 
fibroblasts using the Yamanaka factors (miPS
Yam
), wild-type mouse keratinocytes 
((m)Keratinocytes 1, 2), normal human epidermal keratinocytes transduced with sh∆Np63 or 
shDGCR8 ((h)NHEKsh∆Np63 or (h)NHEKshDGCR8), human iPS cells generated from 
fibroblasts using the Yamanaka factors (hiPS
Yam
), and (h)NHEK cells.  Low miRNA 
expression is indicated in green and high expression in red.  Analyses shown are Pearson’s 
correlation analysis (A), Principal component analysis (B), and supervised hierarchical 
clustering (C).                          
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4.2.15. ∆Np63 deficient mouse and human epidermal cells have a similar mRNA 
signature to mouse and human iPS cells reprogrammed with the Yamanaka factors 
 We also performed mRNA-Seq using RNA isolated from NHEKs with knock down of 
ΔNp63 or DGCR8 (Figure 50). We performed Pearson’s correlation analysis between the 
mouse and the human cells to identify common targets required for the reprogramming process 
(Figure 49 A&B and Appendices 8 and 9), Interestingly, we found that the gene expression 
signature of these cells clustered with ΔNp63 -/-epidermal cells, miPSYam , and mES cells 
indicating that pluripotency can be induced by acute knock down of ΔNp63 or DGCR8 in 
human keratinocytes. Additionally, NHEKs with knock down of ΔNp63 or DGCR8 had a 
nearly identical micoRNA expression signature, indicating that cells deficient for ΔNp63 
regulate the same genes in differentiation and stem cell specification as DGCR8 as 
demonstrated by a cross-species comparison heat map analysis (Figure 50 and Appendix 12).  
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Figure 47: mRNA-seq data analysis in mouse and humans 
A-B) Bioinformatic analysis of a human to mouse comparison of mRNA-Seq data of the 
following genotypes: mouse embryonic stem cells (mES), mouse iPS cells generated from 
fibroblasts using the Yamanaka factors (miPS
Yam
), wild-type mouse keratinocytes 
((m)Keratinocytes 1, 2), normal human epidermal keratinocytes transduced with sh∆Np63 or 
shDGCR8 ((h)NHEKsh∆Np63 or (h)NHEKshDGCR8), human iPS cells generated from 
fibroblasts using the Yamanaka factors (hiPS
Yam
), and (h)NHEK cells.  Low mRNA 
expression is indicated in green and high expression in red.  Analyses shown are Pearson’s 
correlation analysis (A), Principal component analysis (B). 
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Figure 48: Unsupervised mRNA seq clustering comparing human and mouse cell line. 
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4.2.15. Deregulated microRNA processing in the NHEK-sh ΔNp63 /shDGCR8 cells 
demonstrated by Northern blot analysis 
We further validated miRNA expression using Northern blot analysis (Figure 51A-C) 
and found that there was an accumulation in the primary miRNAs in NHEKs expressing 
sh∆Np63 or shDGCR8 suggesting defects in miRNA processing to the precursor form due to 
low expression levels of DGCR8 in these cells.  
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Figure 49: Northern blot analysis in the NHEK-sh ΔNp63 /shDGCR8 cells 
Northern blot analysis of RNA from cells of indicated genotypes showing expression of 
primary, precursor, and mature miRNA-141 (A) and a short (B) and long exposure of miR-9 
(C). 
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4.3. Discussion 
Here, we show that deletion or knock down of ΔNp63 or DGCR8 in primary mouse and 
human epidermal keratinocytes, respectively, results in efficient reprogramming of cells with 
remarkable plasticity that can differentiate into multiple lineages of the mesoderm, endoderm, 
and ectoderm.  Mice with a germline deletion of ΔNp63 have a rudimentary, disorganized 
epidermis that forms around the developing mouse embryo and fails to completely terminally 
differentiate.  These epidermal phenotypes are reminiscent of mice lacking DGCR8 and Dicer 
expression in the skin (159, 248). Accordingly, ΔNp63 transcriptionally regulates DGCR8 and 
modulation of DGCR8 in ΔNp63 -/- epidermal cells represses the pluripotency factors, Oct4, 
Sox2, and Nanog (150, 251), and regulates a unique miRNA and mRNA signature in these 
cells. We also found that ΔNp63 -/- epidermal cells had a miRNA signature similar to that of 
ES cells and iPS cells (252-255).  Importantly, we found that acute deletion of ΔNp63 or 
DGCR8 in human keratinocytes resulted in pluripotent stem cells that resemble ES and human 
iPS cells and can be differentiated in vivo to express genes representative of the three 
embryonic germ layers.  This reprogramming occurs in 6 days and is highly efficient 0.07% 
for knock down of ΔNp63 and 0.1% for knock down of DGCR8 compared to 0.03% for 
expression of Oct4, Sox2, Klf4, and c-myc. These data have important implications for 
regenerative medicine and provide evidence that epidermal cells, which are readily accessible 
through the skin, can be reprogrammed to a pluripotent state without the addition of 
oncogenes. 
The presence of a rudimentary epidermis in ΔNp63 -/- mouse embryos and the ability of 
ΔNp63 deficient epidermal cells to hyperproliferate was quite surprising.  The roles of p63 in 
epidermal morphogenesis have been the subject of heated controversy.  Experimental evidence 
supports a role for p63 in both stem cell proliferation and in the initiation of differentiation 
(30, 66, 67, 241).  Experiments using p63 deficient epithelial cells demonstrated that p63 is 
required for stem cell proliferation (67).  Also, data from other studies using p63
 -/-
 mice 
showed that p63 is required for proper differentiation of epithelial tissues (241).  Most of these 
studies were performed using mouse models that are deficient for all isoforms of p63 making 
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the interpretation of the data difficult to decipher due to the existence of multiple p63 isoforms.  
More recently, experiments have been performed using in vivo siRNA knock down of 
ΔNp63α, the isoform predominantly expressed in the skin (75), or germline deletion of the 
ΔNp63 isoforms (ΔNp63gfp/gfp) (247).  Both mouse models are consistent with our data in that 
ΔNp63 is required for complete terminal differentiation.  Moreover, the mouse model with in 
vivo siRNA knock down of ΔNp63α also displayed hyperproliferation of the epidermis 
consistent with our results (75).  Our mouse model has unveiled unknown functions of the 
ΔNp63 isoforms in epidermal stem cell proliferation and in the induction of epidermal 
differentiation.  Our ΔNp63 conditional knockout allele has allowed for germline and acute 
deletion in epidermal cells of ΔNp63.  Importantly, we found that ΔNp63 indirectly regulates 
the expression of the pluripotency factors, such as, Oct4, Sox2, Nanog, and a unique miRNA 
signature by direct transactivation of DGCR8. Our data demonstrate that ΔNp63 is required for 
commitment to terminal differentiation through a unique miRNA and mRNA signature that is 
similar in both mouse and human cells.  In line with our observations, recent evidence 
indicates that factors other than Oct4, Sox2, and Nanog are critical for appropriate 
reprogramming of differentiated cells to pluripotency (249). 
Our data also show that re-expression of DGCR8 in ∆Np63 deficient epidermal cells 
can bypass the terminal differentiation defects and allows differentiation into multiple cell 
fates.  The phenotype of ΔNp63 +/- and ΔNp63 -/- embryos is similar to that of mice with 
DGCR8 ablated in K14 expressing cells within the epidermis.  All three of these mouse 
models have a hyperproliferative epidermis (159, 194, 248).  Moreover, DGCR8
 -/-
 embryonic 
stem cells continue to self-renew and fail to undergo terminal differentiation.  This is similar to 
what we found in mouse epidermal cells that were derived from ΔNp63 germline deleted mice 
(ΔNp63 -/-) as well as those with acutely deleted ΔNp63 (ΔNp63Δ/Δ).   These cells express 
DGCR8 at low levels, continue to proliferate beyond late passages in clonogenic assays, and 
continue to express markers of pluripotency, Oct4, Sox2, and Nanog, after multiple passages 
while wild-type epidermal cells senesce.  We were able to terminally differentiate ΔNp63 -/- 
epidermal cells after re-expression of DGCR8.  Although it has been suggested that ΔNp63 
induces pluripotency (67), our data supports a model whereby deletion of ΔNp63 induces 
pluripotency in epidermal cells.  These ΔNp63 -/- epidermal cells can differentiate into all 
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embryonic lineages in vivo but cannot contribute to the germline because resulting chimeric 
mice die at postnatal day 1 due to skin defects similar to those seen in ΔNp63 -/- mice (Tables 3 
& 4).  Because these cells could not give rise to a fully stratified epithelium, we have dubbed 
them induced multipotent stem cells (iMS) cells.  These cells have remarkable plasticity and 
have the potential to be important for regenerative medicine. 
Importantly, we further demonstrated the induction of pluripotency in normal human 
keratinocytes that were acutely knocked down for ΔNp63 or DGCR8.  Thus, knock down of 
either one of these two factors, ΔNp63 or DGCR8, represents a new way to induce 
keratinocytes to a stem-like state without the expression of proto-oncogenes or deletion of 
tumor suppressor genes.  Importantly, we found that loss of ΔNp63 does not result in loss of 
p53 expression, which has been shown previously to result in efficient reprogramming (127, 
237-240).  This result is significant given that down regulation of tumor suppressor genes, like 
p53, while leading to the generation of cells that are pluripotent, can also lead to the 
production of tumorigenic cells (256).     
The miRNA expression patterns of ΔNp63 -/- epidermal cells were similar to that of 
embryonic stem cells and induced pluripotent stem cells.  Consistent with low levels of 
DGCR8 in ΔNp63 -/- epidermal cells, we found miR-203, miR-205, and the miR-200 family 
(miR-200a, miR-200b, miR-200c, miR-141, miR-145, miR-429) expressed at very low levels.  
Paradoxically, we found a large number of miRNAs that were upregulated.  These included 
miR-290, miR-295, and miR-302, which have been found upregulated in both embryonic stem 
cells and/or induced pluripotent stem cells (249, 252-255), and miR-9.  This result was further 
demonstrated by Northern blot analysis (Figures 51A-C).  The high levels of some miRNA 
expression may be due to the fact that there is still a low level of DGCR8 expression present in 
ΔNp63 -/- epidermal cells.  We also noted that cells deficient for ∆Np63 or DGCR8 had higher 
levels of primary miRNAs compared to wild-type cells (Figures 51A-C) consistent with 
defects in processing to the precursor form.  Another possibility is that these high expressing 
miRNAs may also be processed via DGCR8 independent mechanisms (257).  Re-expression of 
DGCR8 in ∆Np63 -/- epidermal cells rescued expression of these miRNAs (Figure 4).  Another 
striking finding was that the miRNA expression of ∆Np63 -/- epidermal cells clustered with 
mouse iPS cells generated with the Yamanaka factors (miPS
Yam
) and mES cells while ∆Np63 -
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/-
 epidermal cells expressing DGCR8 clustered with wild-type keratinocytes. Importantly, the 
miRNA and gene expression patterns between both mouse and human epidermal cells 
deficient for ∆Np63 clustered together and with human and mouse iPS and mouse ES cells, 
further indicating that ∆Np63 is a key player in reprogramming cells to a stem-like state. 
In summary, ΔNp63 is required for transcriptional activation of DGCR8 in epidermal 
cells leading to a stem-like phenotype.  We have dubbed these cells iMS cells because of their 
remarkable plasticity and ability to differentiate into multiple cell lineages.   ∆Np63 is essential 
for epidermal morphogenesis; therefore, in the absence of ΔNp63, the epidermal stem cells in 
the developing skin fail to suppress expression of Oct4, Sox2, Nanog, and regulate a unique 
miRNA signature critical for pluripotency through DGCR8 transcriptional regulation.  These 
findings have important implications for regenerative medicine.  Based on our results using 
human keratinocytes, we predict that epidermal cells can be extracted from patient skin 
biopsies and reprogrammed into multipotent stem cells by knock down of ΔNp63 or DGCR8.  
Indeed, inducible knock down of ΔNp63 and/or DGCR8 may be preferable to the 
overexpression of potentially oncogenic factors such as c-myc or the down regulation of the 
critical tumor suppressor gene, p53.  In the future, understanding the mechanisms employed by 
the individual p63 isoforms in maintaining progenitor and stem cells in various tissues is key 
to understanding its complex roles in stem cell maintenance as well as cancer development and 
metastasis. 
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5. Chapter 5: Induced multipotent  (iMS) NHEK-sh ΔNp63 /DGCR8 cells can be 
induced to differentiate into epidermal tissue 
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5.1. Introduction 
Since the discovery of iPS cells in 2006 by Yamanaka’s group, they have been used for 
many purposes, the most common purpose being to differentiate into various tissue types. iPS 
cells have been made to differentiate into cardiomyocytes (258), skin cells capable of forming 
functional three dimensional skin architecture with hair follicles and glands (259), pancreatic 
islets capable of producing insulin (260), adipocytes (261), neurons, hematopoietic cells (262) 
and hepatocytes (263). Skin is one of the most accessible tissues of the body. Therefore 
keratinocytes could serve as the most reasonable target for reprogramming. This could 
potentially reduce the chances of rejection in patients. Cells can be taken from patients 
reprogrammed and differentiated and transplanted back to the same individual. Genetic skin 
diseases are very common like psoriasis, epidermolysis bullosa and others. Skin grafting could 
be a probable treatment option for these diseases. This necessitates the excision of skin from 
certain areas and grafting fresh skin. This would be feasible if methods could be devised to 
differentiate the iPS cells or iMS cell into functional skin, which could differentiate into all the 
epidermal components. This would certainly circumvent the problem of graft versus host 
rejection. Skin transplants are also very important for burn victims. The artificial skin can 
cover the burnt area and protect from contamination and infections. Also this helps is burns to 
heal faster. If a method could be devised where cells could be taken from such patients and 
differentiated back into a limit less supply of skin that would certainly save lives.  Also disease 
models for various types of skin diseases could be designed to be studied in petridishes and 
drugs to be tested on them. In this chapter we describe a method of differentiating NHEK-sh 
ΔNp63 /shDGCR8 (induced multipotent cells) to skin cells with the help of an established 
method of in vitro raft culture ref.  These cells were able to differentiate to certain extent and 
express cytokeratin 5 when cultured in keratinocyte specific media. They were also able to 
form multilayered sheath on raft cultures, which were cytokeratin 5 positive. Further work 
need to be done to investigate their differentiation potential and optimization of the raft culture 
conditions. 
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5.2. Results 
5.2.1. NHEK-shΔNp63/shDGCR8 can be induced to differentiate to ectodermal lineage 
NHEK-shΔNp63 or the NHEK-shDCGR8 cells are grown in stem cell specific media 
containing LIF (leukemia inhibitory factor) and on 0.1% gelatin. This maintains the cells in 
their undifferentiated state. To investigate whether these cells could be differentiated into 
epidermal lineage, they were cultured in keratinocyte specific media containing EGF and 
insulin (called F-media). This media was formulated to grow differentiated keratinocytes. 
These cells were cultured in differentiating conditions for 3-4 days. At 4 days the cells were 
collected lysed and western blot was performed for cytokeratin 5 (K5). We also used lysates 
from NHEK cells as positive control for K5. This experiment showed that the NHEK-
shΔNp63/shDGCR8 cells grown in stem cell specific media did not express K5. When grown 
in keratinocyte specific media for 4 days these cells started to express keratin 5 albeit at lower 
levels than the NHEK cells (Figure 52). This suggests that the NHEK-shΔNp63/shDGCR8 
cells have potential to be differentiated into ectodermal lineage. The defect in keratin 5 
expression could be attributed to the low levels of ΔNp63 and DGCR8 in these cells which we 
have shown previously is required for terminal differentiation. 
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Immunoblotting performed with NHEK cells grown in keratinocyte specific media (KC 
media), NHEK-shΔNp63/shDGCR8 grown in stem cell media (ES media) and NHEK-
shΔNp63/shDGCR8 grown in keratinocyte media (KC media) for cytokeratin 5.  Actin is used 
as loading control. 
  
Figure 50: Cytokeratin 5 expression in NHEK-shΔNp63/ shDGCR8 
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5.2.2. Loss of pluripotency marker expression in NHEK-shΔNp63/shDGCR8 cells under 
differentiating conditions 
Immunofluorescence, with antibodies towards Oct-4, Sox-2, Nanog and cytokeratin5, 
was performed on the NHEK-shΔNp63/shDGCR8 colonies grown in either stem cell media or 
under differentiating conditions in F-media. Interestingly both the cell types show a decrease 
in the expression of the stem cell markers when grown in F-media (Figure 52A-F & 53A-F) 
and an increase in cytokeratin 5 expression (Figure 53 G&H, 54 G&H). Also the NHEK-
shDGCR8 cells showed a much higher level of keratin 5 expression when grown in the F-
media suggesting that loss of ΔNp63 may regulate other factors which affect differentiation. 
On the other hand loss of DGCR8 seems to compromise differentiation to a lesser extent. And 
these cells can be induced to differentiate more promptly. Further work needs to be done to 
validate the level of the pluripotency markers and the differentiation markers in these cells. 
Quantitative assays like western blot analysis will also have to be performed to accurately 
assess the levels of these markers. Further characterization with other differentiation markers 
needs to be performed on these cells. 
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A-H) Immunostaining of colonies from NHEK-sh ΔNp63  cells. A,C,E) Oct-4, Sox-2 and 
Nanog expression of colonies grown in stem cell (ES media) media. G) Cytokeratin-5 
expression in stem cell media (ES media). B,D,F) Oct-4, Sox-2 and Nanog expression of 
colonies grown in keratinocyte media (F media). H) Cytokeratin-5 expression in colonies in 
keratinocyte media (KC media). White arrows denote positive cells. Magnification 400x 
 
 
 
 
Figure 51: Differentiation of NHEK-shDNp63 towards ectodermal lineage 
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A-H) Immunostaining of colonies from NHEK-shDGCR8 cells. A,C,E) Oct-4, Sox-2 and 
Nanog expression of colonies grown in stem cell (ES media) media. G) Cytokeratin-5 
expression in stem cell media (ES media). B,D,F) Oct-4, Sox-2 and Nanog expression of 
colonies grown in keratinocyte media (F media). H) Cytokeratin-5 expression in colonies in 
keratinocyte media (KC media). White arrows denote positive cells. Magnification 400x 
  
Figure 52: Differentiation of NHEK-shDGCR8 towards ectodermal lineage 
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5.2.3. Defects in terminal differentiation of the NHEK-shΔNp63/shDGCR8 cells as 
demonstrated in raft culture assay 
The NHEK-ΔNp63 and NHEK-shDGCR8 cells were plated on collagen rafts. This 
method is an established method for differentiating keratinocytes to full thickness epidermis. 
The cells are plated onto the collagen rafts initially in a submerged culture followed by lifting 
them such that the cells are in a air-liquid interface. They get their media supplement only 
from the basal layer whereas their apical surface is in contact with air. This creates an artificial 
skin like environment. The basal cells at first proliferate but once lifted starts to differentiate 
into the epidermal layers, spinous, granular and finally gives rise to the cornified epithelium on 
the top surface.  
When the NHEK-shΔNp63 and NHEK-shDGCR8 cells were subjected to such an 
assay they could form a thin multilayer structure with a slight cornified upper layer (Figure 
54A-C). Unfortunately our control experiment with BC-1-EP/SL (Figure 54A) did not work 
as well. Although when stained with cytokeratin 5 we saw a similar expression of keratin 5 as 
seen in the 2D culture method (Figure 54D-F), but conclusions could not be drawn from these 
assays as our control cells demonstrated defective stratification and no expression of further 
differentiation markers other than keratin 5. We are still optimizing this assay. 
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A-C) Hemtaoxylin staining of skin rafts from BC-1-EP/SL(A), NHEK-sh ΔNp63  (B) and 
NHEK-shDGCR8 (C). D-F) Immunofluorescence staining of rafts with anti-keratin 5. Green 
(anti-FITC secondary antibody staining) staining denoting keratin 5 expression in the rafts 
from the indicated cell type.  
 
 
 
 
 
 
  
Figure 53: Raft culture assay to differentiate NHEK-shDNp63/shDGCR8 cells to full 
thickness epidermis 
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5.3. Discussion 
Here we show that the NHEK-shΔNp63 and NHEK-shDGCR8 cells may be useful tools for 
the reconstruction of ectodermal tissues. Currently we are trying to optimize the raft culture 
protocol and devise a tool which can be used to generate functional epidermis. We are also 
currently working on the generation of other tissue lineages like the hematopoietic tissue. The 
complete differentiation of these cells may be difficult due to the absence of ΔNp63 and 
DGCR8 based on our model. Therefore efforts are being made to generate an inducible and 
titratable DGCR8 vector. This will allow us to express sufficient levels of DGCR8 in these 
cells which will be enough to drive terminal differentiation in such tissue differentiation 
assays. We are also working on over-expressing or repressing the expression of the panel of 
microRNA as shown earlier to be a pluripotency signature in Figure 48C. Many if these 
microRNAs have been shown to be potent in inducing differentiation in tissues of embryos. 
The loss of these microRNAs leads to a loss in differentiation, for example let-7, miR-141 and 
miR-205. We are in the process of expressing these microRNAs in the NHEK-shΔNp63 and 
NHEK-shDGCR8 cell and test their efficiency in driving differentiation in raft culture assays. 
We would also knock-down few of the over-expressed microRNAs like miR-9-5p and miR-
146b-5p in the NHEK cells and test their potential to induce pluripotency. It is a possibility 
that both the differentiation assay and the induction of pluripotency by microRNAs, would 
require the modulation of several microRNAs from the cross-species microRNA analysis.            
 Differentiation of stem cells, iPS cells and iMS cells may be a valuable tool for 
treatment of various diseases. These methods have to be thoroughly validated. One of the 
common con of these methods are the undifferentiated stem like cells which are left behind 
after differentiation of the majority of the cells. This then could lead to the formation of 
tumors. Several trials have to be done to verify this. Also currently there is no method for 
validating the existence of these undifferentiated cells in a differentiated cell population. 
Methods have to be designed to calculate percentage of these cell types and what can be done 
to improve the technique so all cells are differentiated uniformly. Work is currently going on 
to assess the graft versus host rejection issue. More work needs to be done in this field.  
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6. Chapter 6: Role of ΔNp63 in tumor suppression and oncogenesis is context dependent 
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6.1. Introduction 
The role of p63 in tumorigenesis has been a topic of constant debate. Previously we 
have shown that TAp63 is a suppressor of tumorigenesis and metastasis through its regulation 
of Dicer and other microRNAs (65). We also found that ΔNp63 regulates the microRNA 
biogenesis pathway by regulating DGCR8 and plays an important role in induced pluripotency 
of epidermal cells (Manuscript in Review at PNAS). Therefore we wanted to delineate the role 
of ΔNp63 in tumorigenesis. p63 has been shown to be highly expressed in human tumors (45, 
46, 73). This together with the fact that expression of p63 is hardly lost in tumors unlike p53, 
which is mutated or lost in 50% of all tumors (264, 265), led researchers to hypothesize that 
p63 is an oncogene. In some tumors p63 locus also demonstrates amplification (46), a 
characteristic of an oncogene like MYC (266-268). Although, there is contradictory literature 
demonstrating the loss of p63 in certain tumor type (56). Recent accumulating sequencing data 
from the TCGA also suggests that p63 undergoes point mutation in lung cancers (63). There 
are several independent case studies of CML and AML patients, where p63 have been shown 
to have point mutations (60). This dual evidence further makes it very difficult to determine 
the role of p63 in tumorigenesis. The other critical problem in the field is the lack of antibodies 
capable of detecting the different isoforms of p63. A lot of previous literature on p63 is 
muddled due to the use of an antibody that detects primarily ΔNp63 over the TAp63 isoforms. 
This makes it hard to discern the true expression patterns (loss or gain) of the two different 
isoforms in tumors. TAp63 expression pattern being similar to p53 also creates difficulties in 
detecting TAp63 in tissues and tumors under unstressed conditions. For a period of time it was 
believed that TAp63 did not play any crucial role in the biological processes, as it could be 
hardly detected in adult tissues (except in female germ cells) (71) . But now we know that the 
subtle expression of TAp63 is sufficient to suppress tumorigenesis and metastasis in healthy 
tissues (65). We have shown that TAp63 expression is certainly lost in a wide variety of 
aggressive metastatic tumors including head and neck squamous cell carcinomas, mammary 
adenocarcinomas and mammary adenocarcinoma (65). It has therefore become imperative to 
sort out the differences in the functions of the two isoforms in tumorigenesis. This is also now 
possible with the two conditional knock-out mouse models generated by our laboratory for the 
two different isoforms. 
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6.2. Results 
6.2.1. ΔNp63 heterozygous mice develop tumors of the epithelial origin 
To investigate whether ΔNp63 is a tumor suppressor or an oncogene, we generated a 
cohort of ΔNp63 +/- mice (30mice) and wild-type mice (30mice) and aged them to 3 years, 
since the ΔNp63 -/- mice die a few hours after birth as specified in section 4.2.2, Figure 27C. 
We found that the ΔNp63 +/- mice had a shorter survival compared to the WT mice. On 
analysis, we found that the ΔNp63 +/- mice develop mainly epidermal carcinomas (Figure 
56A). We are currently analyzing more animals for this study. 
  To further understand the collaboration between p53 and ΔNp63 as mentioned earlier, 
we crossed these mice to p53
 -/-
 and p53
 +/-
 mice. We generated a cohort of (30 mice for each 
cohort) ΔNp63 +/-;p53 -/- mice to be compared to p53 -/- mice and ΔNp63 +/-;p53 +/-, mice to be 
compared to p53
 +/-
 mice. Interestingly we found that the ΔNp63 +/-;p53 -/- mice develop a wide 
spectrum of tumors like thymic lymphomas, osteosarcomas, histiocytic squamous cell 
carcinoma, adenocarcinoma of the lungs and  testicular adenocarcinoma. Surprisingly only 
30% of the ΔNp63 +/-;p53 -/- mice developed thymic lymphoma, compared to the 90% of the 
p53
 -/-
 mice which developed thymic lymphomas. Curiously when we analyzed the survival 
curves of the ΔNp63 +/-;p53 -/- mice and the p53 -/- mice, there was no difference between the 
survival of the animals (Figure 56B). We therefore went on to determine whether mortality 
was due to the other tumor types and not due to the thymic lymphomas. We found that if we 
plot the survival curves of the ΔNp63 +/-;p53 -/- and p53 -/- mice with only thymic lymphomas 
(Figure 56C), the median survival time of the ΔNp63 +/-;p53 -/- mice (6.7 months)  was greater 
than the p53
 -/-
 mice (4.5months). Also there were some mice, which lived until 8.2 months, 
while all the p53
 -/-
 mice died at 6 months of age. This suggests that ΔNp63 plays an oncogenic 
role atleast in the thymus, whereas in the other epidermal tissues it seems to be playing a more 
tumor suppressive function.  
 The ΔNp63 +/-;p53 +/- mice on the other hand had similar survival curves to the p53 +/- mice. 
Although a cohort of these mice develop carcinomas too. These cohorts of mice are still under 
analysis. 
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Table 8: Tumor spectrum of ΔNp63 
+/-
;p53 
-/-
 
 p53 
 -/-
 ΔNp63 
 +/-
; p53 
 -/-
 
Lymphoma 85% 30% 
Sarcoma 5% 14% 
Carcinoma 0 40% 
Others 10% 16% 
   
Percentage of mice within each cohort of the indicated genotype with specific tumor types. 
N=20 for p53
 -/-
, n=42 for ΔNp63 +/-;p53 -/- 
 
 
A-C) Kaplan Meier survival curve for the indicated genotypes. A) Kaplan Meier survival 
curves of ΔNp63 +/- (n= 20) and wild-type (n=15). ΔNp63 +/- mice. The median survival time of 
the ΔNp63 +/- mice are significantly shorter than the survival curve for wild-type mice. Asterisk 
indicate significance . (p value ≤0.05).  B) Kaplan Meier survival curves of ΔNp63 +/- ;p53 -/-
(n= 20) , p53
 -/-
 (n=20) mice, with a wide range of tumor spectrum, and wild-type (n=15) mice. 
The median survival time of the ΔNp63 +/-;p53 -/- mice are not different  from the median 
survival time of the p53
 -/-
 mice. Asterisk indicate significance. . (p value ≤0.05).   C) Kaplan 
Meier survival curves of ΔNp63 +/- ;p53 -/-(n= 15) , p53 -/- (n=16) mice with thymic lymphomas 
and wild-type (n=15) mice. The median survival time of the ΔNp63 +/-;p53 -/- mice are different  
from the median survival time of the p53
 -/-
 mice with thymic lymphomas.  Asterisks indicate 
significance. P-value≤0.05.  
 
 
 
 
 
 
 
Figure 54: Loss of ΔNp63 leads to a shortened life-span 
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  6.2.2. Loss of ΔNp63 is tumor protective in the thymus in vivo 
  We investigated this lack of thymic lymphomagenesis in these animals and further 
evaluated the function of ΔNp63 in the thymus, by performing quantitative real time PCR for 
some of the well p63 apoptotic targets like Puma and Noxa. We found that apoptotic targets 
like PUMA and NOXA was up regulated in the thymic lymphomas of the ΔNp63 +/-;p53 -/- 
compared to the lymphomas from the p53
 -/-
 mice (Figure 57B,C). We also validated the 
senescence targets of p53/p63 like p21. We found that p21 was indeed up regulated in the 
ΔNp63 +/-;p53 -/- tumors in comparison to the lymphomas from the p53 -/- mice (Figure 57A). 
TAp63 has been shown to be a transcriptional activator of these apoptotic and senescence 
targets in others tissue. We performed a quantitative real-time PCR for TAp63 from the thymic 
lymphoma tissue of these mice and found that TAp63 was up regulated in these lymphomas to 
very high levels (36 folds higher), while the p53
 -/-
 lymphomas showed no such upregulation of 
TAp63 (Figure 57D).  
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A-D) Quantitative real-time PCR performed on thymic tumor tissues from p53
 -/-
 and ΔNp63 +/-
;p53
 -/-
 (n=3). mRNA levels for p21 (A), PUMA (B), NOXA (C) and TAp63 (D). Asterisk 
indicates significance. P-value≤0.05.  
  
Figure 55: Loss of ΔNp63 is tumor protective in the thymic lymphomas 
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6.2.3. Loss of ΔNp63 leads to increased apoptosis and reduced proliferation in vivo 
  In order to investigate the events leading upto the increase in the senescence and the 
apoptotic targets we analyzed the thymii from young mice for signs of apoptosis and 
senescence. We performed immunostaining for cleaved caspase-3 in the thymii of 3.5 month 
old p53
 -/-
 and ΔNp63 +/-;p53 -/- mice in order to determine the difference in apoptosis during 
early lymphomagenesis (Figure 58A). Our goal was to determine whether a cohort of mice of 
the ΔNp63 +/-;p53 -/- genotype exhibit more apoptosis at this early stage explaining the low 
percentage of thymic lymphomas in these mice. We found high number caspase positive cells 
in all the thymii that we tested (n=3). We also analyzed these thymii for PCNA staining to 
determine the proliferation rate of the thymocytes, We found that the ΔNp63 +/-;p53 -/- thymus 
has a much lower proliferation rate than the thymus from the p53
 -/- 
animals (Figure 58B). 
Analysis remains to be done in more mice. The thymii from the ΔNp63 +/-;p53 -/- mice were 
also phenotypically more ‘normal’ and retained its tissue architechture than the thymii from 
the p53
 -/-
 mice at this age (data not shown). This indicates that the ΔNp63 +/-;p53 -/- mice 
positively have an upregulation of apoptotic and senescence pathways in the thymii. 
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A) Immunostaining for cleaved-caspase 3 in thymic lymphoma tissue from ΔNp63 +/-;p53 -/- 
and p53
 -/-
 mice (n=3). B) Immunostaining for PCNA in thymic lymphoma tissue from ΔNp63 
+/-
;p53
 -/-
 and p53
 -/-
 (n=3) mice. Arrows indicate positive cells. Magnification 200x.Insets are 
400X magnification.  
  
Figure 56: Loss of ΔNp63 leads to increased apoptosis and reduced proliferation in vivo 
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6.2.4. Loss of ΔNp63 induces apoptosis, senescence and cell cycle arrest in vitro 
  To further validate and emulate the events during thymic lymphomagenesis, we 
isolated thymocytes from untreated or γ-irradiated (10Gy) animals of the following genotypes, 
wild-type, p53
 -/-
 and ΔNp63 +/-;p53 -/- at 6 weeks of age. We performed quantitative real-time 
PCR for the apoptotic targets, Puma and Noxa and senescence target p21. We observed a 
similar effect in the thymocytes. The γ-irradiated thymocytes from the ΔNp63 +/- p53 -/- mice 
had a higher level of expression of Puma, Noxa and p21 two hours post–radiation with 
continued increase upto 6 hours post-radiation compared to the p53
 -/-
 irradiated thymocytes 
(Figure 59A-F), which showed almost no upregulation of these genes. This indicates loss of 
ΔNp63 to be a major player in suppression of apoptosis and senescence in these cells.  We also 
validated the expression level of TAp63 and found that TAp63 mRNA expression was 2.5 folds 
higher in the irradiated ΔNp63 +/-;p53 -/- thymocytes compared to the p53 -/- thymocytes, which 
showed no signs of TAp63 induction (Figure 59 G& H). 
ΔNp63 mRNA levels was found to be low in the thymocytes and the level further went down 
after irradiation (data not shown). 
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A-H) Quantitative real-time PCR performed on RNA from p53
 -/-
 and ΔNp63 +/-;p53 -/- (n=6) 
thymii treated with or without γ-radiation. A,C,E,G) mRNA levels of the indicated target 
genes at 2hours after γ-radiation. B, D, F, H) mRNA levels of the indicated target genes 6 
hours after γ-radiation. Asterisk indicates significance. P-value≤0.05.  
  
Figure 57: Loss of ΔNp63 leads to increased apoptosis and senescence in vitro 
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6.2.5. ΔNp63 undergoes proteasomal degradation on γ-radiation 
  We were keen on determining the change in ΔNp63 status after γ-radiation. We 
irradiated MEFs with 10Gy and verified the change in ΔNp63 protein expression. Researchers 
have shown that ΔNp63 undergoes proteasomal degradation after treatment with γ-radiation. 
We wanted to verify this in our system. We treated wild-type MEFs with 10 micromolar 
solution of MG-132 for one hour before irradiating them. 6 hours post radiation these cells 
were collected and immunoblotting was performed. There was degradation of the ΔNp63 
protein post radiation compared to the untreated cells. Also treating the cells with MG-132 
inhibited this degradation stabilizing ΔNp63 levels. TAp63 protein levels were shown to be 
comparable in the untreated cells with or without the treatment of MG-132. Post-radiation the 
MG-132 treated cells showed a decrease in the level of TAp63 compared to the MG-132 
untreated cells, suggesting that when once ΔNp63 is degraded post radiation, TAp63 protein 
levels increase. But when MG-132 is added post-radiation, stabilizing ΔNp63, TAp63 protein 
levels are further decreased due to the possible inhibition by ΔNp63 (Figure 60). Therefore 
ΔNp63 could be a negative regulator of TAp63. 
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Immunoblotting with lysates from wild-type MEFs treated or untreated with γ-radiation and 
MG-132 with antibodies against ΔNp63 and TAp63. Lysate from ΔNp63 -/- MEF is used as 
control. Actin is used as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 58: Loss of ΔNp63 leads to upregulation of the TAp63 protein 
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6.2.6. ΔNp63 transcriptionally represses the TAp63 promoter 
  These data taken together indicated there was an inter-regulation between ΔNp63 and 
TAp63. The loss of ΔNp63 induces TAp63 at the mRNA level. We therefore asked whether 
ΔNp63 suppressed the expression of TAp63 by binding to its promoter region. We searched for 
putative p53/63 binding site in the TAp63 promoter region. We performed chromatin 
immunprecipitation analysis with p63 antibody with either wild-type MEFs, ΔNp63 -/- MEFs 
or p63
-/-
 MEFs treated with or without γ -irradiation. We found that in control cells, ΔNp63 
binds strongly to the TAp63 promoter region in the wild-type cells, under stress like γ-
irradiation there is a reduction in binding to the TAp63 upstream promoter site at -3515 
upstream of the TAp63 transcription start site as determined by a ChIP assay (Figure 61 and 
Table8). In the ΔNp63 -/- and also in the p63-/- MEFs cells we detected no binding at the TAp63 
promoter due to the lack of ΔNp63 isoform. This also suggests that TAp63 does not bind to its 
own promoter site.  
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Table 9: p53/p63 response element on the TAp63 promoter 
Element Location Sequence MM/Spacer 
TAp63 -3515 to -3436 ttgCAAGgcc   tgcaagaa   gctCAAGgtc 6/8 
 
 
qRT-PCR of ChIP assay for p63 on a specific binding site on TAp63 promoter (TAp63 
specific) and non-specific binding site (Non-specific). Cells from the indicated genotypes were 
used. Experiments were done in triplicate. Asterisks indicate significance. p value ≤0.05. 
 
 
 
 
 
 
 
Figure 59: ΔNp63 suppresses TAp63 transcription by binding to its promoter 
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6.2.7. ΔNp63
 +/-
;p53
 -/-
 mice die of  multiple metastatic tumors 
  We analyzed the cohort of ΔNp63 +/-;p53 -/- mice which does not develop thymic 
lymphomas (70%) and found that they develop metastatic carcinomas like a metastatic lung  
adenocarcinoma which metastasized to the diaphragm (image not shown) . These carcinomas 
are highly aggressive. They are of various tissue origins. Interestingly unlike the ΔNp63 +/-;p53 
-/-
 mice which develop thymic lymphomas and have comparatively longer median life span 
(Figure 56 C.), these mice die earlier (Figure 62 & Table 9). Their median survival is similar 
to the p53
 -/-
 mice, suggesting that ΔNp63 plays an oncogenic role in the thymus, whereas it 
may behave like a tumor suppressor in other tissues. 
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Table 10: Tumor spectrum of ΔNp63 
+/-
;p53 
-/-
 mice 
 p53 
 -/-
 ΔNp63 
 +/-
; p53 
 -/-
 
Lymphoma 85% 30% 
Sarcoma 5% 14% 
Carcinoma 0 40% 
Others 10% 16% 
 
Percentage of mice with the indicated tumor types. N=20 for p53
 -/-
 cohort and n=42 for ΔNp63 
+/-
;p53
 -/-
 cohort. 
Kaplan Meier survival curves of ΔNp63 +/- ;p53 -/-(n= 30) , p53 -/- (n=20) mice, with a wide 
range of tumor spectrum, and wild-type (n=15) mice. The median survival time of the ΔNp63 
+/-
;p53
 -/-
 mice are not different  from the median survival time of the p53
 -/-
 mice. Asterisk 
indicate the median survival. 
  
Figure 60: ΔNp63+/-;p53-/- mice die of  multiple metastatic tumors 
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6.2.8. ΔNp63
 +/-
;p53
 +/-
 mice develop varied metastatic carcinomas 
  A cohort of ΔNp63 +/-;p53 +/- mice we generated and aged for 2.5 years. These mice 
demonstrate similar survival to the p53
 +/-
 mice and earlier than the mice from the wild-type 
cohort (Figure 63). These mice developed various types of tumors. The moribund mice were 
euthanized and their tumors collected. On a detailed analysis it appears that the ΔNp63 +/-;p53 
+/-
 mice develop many different types of carcinomas along with sarcomas. These mice develop 
mammary adenocarcinomas, squamous cell carcinomas and ovarian carcinomas. Carcinomas 
were not found to be present in most of the p53
 +/-
 mice. Many of these carcinomas are 
aggressive and malignant. Further work has to be done for a detailed analysis of these tumors. 
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Kaplan Meier survival curves of ΔNp63 +/- ;p53 +/- (n= 21) , p53 +/- (n=16) mice, with a wide 
range of tumor spectrum, and wild-type (n=15) mice. The median survival time of the ΔNp63 
+/-
;p53
 +/-
 mice are not different  from the median survival time of the p53
 +/-
 mice. 
Figure 61: ΔNp63
+/-
;p53
+/-
 mice develop varied metastatic carcinomas 
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6.2.9. ΔNp63 
-/-
 MEFs and keratinocytes have high migration and invasion potential 
  We went on to characterize the invasive potential of ΔNp63 -/- MEFs and keratinocytes 
in vitro with a Boyden chamber assay. We found that the ΔNp63-/- MEFs and keratinocytes are 
highly invasive when assayed by this method (Figure 64 A-D).  
We also performed time-lapse microscopic imaging on scratch assays with the wild-
type and ΔNp63 -/- keratinocytes. A scratch was made on a confluent plate of wild-type 
keratinocytes and ΔNp63 -/- epidermal cells with the tip of a 200um pipette. The ΔNp63 -/- 
cells were more migratory and could cover the scratch within 24 hours, while the wild-type 
keratinocytes took close to 48 hours to cover the scratch (Figure 64E). When the movement 
of these cells was analyzed, we found that the ΔNp63 -/- cells exhibited a loss of contact 
inhibition and loss of directional movement. While the wild-type cells all moved towards the 
scratch in a coordinated fashion, the ΔNp63 -/- keratinocytes showed a more rapid but random 
movement.  
  We determined the average path length covered by the ΔNp63 -/- cells (n=30) for a 
given time (12 hours) and compared this to the path length covered by the wild-type 
keratinocytes (n=30) in the same time. This showed that the ΔNp63 -/- cells covered a longer 
path in the same amount of time in comparison to the wild-type keratinocytes. Suggesting that 
these cells are highly migratory, but lack directionality (Figure 64F). 
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Figure 64: ΔNp63 deficient keratinocytes and MEFs are highly migratory and invasive 
A-D)Bargraphs indicating migration and invasion in MEFs and keratinocytes of the indicated 
genotyopes. E) Real time-lapse scratch assay with keratinocytes of the indicated genotypes 
monitored over 24 hours. The colored lines indicate the path taken by each cell in closing the 
scratch. F) Calculation of the average pathlength travelled by 30 cells from the indicated 
genotypes over a period of 12 hours. (n=3). Magnification 200x. Asterisk indicate 
significance. p value ≤0.05. 
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6.3. Discussion 
  For the past 12 or more years researchers have speculated about the role of p63 in 
tumorigenesis. Since the construction of the p63 knock-out mice, which are postnatally lethal 
and have developmental defects, p63 have been thought to mainly play roles in development 
and not so much in the suppression of tumorigenesis. In 2005 Dr.Elsa Flores found that p63
 +/-
 
mice develop spontaneous tumors. Also when crossed to the p53
 +/-
 mice, which mainly 
develop sarcomas and lymphomas, there was a significant reduction in the median survival (7 
months compared to 10 months) of the p63
 +/-
;p53
 +/-
 mice primarily due to the development of  
spontaneous carcinomas which were highly aggressive. 50% of the mice got metastatic disease 
(ref). This led to a major shift in belief about the role of p63 in suppression of tumorigenesis. 
The Flores lab along with other labs have shown that p63 indeed has tumor suppressive roles 
(129-131). TAp63 has been shown to be a tumor suppressor by the regulation of Dicer and 
microRNAs (65). The role of ΔNp63 on the other hand has not been investigated in the 
suppression of tumorigenesis as much mainly due to the post-natal lethality of these mice, 
similar to the total p63 knock-out mice (74). Thus the study of the ΔNp63 mutant mice has to 
be performed in a heterozygous background. Inspite of the retention of one allele of ΔNp63 in 
these mice, they develop carcinomas and have a reduced median survival in comparison to the 
wild-type. Suggesting a role of ΔNp63 in suppression of tumorigenesis. Interestingly in a p53 -
/-
 background only 30% of these mice develop thymic lymphomas, a drastic reduction from 80-
90% thymic lymphoma incidence in the p53
 -/-
 mice suggesting, in thymus ΔNp63 could 
potentially play a role as an oncogene. This could be explained by its ability to bind to the 
TAp63 isoform and also TAp73 isoforms (data not shown) and suppress their activity in 
inducing cell death.  
  Further analysis is going on to test this hypothesis in our lab. While the other ΔNp63 +/-
; p53
 -/-
 mice develop metastatic carcinomas and other aggressive tumor types which leads to 
the early death of these mice. This suggests that ΔNp63 could play tumor suppressive role in 
other tissue types.  
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  The phenotype of the ΔNp63 +/-;p53 -/- mice suggests that ΔNp63 could play oncogenic 
roles in certain tumor types. This finding is remarkable in it that this could lead to therapies 
where the p53 protein is lost or mutated. The reduction in the levels of ΔNp63 could lead to the 
upregulation of TAp63 (and possibly TAp73) causing critical apoptosis and senescence in 
Specific tumor types. This is reminiscent of the study by Leif W.Ellisen’s group, where they 
demonstrated that in triple negative breast cancer overexpressing ΔNp63, ΔNp63 and can 
specifically sequester TAp73 inhibiting apoptosis. This interaction is dissociated when 
platinum based chemotherapeutic agent, cisplatin is administered, releasing TAp73 to be able 
to induce apoptosis through Puma. When they knocked-down ΔNp63 with siRNAs, liberating 
TAp73 in cells lines, there was an increase in apoptosis (ref). Taken together this could lead to 
specific and successful therapeutic strategies in p53 mutated or lost tumors. The fact that p63 
is not so frequently mutated in tumors could be used towards advantage of such therapies.   
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7. Conclusion and Future Directions 
  My thesis work demonstrates an intricate network of genes and microRNAs 
regulated by the p63 isoforms that regulate various biological processes like tumorigenesis, 
metastasis, stem cell maintenance and the generation of stem like cells (iMS cells) from 
differentiated cells. For the first time I have shown that p63, both TAp63 and ΔNp63 can 
regulate the microRNA biogenesis network of proteins thereby placing p63 in the center of the 
microRNA biogenesis network and various biological processes. We found that TAp63 
transcriptionally regulates Dicer and ΔNp63 transcriptionally regulates DGCR8. Dicer and 
DGCR8 are crucial to the microRNA biogenesis pathway. In the absence of these proteins 
there is a loss in the mature and precursor microRNA production. 
   The TAp63 knock-out mice develop spontaneous highly metastatic carcinomas 
and sarcomas. These tumors metastasize to the liver bone, lungs and even to the brain, a rare 
occurrence in spontaneous mouse tumor models. Cells and cell lines from these mice express 
low levels of Dicer and microRNAs and this causes increased metastasis (65). We assayed for 
metastasis by in vitro Boyden chamber assay, which measures invasive potential of cells. This 
assay is correlative, but very useful in determining the metastatic potential of the cells in vivo 
since invasion is an early step of metastasis (65). Also this assay allows us to manipulate 
proteins and microRNAs in a system to assess their effects on invasion and therefore 
metastasis. We found that the TAp63-/- MEFs are highly invasive in vitro which correlates 
with the TAp63-/- metastatic tumor development in mice. Re-expression of Dicer in the MEFs 
from these mice rescues the invasive phenotype in vitro (65).  We also found that TAp63 can 
transcriptionally regulate miR-130b. Re-expression of this microRNA by itself did not affect 
the rate of invasion in these cells (65). Whereas co-expression of Dicer and miR-130b in 
MEFs reduced their invasive potential in a Boyden chamber assay, suggesting that there is co-
operation between Dicer and miR-130b in the regulation of invasion in vitro (65). 
  Primary and metastatic human lung adenocarcinomas, mammary adenocarcinomas and 
head and neck squamous cell carcinomas were assayed for their metastatic potential. The high 
grade metastatic tumors exhibited a concomitant loss of TAp63, Dicer and miR-130b 
suggesting that the regulation of metastasis by these proteins are dependent upon TAp63 status 
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in these tumors. The loss of TAp63 seems to be gradual in these tumors. The lower grades of 
tumors (GradeI &II) retain some expression of TAp63, Dicer and miR-130b, whereas total loss 
is seen in the higher grades of tumors (Grade II&III) (65). The TAp63-/- mice develop 
metastases later in the tumor development course. Most of these mice start developing tumors 
at the age of 12 months and more (65). This could be due to the fact that the latency period for 
tumor development is longer in these mice, but once the tumors develop they become highly 
metastatic. This could be because with the loss of TAp63 there is increased DNA damage and 
genomic instability. Genomic instability has been shown to be a precursor of cellular 
senescence. The primary tumors overcome this senescent phenotype by genomic instability 
and respond by further mutations in other pathways. This genetic makeover leads to aggressive 
metastasis of these tumors in the TAp63-/- mice.  
  Interestingly the carcinomas from the TAp63 mutant mice do exhibit high levels of 
metastases. This is also true when these mice are crossed to the p53 mutant mice. Interestingly 
the level of senescence was to be higher in the TAp63-/-;p53+/- and TAp63+/-;p53+/-   
sarcomas than in the carcinomas (65). The sarcomas from these mice were found to have 
higher levels of age-related senescence. On the contrary the carcinomas from both these 
cohorts had a lower level of senescence and a higher level of metastasis (65). This could be 
explained by the fact that there is an increased level of genomic instability in the carcinomas 
from the TAp63-/-, TAp63-/-;p53+/- and TAp63+/-;p53+/- mice when compared to the 
sarcomas from the same mice (65). This could be due to the fact that TAp63 plays a more 
important role in the epithelial compartment than the mesenchymal compartment. Loss of 
TAp63 in the epithelium is therefore more deleterious to the organism (65).  
  We found that ΔNp63 transcriptionally regulates DGCR8. Loss of ΔNp63 leads to a 
loss in terminal differentiation in the epidermis. We also found that re-expression of DGCR8 
in these isolated epidermal cells from the ΔNp63 knock-out mice may be able to induce 
differentiation in these cells. These cells were shown to possess characters of stem cells. They 
can differentiate into multiple cells types in vitro and can even give rise to chimeras when 
injected into the blastocysts of a pseudopregnant mouse. Although the chimeras generated 
from these blastocysts look phenotypically similar to the ΔNp63-/- embryos. They have a 
defect in the terminal differentiation of their epidermis and express some the markers of 
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epidermal stem cells like K8 and K18 in a similar manner to the epidermis of the ΔNp63-/- 
embryos. These chimeras also die a few hours after birth. This defect in terminal 
differentiation can be partially rescued by the re-expression of DGCR8 in these cells. 
Teratomas generated from the ΔNp63-/- epidermal cells without the expression of DGCR8 is 
extremely undifferentiated, whereas teratomas from these cells expressing DGCR8 is well 
differentiated. This suggests that DGCR8 plays an important role in the regulation of 
differentiation and that ΔNp63 regulates differentiation through the regulation of DGCR8 (in 
review, PNAS).    
  Moreover when ΔNp63 or DGCR8 is knocked down in normal human keratinocytes 
(NHEK) cells with the help of lentiviral shRNAs for ΔNp63 or DGCR8, these cells behave in a 
stem like manner. They express stem cells markers like SSEA-1, Oct-4, Sox-2, Tra-1-81 and 
can form teratomas when injected into SCID mice. The cells deficient for ΔNp63 form 
teratomas, which are less differentiated than the cells, which are deficient for DGCR8. This 
could be because ΔNp63 regulates many other genes important for the regulation terminal 
differentiation like E-cadherin and keratin 14. This method could prove to be a robust method 
for the generation of multipotent stem cells as mentioned earlier in chapter 4.    
 Finally we also found, by cross-species microRNA comparison, a set of microRNAs 
which are common between the human shRNA knock-down cells and the murine ΔNp63 
deficient epidermal cells. These were in turn compared with the human iPS cells and mouse 
iPS cells generated by the introduction of the Yamanaka factors. These microRNAs as 
mentioned earlier could be the key microRNAs involved in the reprogramming potential of 
these cells. There has been an explosion in knowledgebase about the microRNAs and other 
proteins that are involved in reprogramming somatic cells to pluripotent stem cells. Research 
is still ongoing to identify the key factors and also to find a way of reducing the number of 
factors required for this purpose. My thesis work may facilitate refining the search for the core 
factors and indicating the most important microRNAs required to be modulated for this 
process. 
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7.1. p63, microRNAs and cancer 
  We found that TAp63 transcriptionally regulates Dicer and ΔNp63 transcriptionally 
regulates DGCR8. In many cancers there is a loss of these p63 isoforms (56, 73). There is also 
a global downregulation of microRNAs in many cancers; therefore the regulation of Dicer, 
Drosha, Ago2, TARBP and the other proteins involved in the microRNA biogenesis pathway 
possibly plays a critical role in the regulation of tumorigenesis and metastasis of tumors (269, 
270). Interestingly the loss of Dicer and Drosha has been shown to have prognostic value in 
ovarian, breast and colorectal cancers (271). Loss of these proteins is generally deleterious to 
the survival of patients with such diseases. Approaches are being made towards the re-
expression of Dicer, Drosha or TARBP in some types of tumors. This may help in the 
increased microRNA biogenesis and the improvement in patient survival(270). There is 
evidence that p63 is amplified and overexpressed in cancers (73). It would be intriguing to 
profile the microRNAs from those tumors and delineate the regulation of Dicer and DGCR8. 
Dicer and DGCR8 have also been shown to be regulated by microRNAs themselves. 
Therefore it will be intriguing to delineate the network of these microRNAs and to determine 
whether p63 plays any role in these interactions.  
  Recently there has been a lot of development of microRNA therapeutics. A number of 
tumor suppressor microRNAs have been shown to be lost in cancer. Attempts are being made 
to express some of these microRNAs. In 2009, Taulli et al. reexpressed miR-1/miR-206 in 
skeletal muscle. These microRNAs are shown to be lost in RMS. When expressed in these 
cells in vitro they led to loss of growth in soft agar assay and loss of proliferation and invasion. 
This also induced forced myogenic differentiation in these cells (272) . Other microRNA like 
miR-375 can induce drug sensitivity and reduce EMT like properties in tamoxifen resistant 
MCF-7 cells in vitro (273). Several studies are underway which test whether the re-expression 
of different microRNAs can reduce proliferation, invasion, induce cell death or senescence in 
cells (274),(275). Recently a microRNA based drug was developed against the Hepatitis C 
viral antigen. This drug is in phase II clinical trial. The drug is based on microRNA 122 which 
have been modified by LNA insertion into its backbone. Some of the major problems with 
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microRNA based therapy is non-specific targeting, instability in body fluids and therefore high 
dose requirement, (276). 
 
7.2. p63 and EMT 
Dicer has been shown to regulate many microRNAs which regulate EMT. miR-200 
family of microRNAs has been demonstrated to be major regulators of EMT (203). These 
microRNAs can regulate E-cadherin, one of the main proteins in maintaining tissue integrity 
(277). Loss of miR-200 family is an early event in metastasis and is thought to mark the 
initiation of EMT events. Therefore the loss of Dicer and the other microRNA biogenesis 
pathway proteins may be investigated as a biomarker for cancer progression along with other 
proteins involved in EMT (Epithelial Mesenchymal Transition). EMT marks the first stages of 
metastasis, therefore it seems that loss of TAp63 could potentially induce EMT in these 
tumors, which would then become highly metastatic. Dicer has also been implicated in this 
process of EMT, indirectly through the regulation of microRNA like the miR-200 family 
(278). It would be interesting to see whether re-expression of Dicer and TAp63 or ΔNp63 in 
tumor cells revert back their mesenchymal phenotype to a more epithelial phenotype. Some of 
the factors important in EMT are snail, slug, Twist and E-cadherin. It will be interesting to see 
whether the loss TAp63 and ΔNp63 can cooperate with any of these factors to induce EMT. It 
is possible that the loss of ΔNp63 may make the cells more mesenchymal as seen in the 
epidermal cells from the ΔNp63-/- mice. These cells are highly invasive in Boyden chamber 
assay. They seem to lose contact inhibition as they come in contact with other cells 
(unpublished work from Chakravarti and Flores, chapter 6). Further work needs to be done to 
demonstrate that.   
   
7.3. p63, stem cell maintenance, differentiation and stratification 
p63 has been shown to be important in differentiation. TAp63 has been shown to be 
required to maintain homoeostasis in the transiently amplifying stem cells of the epidermis 
(72), while ΔNp63 maintains the stem cells in the basal layer of the epidermis in their stem like 
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state. ΔNp63 has also been shown to be important in the induction of differentiation in the 
basal layer of the epidermis. Therefore there is a divide in thoughts over ΔNp63’s role in stem 
cell maintenance or induction of terminal differentiation. Overexpression of TAp63α in the 
K14 cells of the basal layer in a induced mouse model leads to an expansion in the epidermal 
compartment and delayed differentiation as detected by keratin1 expression. This suggests that 
overexpression of TAp63 possibly leads to an expansion in the stem cells in the epidermis and 
in turn leads to hyperproliferation of these stem cells (78). Overexpression of ΔNp63a has also 
shown to be inhibitory in the induction of differentiation (98). Depletion of ΔNp63 on the other 
hand as shown by others and us leads to a defect in the epidermis formation (247). Although 
the epidermal cells from the ΔNp63 knock-out mice express all the differentiation markers, 
they do not undergo proper stratification. One explanation for this is that the cells in the 
epidermis receive signals from the dermis to differentiate, but they require ΔNp63 for proper 
stratification and also to regulate the timing of differentiation. Since stratification and 
differentiation are two different aspects in the development of the epidermis, it is possible that 
ΔNp63 is a major regulator of the stratification process. The current idea in the field is that 
ΔNp63 is required to maintain the cells in their stem like state in the basal layer of the 
epidermis. But it could be a possibility that ΔNp63 expression is really a signal for the cells in 
the basal layer to differentiate and stratify, since others and we have found that the stem cells 
in the skin are present even in the absence of ΔNp63. Further work has to be done to test this 
hypothesis.  
 
7.4. Role of p63/p73 in iPS cell generation 
Recently there were few reports on the effects of p63 and p73 on iPS cell generation. 
Researchers found that overexpression of ΔNp73 in human fibroblasts along with induction 
with the four Yamanaka factors increase the reprogramming potential of the cells by 12.67%. 
Also when injected into SCID mice these cells are resistant to differentiation. On analysis of 
10 random microscopic fields (400x), they found that in the control iPS cell teratomas 100% 
of the field  had differentiated cells with less than 30% of the fields showing non-specific cells. 
But in the ΔNp73 overexpressing teratomas only 20% of the fields had differentiated cells and 
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30%-100% of the fields showed presence of non-specific or undifferentiated cells suggesting 
that overexpression of ΔNp73 inhibits differentiation potential of the iPSCs in vivo. They 
further explained that this defect could be contributed to the repression of the Nanog promoter 
by ΔNp73 as tested by luciferase assay (279). 
Another paper reported that iPS cells generated from patients with EEC syndrome with 
2 point mutations (R304W and R204W) in the DNA binding domain display defects in 
ectodermal differentiation. This paper showed that when these cells were infected with the 
Yamanaka factors and subjected to embryoid body formation assay, they could form embryoid 
bodies and on attachment give rise to cells from all three germ layer. On treatment with BMP4 
and SB431542, which induce ectodermal differentiation in the iPSCs from wild-type 
fibroblasts evident by the expression of keratin 14 positive cells, the iPSCs from the EEC 
patient cells did not differentiate into keratin 14 expressing cells. Although a small percentage 
of cells expressed keratin 18, a marker of ectodermal progenitor. These cells demonstrated a 
similar defect to differentiate in to corneal epithelial cells when cultured on corneal fibroblasts 
and treated with BMP-4. Recently APR-246/PRIMA-1
MET
 has been shown to induce apoptosis 
through p63. In order to test whether this compound has effects on p63-mediated 
differentiation, the patient specific iPSCs were treated with APR-246/PRIMA-1
MET
. This led 
to an increase in keratin 14 positive cells in the EEC patient specific cells from about 43 ± 
12% in iPSC
R304W/+
 and to 24 ± 15% and iPSC
R204W/+
, while the wild-type iPSCs remain 
unaffected at 27.5% (279, 280) . 
 
7.5. p63 and cancer stem cells 
TAp63 has been shown to be important in maintaining stem cells homeostasis by Su 
et.al, 2009. Loss of TAp63 leads to a hyperproliferation in the stem cell compartment. TAp63 
has also been shown to be important in the induction of senescence under oncogenic stress. 
The TAp63-/- mice develop squamous cell carcinomas. This could possibly be due to a 
hyperproliferation in the SKP cells in the adult skin cell compartment. This demonstrates its 
role in tumor suppression to be varied. Therefore it would be interesting to identify its role in 
cancer stem cell regulation. 
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7.6. ΔNp63 and tumor suppression 
  We have shown that ΔNp63 heterozygote mice develop highly malignant tumors. 
These tumors are metastatic. Also ΔNp63 mutant cells are highly invasive and migratory. 
Therefore it is tempting to speculate that ΔNp63 has tissue tumor suppressive functions. This 
finding is significant because until now researchers believed ΔNp63 is an oncogene based on 
its overexpression in human tumors. This is the first demonstration of tumor suppressive 
capability of ΔNp63. It will be interesting to understand the co-operation of ΔNp63 and TAp63 
in this function. We have also shown that TAp63 is transcriptionally regulated by ΔNp63. This 
regulation may be of prime importance in the regulation of tumorigenesis. ΔNp63 has been 
shown to have a dominant negative effect on the entire p53 family. It may be worth 
speculating that it perhaps counteracts the effects of overactive p53, TAp63 and TAp73 after 
stress response and returns the cells to normalcy.  
  My work places p63 in an important junction of the microRNA biogenesis pathway. 
This sheds light on the previously unknown functions of this family of proteins and makes it 
an important regulator of biological processes which were seemingly unrelated to this protein. 
It is interesting that p63 and not p53 regulates these proteins by direct transcriptional 
activation at these sites. Although we do not know whether there is co-operation between the 
family members in this regulation. Furthermore p63 has always thought to be important in the 
epithelial morphogenesis. It is exciting to find that its regulatory effect on the microRNA 
biogenesis pathway is not restricted to the epithelium. The regulation of this pathway in the 
keratinocytes and fibroblasts suggest that it has a broader role than appreciated earlier. This 
also links p63 to a diverse range of biological processes, which were thought to be p63 
independent. Finally we have shown conclusively that TAp63 suppresses tumorigenesis. It 
would be intriguing to investigate the role of ∆Np63 in tumorigenesis. It appears from the 
preliminary data generated by our lab that ∆Np63could have dual role in both tumor 
suppression and oncogenesis. 
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Appendix 2 : mouse-miRNA heat map      
         
miRNA mES miPS
yam ΔNp63-/-1 ΔNp63-/-2 
Keratinocytes 
1  Keratinocytes 2  
ΔNp63-/- 
+DGCR8-1 
ΔNp63-/- 
+DGCR8-2 
mmu-mir-205-5p -0.670 -0.341 -0.770 -1.011 0.676 0.676 -1.109 -1.105 
mmu-mir-666-5p 0.503 0.214 1.779 1.625 -1.121 -1.100 0.017 -0.490 
mmu-mir-450a-5p 0.092 -0.707 -1.030 -2.010 0.210 0.453 0.820 1.237 
mmu-mir-582-5p -1.123 -1.327 -0.622 -1.257 0.465 0.510 0.638 0.896 
mmu-mir-455-5p -1.852 -1.370 -0.662 0.611 0.882 0.984 1.099 0.868 
mmu-mir-465c-5p 2.402 0.414 0.622 -0.368 -0.684 -0.645 -0.773 -0.757 
mmu-mir-337-3p 1.118 0.890 0.012 2.173 -0.740 -0.718 -0.792 -0.783 
mmu-mir-369-5p 0.907 0.798 1.663 1.389 -0.809 -0.789 -0.857 -0.848 
mmu-mir-150-5p 1.336 1.989 0.544 -0.424 -0.732 -0.694 -0.819 -0.803 
mmu-mir-190-5p -1.183 -0.894 -0.713 -1.420 0.412 0.566 1.550 1.266 
mmu-mir-299-5p 1.135 0.816 -0.274 1.895 -1.059 -1.036 0.460 0.133 
mmu-mir-290-3p 2.244 1.259 0.356 -0.433 -0.685 -0.654 -0.756 -0.743 
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mmu-mir-1968-5p 2.045 1.627 0.271 -0.448 -0.677 -0.649 -0.742 -0.730 
mmu-mir-871-3p 2.373 0.968 0.323 -0.496 -0.045 -0.725 -0.831 -0.818 
mmu-mir-431-5p 0.927 0.751 1.554 1.514 -0.885 -0.866 -0.337 -0.922 
mmu-mir-376b-5p 1.214 0.814 1.576 1.191 -0.963 -0.941 -0.521 -0.521 
mmu-mir-361-5p -0.806 -0.999 -1.475 -0.140 -0.174 -0.099 -0.344 -0.174 
mmu-mir-465a-3p 2.471 1.045 0.236 -0.428 -0.639 -0.613 -0.699 -0.688 
mmu-mir-465b-3p 2.471 1.045 0.236 -0.428 -0.639 -0.613 -0.699 -0.688 
mmu-mir-465c-3p 2.471 1.045 0.236 -0.428 -0.639 -0.613 -0.699 -0.688 
mmu-mir-1843-5p -1.673 -1.499 -0.802 -0.074 1.007 0.922 0.749 0.903 
mmu-mir-758-5p 2.576 0.800 0.259 -0.413 -0.626 -0.600 -0.687 -0.676 
mmu-mir-363-5p 1.552 2.214 0.135 -0.451 -0.638 -0.615 -0.691 -0.682 
mmu-mir-1965 2.246 1.518 0.126 -0.451 -0.634 -0.612 -0.686 -0.677 
mmu-mir-667-5p 1.674 1.070 -0.151 1.695 -0.790 -0.771 -0.433 -0.825 
mmu-mir-673-5p 1.657 1.428 -0.181 1.396 -0.810 -0.792 -0.310 -0.846 
mmu-mir-295-5p 2.178 1.672 0.046 -0.456 -0.616 -0.596 -0.661 -0.653 
mmu-mir-224-5p -1.565 -1.663 -1.200 0.302 0.473 0.531 0.357 -0.014 
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mmu-mir-1893 1.458 0.813 1.835 0.135 -0.954 -0.937 -0.993 -0.986 
mmu-mir-136-5p 1.047 1.016 1.358 0.439 -0.770 -1.216 0.836 0.157 
mmu-mir-194-5p -0.983 -1.169 -0.878 -1.380 0.806 0.856 0.953 1.023 
mmu-mir-540-3p 1.730 1.562 -0.218 1.209 -0.778 -0.762 -0.388 -0.810 
mmu-mir-423-3p -1.939 -1.329 0.023 -0.141 -0.141 0.035 -0.006 -0.079 
mmu-mir-33-5p -0.632 -0.768 -0.932 -1.428 -0.013 -0.066 -0.283 0.004 
mmu-mir-679-5p 1.603 1.482 -0.323 1.419 -0.861 -0.845 -0.110 -0.539 
mmu-mir-323-3p 1.405 1.317 1.635 0.152 -0.840 -0.825 -0.873 -0.867 
mmu-mir-878-5p 2.303 1.530 0.020 -0.452 -0.603 -0.584 -0.645 -0.638 
mmu-mir-3068-5p -1.616 -1.619 -1.361 0.651 0.697 0.697 0.495 0.378 
mmu-mir-23b-5p -0.957 -1.024 -0.599 -0.969 1.390 1.374 1.016 1.126 
mmu-mir-382-5p 1.090 1.010 1.238 1.391 -1.024 -1.010 0.053 -0.309 
mmu-mir-34b-5p -1.333 -1.333 -0.546 -0.982 0.873 0.857 1.308 1.308 
mmu-mir-130a-5p -1.133 -1.246 -0.848 0.015 0.910 0.958 1.423 1.357 
mmu-mir-337-5p 1.538 1.271 1.215 0.447 -1.037 -1.021 0.215 -0.257 
mmu-mir-345-3p -1.647 -1.530 -1.251 -0.237 0.559 0.587 0.683 0.938 
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mmu-mir-409-3p 1.642 1.492 -0.365 1.372 -0.865 -0.850 -0.123 -0.412 
mmu-mir-363-3p 1.775 2.140 -0.039 -0.458 -0.592 -0.576 -0.630 -0.623 
mmu-mir-369-3p 1.494 1.459 0.715 0.849 -1.050 -1.036 0.091 -0.066 
mmu-mir-291b-5p 0.008 2.876 0.150 -0.348 -0.507 -0.488 -0.552 -0.544 
mmu-mir-380-3p 1.426 1.295 1.157 1.064 -0.913 -0.901 -0.455 -0.529 
mmu-mir-294-5p 2.129 1.816 -0.090 -0.459 -0.577 -0.562 -0.610 -0.604 
mmu-mir-200a-5p -0.963 -0.963 -0.788 -1.170 1.546 1.546 -0.463 -0.444 
mmu-mir-106a-5p 1.940 2.029 -0.122 -0.460 -0.567 -0.554 -0.598 -0.592 
mmu-mir-322-5p -0.929 -1.155 -1.906 -0.648 0.726 0.651 0.957 1.023 
mmu-mir-290-5p 2.087 1.882 -0.130 -0.460 -0.564 -0.551 -0.594 -0.589 
mmu-mir-200b-5p -0.704 -0.927 -0.875 -1.245 1.575 1.537 -0.465 -0.561 
mmu-mir-434-3p 1.155 1.065 1.172 1.030 -1.085 -1.075 0.323 0.163 
mmu-mir-30b-5p -1.319 -1.467 -0.864 -0.644 -0.111 0.161 0.198 0.319 
mmu-mir-23a-5p -0.920 -1.030 -0.507 -0.796 1.219 1.198 1.232 1.297 
mmu-mir-380-5p 1.314 1.279 1.100 1.016 -1.024 -1.013 0.052 -0.171 
mmu-mir-18b-5p 1.919 2.058 -0.143 -0.460 -0.560 -0.548 -0.589 -0.584 
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mmu-mir-302a-5p 1.541 2.355 -0.103 -0.452 -0.564 -0.550 -0.595 -0.590 
mmu-mir-20b-5p 1.972 2.012 -0.154 -0.460 -0.557 -0.545 -0.585 -0.580 
mmu-mir-9-5p 0.815 0.815 0.709 1.548 -0.801 -0.877 0.744 0.365 
mmu-mir-210-5p -1.164 -1.076 -0.714 -1.029 1.240 1.240 1.093 1.113 
mmu-mir-185-5p -0.985 -0.978 -1.833 -0.915 0.883 0.845 0.978 1.026 
mmu-mir-27a-5p -1.101 -1.355 -0.785 -0.379 1.391 1.340 0.939 1.045 
mmu-mir-434-5p 1.292 1.190 1.060 1.060 -1.047 -1.037 0.210 -0.076 
mmu-mir-199b-5p -1.377 -1.377 -0.796 0.029 1.006 1.019 1.213 1.224 
mmu-mir-485-5p 1.581 1.265 0.845 1.022 -1.064 -1.053 -0.014 -0.362 
mmu-mir-292-3p 2.034 1.959 -0.180 -0.459 -0.548 -0.537 -0.574 -0.569 
mmu-mir-291a-3p 1.998 1.998 -0.188 -0.459 -0.546 -0.535 -0.570 -0.566 
mmu-mir-291a-5p 2.016 1.983 -0.193 -0.459 -0.544 -0.533 -0.568 -0.564 
mmu-mir-200c-5p -0.981 -0.853 -0.423 -0.732 1.910 1.939 -0.180 -0.145 
mmu-mir-293-5p 2.076 1.918 -0.190 -0.459 -0.545 -0.534 -0.569 -0.565 
mmu-mir-134-5p 1.390 1.234 0.925 1.015 -1.096 -0.815 0.210 -0.044 
mmu-mir-27b-5p -1.037 -1.066 -0.981 -0.460 1.447 1.409 0.889 0.922 
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mmu-mir-29a-5p -1.231 -1.231 -0.727 -0.279 1.091 1.062 1.231 1.378 
mmu-mir-31-5p -1.470 -1.234 -0.534 -0.957 1.130 1.229 -0.281 -0.144 
mmu-mir-411-5p 1.330 1.203 1.107 0.995 -1.134 -1.124 0.112 -0.195 
mmu-mir-148b-5p -0.618 -0.521 -2.081 -0.471 0.874 0.947 1.237 1.218 
mmu-mir-24-1-5p -1.617 -1.727 -0.336 -0.209 1.164 1.164 0.843 0.894 
mmu-mir-221-5p 0.440 0.669 1.047 1.207 -1.359 -1.388 -1.052 -1.052 
mmu-mir-152-5p -1.170 -1.133 -0.734 0.043 1.135 1.135 1.241 1.271 
mmu-mir-292-5p 2.062 1.942 -0.211 -0.459 -0.537 -0.528 -0.560 -0.556 
mmu-mir-148a-5p -0.611 -0.789 -1.251 -0.858 1.059 1.059 1.459 1.270 
mmu-mir-203-5p -1.185 -1.185 -0.764 -0.997 1.652 1.652 0.245 0.133 
mmu-mir-379-5p 1.180 1.072 1.180 1.072 -1.159 -1.152 0.223 0.020 
mmu-mir-378-5p -1.051 -0.958 -0.630 -0.863 1.110 1.110 1.309 1.401 
mmu-mir-30d-5p -1.414 -1.224 -1.414 0.116 -0.154 -0.154 1.312 1.312 
mmu-mir-103-2-5p -0.983 -0.997 -0.133 -0.940 1.225 1.225 1.225 1.225 
mmu-mir-34c-5p -2.587 -0.582 -0.129 -0.582 0.392 0.392 0.392 0.392 
mmu-mir-146b-5p -1.696 -1.364 -0.866 -0.866 0.883 0.883 0.883 0.883 
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Appendix 3 : mouse up-regulated miRNAs and gene targets from mRNA-seq    
       
Category Term 
Count in 
Selected Genes 
Count in Total 
Population P-value Gene 
173 down-regulated 
genes 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 105732 Fam83h 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 106582 Nrm 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 107684 Coro2a 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 108150 Galnt7 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 116972 Fam57a 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 12142 Prdm1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 13728 Mark2 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 15220 Foxq1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 16848 Lfng 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 16969 Zbtb7a 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 170742 Sertad3 
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TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 17122 Mxd4 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 17347 Mknk2 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 17920 Myo6 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 18003 Nedd9 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 18554 Pcsk7 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 18583 Pde7a 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 19340 Rab3d 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 195733 Grhl1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 20111 Rps6ka1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 20354 Sema4d 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 211945 Plekhh1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 212168 Zswim4 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 214112 Nipal4 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 214531 Tmprss13 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 218215 Rnf144b 
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TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 218442 Serinc5 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 22337 Vdr 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 228543 Rhov 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 230857 Ece1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 231287 Atp10d 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 232146 Fam176a 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 235584 Dusp7 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 235627 Nbeal2 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 240505 Cdc42bpg 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 26403 Map3k11 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 26569 Slc27a4 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 269181 Mgat4a 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 30838 Fbxw4 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 330192 Vps37b 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 360013 Myo18a 
    
  
2
2
1
 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 52588 Tspan14 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 53883 Celsr2 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 53970 Rfx5 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 54325 Elovl1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 57912 Cdc42se1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 66451 2610528J11Rik 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 668158 Ccdc85c 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 67998 Fam134c 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 69727 Usp46 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 70737 Cgn 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 71145 Scara5 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 71653 4930506M07Rik 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 71911 Bdh1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 74559 Elovl7 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 75146 Tmem180 
    
  
2
2
2
 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 76459 Car12 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 77053 Sun1 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 78255 Ralgps2 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 78334 Cdk19 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 79566 Sh3bp5l 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 83796 Smarcd2 
TargetScan6.0 mmu-mir-125b-5p 63 704 8.36196E-10 97130 C77080 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 100532 Rell1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 100737 Dcun1d4 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 101476 Plekha1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 101772 Ano1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 105445 Dock9 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 108100 Baiap2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 114301 Palmd 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 11658 Alcam 
    
  
2
2
3
 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 12142 Prdm1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 12224 Klf5 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 12227 Btg2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 12306 Anxa2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 12550 Cdh1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 12822 Col18a1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 13367 Diap1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 13636 Efna1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 14425 Galnt3 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 15205 Hes1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 16403 Itga6 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 16480 Jup 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 16564 Kif21a 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 17691 Sik1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 17761 Mtap7 
    
  
2
2
4
 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 17988 Ndrg1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 20530 Slc31a2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 20623 Snrk 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 208618 Etl4 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 20969 Sdc1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 212531 Sh3bgrl2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 212632 Iffo2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 214230 Pak6 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 215819 Nhsl1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 216551 1110067D22Rik 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 21810 Tgfbi 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 218442 Serinc5 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 22417 Wnt4 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 22779 Ikzf2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 229658 Vangl1 
    
  
2
2
5
 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 230257 Rod1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 231070 Insig1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 231207 Cpeb2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 233011 Itpkc 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 238988 Erc2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 244049 Mctp2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 26569 Slc27a4 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 27428 Shroom3 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 30945 Rnf19a 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 387524 Znrf2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 52392 D1Ertd622e 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 53883 Celsr2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 64297 Gprc5b 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 66044 Dtd1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 66540 Fam107b 
    
  
2
2
6
 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 668225 Fignl2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 67486 Polr3g 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 69354 Slc38a4 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 69386 Hist1h4h 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 70584 Pak4 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 71436 Flrt3 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 71720 Osbpl3 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 71885 2310003H01Rik 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 72504 Taf4b 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 72549 Reep4 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 73102 Slc22a23 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 73469 Rnf38 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 75599 Pcdh1 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 78255 Ralgps2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 83603 Elovl4 
    
  
2
2
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TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 83796 Smarcd2 
TargetScan6.0 mmu-mir-9-5p 70 1069 1.57902E-05 98878 Ehd4 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 103710 Slc35e4 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 108100 Baiap2 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 108902 B3gnt1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 12305 Ddr1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 12389 Cav1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 14368 Fzd6 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 16477 Junb 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 211945 Plekhh1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 22422 Wnt7b 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 226250 Afap1l2 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 230857 Ece1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 232431 Gprc5a 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 26403 Map3k11 
    
  
2
2
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TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 28075 Pppde2 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 50767 Pnpla6 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 50799 Slc25a13 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 50932 Mink1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 54324 Arhgef5 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 54648 Ccdc120 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 56430 Clip1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 56496 Tspan6 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 57278 Bcam 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 58235 Pvrl1 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 66540 Fam107b 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 66960 Fam188a 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 69727 Usp46 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 70178 Fam108c 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 70584 Pak4 
    
  
2
2
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TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 71085 Arhgap19 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 71436 Flrt3 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 73469 Rnf38 
TargetScan6.0 mmu-mir-199a-5p 32 369 2.22547E-05 77053 Sun1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 105445 Dock9 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 110075 Bmp3 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 12224 Klf5 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 12388 Ctnnd1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 13512 Dsg3 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 13638 Efna3 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 14012 Mpzl2 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 15402 Hoxa5 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 16564 Kif21a 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 17240 Mdfi 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 18003 Nedd9 
    
  
2
3
0
 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 18569 Pdcd4 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 20166 Rtkn 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 20682 Sox9 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 211945 Plekhh1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 218215 Rnf144b 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 218442 Serinc5 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 226352 Epb4.1l5 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 22779 Ikzf2 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 230857 Ece1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 231070 Insig1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 26403 Map3k11 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 26921 Map4k4 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 27360 Add3 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 382236 Brwd3 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 53892 Ppm1d 
    
  
2
3
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TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 54648 Ccdc120 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 56349 Net1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 56430 Clip1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 56496 Tspan6 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 58235 Pvrl1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 66540 Fam107b 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 69727 Usp46 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 69743 Casz1 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 70178 Fam108c 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 70584 Pak4 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 71889 Epn3 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 75678 Ippk 
TargetScan6.0 mmu-mir-145-5p 39 528 0.00010874 77053 Sun1 
TargetScan6.0 mmu-mir-100-5p 6 46 0.008425052 15394 Hoxa1 
TargetScan6.0 mmu-mir-100-5p 6 46 0.008425052 16969 Zbtb7a 
    
  
2
3
2
 
TargetScan6.0 mmu-mir-100-5p 6 46 0.008425052 211770 Trib1 
TargetScan6.0 mmu-mir-100-5p 6 46 0.008425052 232174 Cyp26b1 
TargetScan6.0 mmu-mir-100-5p 6 46 0.008425052 69274 Ctdspl 
TargetScan6.0 mmu-mir-100-5p 6 46 0.008425052 76787 Ppfia3 
 
 
 
 
 
 
 
 
 
 
 
    
  
2
3
3
 
Appendix 4 : mouse down-regulated miRNA and their gene targets from mRNA-seq   
       
Category Term 
Count in Selected 
Genes 
Count in Total 
Population P-value Gene 
750 up-regulated 
genes 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 100515 Zfp518b 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 100710 Pds5b 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 104156 Etv5 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 108012 Ap1s2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 108154 Adamts6 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 108797 Mex3b 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 108899 2700081O15Rik 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 108927 Lhfp 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 114715 Spred1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 11641 Akap2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 12151 Bmi1 
    
  
2
3
4
 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 12321 Calu 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 12361 Cask 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 13527 Dtna 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 13557 E2f3 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 14020 Evi5 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 14247 Fli1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 14254 Flt1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 14299 Ncs1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 14360 Fyn 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 14461 Gata2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 14745 Lpar1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 15227 Foxf1a 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 15228 Foxg1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 15476 Hs3st1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 15526 Hspa9 
    
  
2
3
5
 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 16543 Mdfic 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 16565 Kif21b 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 16597 Klf12 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 16764 Aff3 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 16911 Lmo4 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 16971 Lrp1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 170719 Oxr1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 17698 Msn 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 17984 Ndn 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 18007 Neo1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 18080 Nin 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 18383 Tnfrsf11b 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 19009 Pou6f1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 19248 Ptpn12 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 193813 Mcfd2 
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TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 20112 Rps6ka2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 20444 St3gal2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 20471 Six1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 20868 Stk10 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 208691 Eif5a2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 209131 Snx30 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 209630 Frmd4a 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 21413 Tcf4 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 21417 Zeb1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 215280 Wipf1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 21676 Tead1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 21807 Tsc22d1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 22196 Ube2i 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 22339 Vegfa 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 225020 Fez2 
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TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 226144 Erlin1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 226178 D19Wsu162e 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 226841 Vash2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 229706 Slc6a17 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 231380 Uba6 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 231912 Katnal1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 234875 Ttc13 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 238130 Dock4 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 23821 Bace1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 23893 Grem2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 23908 Hs2st1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 24136 Zeb2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 242481 Palm2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 242509 Bnc2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 244895 C230081A13Rik 
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TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 26564 Ror2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 269713 Clip2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 279653 Pcdh19 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 330627 Trim66 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 381560 Xkr8 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 382252 A830080D01Rik 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 50768 Dlc1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 53614 Reck 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 53619 Blcap 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 54371 Chst2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 56323 Dnajb5 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 56442 Serinc1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 56542 Ick 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 56693 Crtap 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 56807 Scamp5 
    
  
2
3
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TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 59036 Dact1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 67468 Mmd 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 67916 Ppap2b 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 68178 Cgnl1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 68337 Crip2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 68606 Ppm1f 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 70097 Sash1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 70533 Btf3l4 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 70549 Tln2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 71323 Rassf8 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 71532 9030418K01Rik 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 71709 Syde1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 71918 Zcchc24 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 72033 Tsc22d2 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 72611 Zfp655 
    
  
2
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0
 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 72640 Mex3a 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 75717 Cul5 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 80892 Zfhx4 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 83767 Wasf1 
TargetScan6.0 mmu-mir-200b-5p 106 868 1.33959E-23 83814 Nedd4l 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 114249 Npnt 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 11641 Akap2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 117160 Ttyh2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 12167 Bmpr1b 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 12321 Calu 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 12406 Serpinh1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 13401 Dmwd 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 13557 E2f3 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 13852 Stx2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 14465 Gata6 
    
  
2
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1
 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 14489 Mtpn 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 14758 Gpm6b 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 16565 Kif21b 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 16597 Klf12 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 17076 Ly75 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 17967 Ncam1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 18208 Ntn1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 18491 Pappa 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 19270 Ptprg 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 20315 Cxcl12 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 20358 Sema6a 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 20441 St3gal3 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 20471 Six1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 209630 Frmd4a 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 211712 Pcdh9 
    
  
2
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2
 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 21413 Tcf4 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 21417 Zeb1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 215280 Wipf1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 217869 Eif5 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 229706 Slc6a17 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 231380 Uba6 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 235184 BC024479 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 238130 Dock4 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 23821 Bace1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 23908 Hs2st1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 24066 Spry4 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 24136 Zeb2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 242509 Bnc2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 243931 Tshz3 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 244668 Sipa1l2 
    
  
2
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3
 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 244895 C230081A13Rik 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 270669 Mbtps2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 279653 Pcdh19 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 319622 Itpripl2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 319939 Tns3 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 319996 Casc4 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 320827 C530008M17Rik 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 329165 Abi2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 50768 Dlc1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 56741 Igdcc4 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 629378 Dact3 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 66573 Dzip1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 71918 Zcchc24 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 72349 Dusp3 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 72701 Zfp618 
    
  
2
4
4
 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 74051 Steap2 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 77579 Myh10 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 78100 8430410K20Rik 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 78428 Wibg 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 83964 Jam3 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 93759 Sirt1 
TargetScan6.0 mmu-mir-141-5p 62 592 2.46229E-11 93834 Peli2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 114249 Npnt 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 11641 Akap2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 117160 Ttyh2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 12167 Bmpr1b 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 12321 Calu 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 12406 Serpinh1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 13401 Dmwd 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 13557 E2f3 
    
  
2
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5
 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 13852 Stx2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 14465 Gata6 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 14489 Mtpn 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 14758 Gpm6b 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 16565 Kif21b 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 16597 Klf12 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 17076 Ly75 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 17967 Ncam1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 18208 Ntn1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 18491 Pappa 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 19270 Ptprg 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 20315 Cxcl12 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 20358 Sema6a 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 20441 St3gal3 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 20471 Six1 
    
  
2
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6
 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 209630 Frmd4a 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 211712 Pcdh9 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 21413 Tcf4 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 21417 Zeb1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 215280 Wipf1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 217869 Eif5 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 229706 Slc6a17 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 231380 Uba6 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 235184 BC024479 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 238130 Dock4 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 23821 Bace1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 23908 Hs2st1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 24066 Spry4 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 24136 Zeb2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 242509 Bnc2 
    
  
2
4
7
 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 243931 Tshz3 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 244668 Sipa1l2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 244895 C230081A13Rik 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 270669 Mbtps2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 279653 Pcdh19 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 319622 Itpripl2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 319939 Tns3 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 319996 Casc4 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 320827 C530008M17Rik 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 329165 Abi2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 50768 Dlc1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 56741 Igdcc4 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 629378 Dact3 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 66573 Dzip1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 71918 Zcchc24 
    
  
2
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TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 72349 Dusp3 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 72701 Zfp618 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 74051 Steap2 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 77579 Myh10 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 78100 8430410K20Rik 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 78428 Wibg 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 83964 Jam3 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 93759 Sirt1 
TargetScan6.0 mmu-mir-200a-5p 62 592 2.46229E-11 93834 Peli2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 114715 Spred1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 11852 Rhob 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 12151 Bmi1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 12877 Cpeb1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 13527 Dtna 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 14299 Ncs1 
    
  
2
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TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 15476 Hs3st1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 16563 Kif2a 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 17912 Myo1b 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 18227 Nr4a2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 19099 Mapk8ip1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 19165 Psen2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 20429 Shox2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 20742 Spnb2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 21413 Tcf4 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 21417 Zeb1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 217340 Rnf157 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 223527 Eny2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 233489 Picalm 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 238871 Pde4d 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 23893 Grem2 
    
  
2
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0
 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 24060 Slc35a1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 24064 Spry2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 24136 Zeb2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 242481 Palm2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 242509 Bnc2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 26611 Rcn2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 330267 Thsd7a 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 382034 Gse1 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 52592 Brms1l 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 56542 Ick 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 59046 Arpp19 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 74480 Samd4 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93701 Pcdhgb4 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93706 Pcdhgc3 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93707 Pcdhgc4 
    
  
2
5
1
 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93708 Pcdhgc5 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93710 Pcdhga2 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93711 Pcdhga3 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93716 Pcdhga8 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93717 Pcdhga9 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93723 Pcdhga11 
TargetScan6.0 mmu-mir-183-5p 43 332 3.9476E-11 93724 Pcdhga12 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 108116 Slco3a1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 114249 Npnt 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 11492 Adam19 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 12631 Cfl1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 12831 Col5a1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 12877 Cpeb1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 13591 Ebf1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 13712 Elk1 
    
  
2
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2
 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 13823 Epb4.1l3 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14020 Evi5 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14254 Flt1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14360 Fyn 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14389 Gab2 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14432 Gap43 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14573 Gdnf 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14758 Gpm6b 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 14783 Grb10 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 17532 Mras 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 17698 Msn 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 18015 Nf1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 18196 Nsg1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 18491 Pappa 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 18595 Pdgfra 
    
  
2
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TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 19335 Rab23 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 20163 Rsu1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 20358 Sema6a 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 20429 Shox2 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 20441 St3gal3 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 20444 St3gal2 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 207806 Gm608 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 209131 Snx30 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 209630 Frmd4a 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 213760 Prepl 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 21384 Tbx15 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 21413 Tcf4 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 21417 Zeb1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 215280 Wipf1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 21676 Tead1 
    
  
2
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4
 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 217869 Eif5 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 223254 Farp1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 223732 Ldoc1l 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 226144 Erlin1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 226432 Ipo9 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 228602 4930402H24Rik 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 228662 Btbd3 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 229517 Slc25a44 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 233115 Dpy19l3 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 235431 Coro2b 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 237782 Smcr8 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 238130 Dock4 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 24056 Sh3bp5 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 24060 Slc35a1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 242509 Bnc2 
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TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 26949 Vat1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 27426 Nagpa 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 319939 Tns3 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 320150 Zdhhc17 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 320165 Tacc1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 329165 Abi2 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 360213 Trim46 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 53614 Reck 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 546336 Prrg1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 56428 Mtch2 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 58194 Sh3kbp1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 59046 Arpp19 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 64540 Tspan4 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 68404 Nrn1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 68606 Ppm1f 
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TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 69219 Ddah1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 70546 Zdhhc2 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 70676 Gulp1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 71093 Atoh8 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 71323 Rassf8 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 71914 Antxr2 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 72543 Fam125b 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 74136 Sec14l1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 75717 Cul5 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 76438 Rftn1 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 78339 Ttyh3 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 78619 Zfp449 
TargetScan6.0 mmu-mir-96-5p 81 898 4.72988E-11 80892 Zfhx4 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 106585 Ankrd12 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 11551 Adra2a 
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TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 11858 Rnd2 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 12321 Calu 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 12395 Runx1t1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 13591 Ebf1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 13821 Epb4.1l1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 14009 Etv1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 14573 Gdnf 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 16497 Kcnab1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 16764 Aff3 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 16923 Sh2b3 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 17076 Ly75 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 18032 Nfix 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 18208 Ntn1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 18595 Pdgfra 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 20346 Sema3a 
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TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 20361 Sema7a 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 20444 St3gal2 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 209683 Ttc28 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 212712 Satb2 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 21413 Tcf4 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 22629 Ywhah 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 228662 Btbd3 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 235402 Lingo1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 238871 Pde4d 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 53623 Gria3 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 54216 Pcdh7 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 56177 Olfm1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 56542 Ick 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 58194 Sh3kbp1 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 664994 Isoc2a 
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TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 665563 Mthfd2l 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 71323 Rassf8 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 71973 Rbpms2 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 74480 Samd4 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 76108 Rap2a 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 78619 Zfp449 
TargetScan6.0 mmu-mir-33-5p 39 286 6.74602E-11 80892 Zfhx4 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 
10003912
3 Gm14295 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 105000 Dnalc1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 105245 Txndc5 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 108099 Prkag2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 108797 Mex3b 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 11864 Arnt2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 12831 Col5a1 
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TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14225 Fkbp1a 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14254 Flt1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14465 Gata6 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14489 Mtpn 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14681 Gnao1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14696 Gnb4 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14702 Gng2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 14783 Grb10 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 15111 Hand2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 16201 Ilf3 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 16443 Itsn1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 16948 Lox 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 16978 Lrrfip1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 17690 Msi1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 17754 Mtap1a 
    
  
2
6
1
 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 17755 Mtap1b 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 18007 Neo1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 18383 Tnfrsf11b 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 18595 Pdgfra 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 18787 Serpine1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 208440 Dip2c 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 20868 Stk10 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 21676 Tead1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 21814 Tgfbr3 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 22221 Ubp1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 224860 Plcl2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 225358 Fam13b 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 226778 Mark1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 228662 Btbd3 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 229521 Syt11 
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TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 233489 Picalm 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 233545 2210018M11Rik 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 23794 Adamts5 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 238130 Dock4 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 23881 G3bp2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 239393 Lrp12 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 24066 Spry4 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 24136 Zeb2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 242481 Palm2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 242509 Bnc2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 244668 Sipa1l2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 244895 C230081A13Rik 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 319996 Casc4 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 328949 Mcc 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 333433 Gpd1l 
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TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 382034 Gse1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 382793 Mtx3 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 434215 Lrrc32 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 53614 Reck 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 55992 Trim3 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 56323 Dnajb5 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 66262 Ing5 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 67299 Dock7 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 67897 Rnmt 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 67916 Ppap2b 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 68617 1110012J17Rik 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 69976 Galk2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 70292 Afap1 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 71323 Rassf8 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 71738 Mamdc2 
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TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 72033 Tsc22d2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 72611 Zfp655 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 72640 Mex3a 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 72701 Zfp618 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 73467 1700066M21Rik 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 75717 Cul5 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 77579 Myh10 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 78339 Ttyh3 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 78619 Zfp449 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 80892 Zfhx4 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 81703 Jdp2 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 83435 Plekha3 
TargetScan6.0 mmu-mir-181cd-5p 80 891 7.81212E-11 93759 Sirt1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 100515 Zfp518b 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 109676 Ank2 
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TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 12167 Bmpr1b 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 12321 Calu 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 12977 Csf1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 14389 Gab2 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 14783 Grb10 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 15476 Hs3st1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 16323 Inhba 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 16597 Klf12 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 16971 Lrp1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 18576 Pde3b 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 20868 Stk10 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 212712 Satb2 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 21417 Zeb1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 21676 Tead1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 217340 Rnf157 
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TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 217351 Tnrc6c 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 21843 Tial1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 22339 Vegfa 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 228662 Btbd3 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 234839 Fam38a 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 24060 Slc35a1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 246154 Vasn 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 269152 Kif26b 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 269424 Phf17 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 319996 Casc4 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 320184 Lrrc58 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 50493 Txnrd1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 54598 Calcrl 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 56386 B4galt6 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 66725 Lrrk2 
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TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 67468 Mmd 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 71330 Rcbtb1 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 71752 Gtf3c2 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 71973 Rbpms2 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 73230 Bmper 
TargetScan6.0 mmu-mir-205-5p 38 315 4.01818E-09 94223 Dgcr8 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 105000 Dnalc1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 108012 Ap1s2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 108099 Prkag2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 108154 Adamts6 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 108927 Lhfp 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 11737 Anp32a 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 11858 Rnd2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 12151 Bmi1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 12361 Cask 
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TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 12395 Runx1t1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 13591 Ebf1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 13617 Ednra 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 14009 Etv1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 14299 Ncs1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 15904 Id4 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 16011 Igfbp5 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 16563 Kif2a 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 16911 Lmo4 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 170625 Snx18 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 17527 Mpv17 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 18196 Nsg1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 18595 Pdgfra 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 20346 Sema3a 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 20358 Sema6a 
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TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 20692 Sparc 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 20742 Spnb2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 208968 Zfp280c 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 21386 Tbx3 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 21413 Tcf4 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 22196 Ube2i 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 22339 Vegfa 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 228071 Sestd1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 23794 Adamts5 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 238871 Pde4d 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 240427 Setbp1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 242481 Palm2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 26564 Ror2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 26611 Rcn2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 269023 Zfp608 
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TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 279653 Pcdh19 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 320827 C530008M17Rik 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 330267 Thsd7a 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 50706 Postn 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 56542 Ick 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 67916 Ppap2b 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 69675 Pxdn 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 71323 Rassf8 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 71566 9030425E11Rik 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 71914 Antxr2 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 73230 Bmper 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 76108 Rap2a 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 77057 Ston1 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 80892 Zfhx4 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 81904 Cacng7 
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TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 83814 Nedd4l 
TargetScan6.0 mmu-mir-203-5p 56 590 8.29817E-09 93683 Glce 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 105727 Slc38a1 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 108116 Slco3a1 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 11853 Rhoc 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 13591 Ebf1 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 14585 Gfra1 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 14702 Gng2 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 16210 Impact 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 16565 Kif21b 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 16597 Klf12 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 16764 Aff3 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 16800 Arhgef2 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 16923 Sh2b3 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 17690 Msi1 
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TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 18032 Nfix 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 18111 Nnat 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 18412 Sqstm1 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 18491 Pappa 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 20441 St3gal3 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 209131 Snx30 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 209630 Frmd4a 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 20970 Sdc3 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 21413 Tcf4 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 218952 Fermt2 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 22221 Ubp1 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 228602 4930402H24Rik 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 229706 Slc6a17 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 230753 Thrap3 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 24136 Zeb2 
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TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 270669 Mbtps2 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 320706 9830001H06Rik 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 380686 Cnrip1 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 53619 Blcap 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 56316 Ggcx 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 594844 Tceal3 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 629059 Fam124a 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 70551 Tmtc4 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 71566 9030425E11Rik 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 72640 Mex3a 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 78752 Csgalnact2 
TargetScan6.0 mmu-mir-138-5p 40 453 6.47987E-06 93759 Sirt1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 105000 Dnalc1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 108078 Olr1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 12035 Bcat1 
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TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 12321 Calu 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 12361 Cask 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 12395 Runx1t1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 12832 Col5a2 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 12877 Cpeb1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 14489 Mtpn 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 14600 Ghr 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 14852 Gspt1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 15248 Hic1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 15277 Hk2 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 16193 Il6 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 16565 Kif21b 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 16886 Limk2 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 16923 Sh2b3 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 170676 Peg10 
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TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 18208 Ntn1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 18414 Osmr 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 18491 Pappa 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 18933 Prrx1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 19734 Rgs16 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 209131 Snx30 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 214642 A430107O13Rik 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 21814 Tgfbr3 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 21825 Thbs1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 22240 Dpysl3 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 223254 Farp1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 226841 Vash2 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 228071 Sestd1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 228602 4930402H24Rik 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 228662 Btbd3 
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TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 229521 Syt11 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 230233 Ikbkap 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 235402 Lingo1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 23794 Adamts5 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 242509 Bnc2 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 244895 C230081A13Rik 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 270669 Mbtps2 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 277154 Nynrin 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 279653 Pcdh19 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 320024 Nceh1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 330222 Sdk1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 380785 Begain 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 381560 Xkr8 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 433926 Lrrc8b 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 50768 Dlc1 
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TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 52187 Rragd 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 56741 Igdcc4 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 59046 Arpp19 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 66573 Dzip1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 68178 Cgnl1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 68606 Ppm1f 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 69675 Pxdn 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 72033 Tsc22d2 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 72543 Fam125b 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 72640 Mex3a 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 74136 Sec14l1 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 75612 Gns 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 77889 Lbh 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 78923 Chsy3 
TargetScan6.0 mmu-let-7e-5p 63 913 5.68768E-05 83814 Nedd4l 
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TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 105245 Txndc5 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 11551 Adra2a 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 12831 Col5a1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 12890 Cplx2 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 13527 Dtna 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 13591 Ebf1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 13712 Elk1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 14020 Evi5 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 14225 Fkbp1a 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 14489 Mtpn 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 16323 Inhba 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 16800 Arhgef2 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 16978 Lrrfip1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 170625 Snx18 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 17532 Mras 
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TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 18196 Nsg1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 18577 Pde4a 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 20315 Cxcl12 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 20742 Spnb2 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 208440 Dip2c 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 209630 Frmd4a 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 218952 Fermt2 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 23821 Bace1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 240427 Setbp1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 24060 Slc35a1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 269424 Phf17 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 330222 Sdk1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 330627 Trim66 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 433375 Creg1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 53614 Reck 
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TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 53623 Gria3 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 58193 Extl2 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 70676 Gulp1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 73230 Bmper 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 74136 Sec14l1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 75292 Prkd3 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 76108 Rap2a 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 81703 Jdp2 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 93759 Sirt1 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 93834 Peli2 
TargetScan6.0 mmu-mir-135b-5p 41 578 0.00062505 94332 Cadm3 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 114715 Spred1 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 12831 Col5a1 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 13992 Khdrbs3 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 14783 Grb10 
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TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 14852 Gspt1 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 208968 Zfp280c 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 212712 Satb2 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 213760 Prepl 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 215280 Wipf1 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 217869 Eif5 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 22240 Dpysl3 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 223527 Eny2 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 233115 Dpy19l3 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 24066 Spry4 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 320165 Tacc1 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 320827 C530008M17Rik 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 330812 Rnf150 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 57752 Tacc2 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 71709 Syde1 
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TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 72543 Fam125b 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 75717 Cul5 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 80892 Zfhx4 
TargetScan6.0 mmu-mir-31-5p 23 285 0.001870575 83814 Nedd4l 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 104111 Adcy3 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 12321 Calu 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 12832 Col5a2 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 14020 Evi5 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 14173 Fgf2 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 14254 Flt1 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 14260 Fmn1 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 14852 Gspt1 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 18760 Prkd1 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 207806 Gm608 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 211712 Pcdh9 
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TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 228598 Ebf4 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 238130 Dock4 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 24136 Zeb2 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 56693 Crtap 
TargetScan6.0 mmu-mir-335-3p 16 187 0.004954846 76156 Fam131b 
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Appendix 6 : mouse-human miRNA Principal component analysis plot 
   
Samples PC1 PC2 
mES -0.647453275 0.036247611 
miPSyam -0.596911562 0.001834562 
ΔNp63-/-1 0.118460771 -0.502636132 
ΔNp63-/-2 0.158769753 -0.483563594 
ΔNp63-/-3 0.198706084 -0.218191284 
Keratinocytes 1 0.136683214 0.34770748 
Keratinocytes 2 0.129638738 0.357601714 
ΔNp63-/- +DGCR8-1 0.179837435 0.127427349 
ΔNp63-/- +DGCR8-2 0.192831842 0.153209111 
hiPSYam -0.044529441 -0.128145687 
NHEK 0.182937225 0.34928618 
NHEK_shDGCR8 0.008526762 -0.127011174 
NHEK_shDNp63 0.072389336 -0.146813651 
    
  
2
8
6
 
 
 
 
 
 
 
 
 
 
 
    
  
2
8
7
 
  
    
  
2
8
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 9 : mouse-human mRNA Principal component analysis plot 
   
Samples PC1 PC2 
NHEK -0.42794346 -0.109069577 
NHEK_shDGCR8 0.14228023 0.042429771 
NHEK_shDNp63 0.1502105 0.059231079 
hiPSYam 0.13545272 0.007408728 
Keratinocytes 1 -0.29061823 -0.289488466 
Keratinocytes 3 -0.33900544 -0.30777434 
Keratinocytes 2 -0.15839084 -0.14042462 
miPSYam 0.49921979 -0.196523198 
mES 0.5242491 -0.199355859 
ΔNp63-/-2 -0.06710176 0.599467252 
ΔNp63-/-1 -0.05175552 0.588869705 
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Appendix 10 : mouse-differentially expressed miRNA in null vs. ips cells 
      
miRNA mES miPSyam ΔNp63-/-1 ΔNp63-/-2 ΔNp63-/-3 
mmu-mir-330-5p -0.859480032 -0.599228492 0.056537231 1.679855452 -0.277684159 
mmu-mir-1839-3p -0.877676735 -0.942556401 -0.301193989 1.073493244 1.047933881 
mmu-mir-574-5p -0.832995553 -0.792672909 -0.282420208 0.330495737 1.577592933 
mmu-mir-201-5p -0.685225118 -0.685225118 0.027056098 -0.367015388 1.710409526 
mmu-mir-455-5p -1.050513568 -0.534849248 0.223078987 1.584658565 -0.222374736 
mmu-mir-126-5p 1.066205393 1.013129269 -0.281228587 -1.164658854 -0.633447221 
mmu-mir-125a-3p -0.803898973 -0.885139532 1.289615562 0.84290538 -0.443482438 
mmu-mir-3107-5p -1.059874736 -1.059874736 0.808771955 0.309159443 1.001818074 
mmu-mir-486-5p -1.059874736 -1.059874736 0.808771955 0.309159443 1.001818074 
mmu-mir-467d-5p 0.028046456 1.61090862 -0.079189213 -1.08111466 -0.478651203 
mmu-mir-300-5p -0.574665464 -1.25480715 1.257982759 -0.132224971 0.703714826 
mmu-mir-150-5p 0.644470584 1.328778155 -0.185004531 -1.19897529 -0.589268918 
mmu-mir-467e-5p 0.764853612 1.278162943 -0.272033443 -1.149220261 -0.62176285 
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mmu-mir-676-5p -0.633164487 -0.870882714 -0.39477627 0.285313685 1.613509786 
mmu-mir-290-3p 1.456742386 0.531116718 -0.316940662 -1.058372939 -0.612545503 
mmu-mir-1968-5p 1.246838976 0.860757032 -0.392696971 -1.05724896 -0.657650078 
mmu-mir-345-5p -0.945421349 -0.800113023 -0.375444445 0.865857039 1.255121778 
mmu-mir-871-3p 1.569739575 0.301941223 -0.279210117 -1.018507066 -0.573963615 
mmu-mir-466n-3p 1.177722434 0.939078637 -0.386458373 -1.070972447 -0.65937025 
mmu-mir-365-2-5p -0.850240765 -0.675370786 0.023760162 1.670877215 -0.169025826 
mmu-mir-301a-5p -0.981628752 -0.784171351 0.318945829 1.521255501 -0.074401227 
mmu-mir-184-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-652-5p -1.070012452 -0.873969019 1.245184502 -0.035704397 0.734501367 
mmu-mir-494-5p -0.360270816 -1.356421412 1.242643363 -0.195296167 0.669345032 
mmu-mir-465a-3p 1.579347951 0.336157497 -0.368799941 -0.947272028 -0.599433479 
mmu-mir-465b-3p 1.579347951 0.336157497 -0.368799941 -0.947272028 -0.599433479 
mmu-mir-465c-3p 1.579347951 0.336157497 -0.368799941 -0.947272028 -0.599433479 
mmu-mir-1843-5p -1.070005039 -0.868356361 -0.062164057 0.781024245 1.219501212 
mmu-mir-466a-3p 0.539133686 1.45887459 -0.338336967 -1.041133395 -0.618537914 
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mmu-mir-466e-3p 0.539133686 1.45887459 -0.338336967 -1.041133395 -0.618537914 
mmu-mir-758-5p 1.656638628 0.134693773 -0.328861778 -0.904217702 -0.55825292 
mmu-mir-466b-3p 0.528852321 1.474387193 -0.368469295 -1.010376261 -0.624393959 
mmu-mir-466c-3p 0.528852321 1.474387193 -0.368469295 -1.010376261 -0.624393959 
mmu-mir-466p-3p 0.528852321 1.474387193 -0.368469295 -1.010376261 -0.624393959 
mmu-mir-669b-5p 0.796161503 1.314855919 -0.448505792 -0.995801961 -0.666709669 
mmu-mir-335-5p 1.519791727 0.470877912 -0.411970387 -0.951586846 -0.627112407 
mmu-mir-1929-5p -1.314562181 -0.64048103 0.086754696 0.700763714 1.167524801 
mmu-mir-125b-1-3p -1.076280589 -1.110844898 0.791073755 0.758712772 0.637338961 
mmu-mir-363-5p 0.766292574 1.341604426 -0.464865942 -0.974840968 -0.668190091 
mmu-mir-1965 1.364980274 0.735268762 -0.467750909 -0.966070159 -0.666427966 
mmu-mir-195-5p 1.069263899 1.093680246 -0.51275689 -0.959368751 -0.690818504 
mmu-mir-3086-5p -0.920062235 -0.990749997 1.398577586 0.050340142 0.461894504 
mmu-mir-673-5p 0.891966007 0.657274406 -0.989510219 0.624736357 -1.18446655 
mmu-mir-206-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-1940 0.503245945 1.140833798 -0.78197301 -1.286081426 0.423974694 
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mmu-mir-295-5p 1.283648837 0.856786765 -0.51591659 -0.939658805 -0.684860207 
mmu-mir-224-5p -0.776377901 -0.855491178 -0.480617751 0.737591198 1.374895632 
mmu-mir-181d-5p 0.342660853 0.85249792 -1.734308959 0.306056651 0.233093534 
mmu-mir-467c-5p 0.865325139 1.277385655 -0.518761473 -0.938028474 -0.685920847 
mmu-mir-532-5p -0.867789916 -1.254921723 0.621696224 0.468477305 1.032538111 
mmu-mir-3082-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-149-5p -0.773153606 -0.763083444 -0.472257364 0.465784005 1.542710408 
mmu-mir-142-3p 1.1306458 1.039485233 -0.548524296 -0.923558452 -0.698048285 
mmu-mir-709 1.031537577 0.591271173 0.516955422 -1.191927902 -0.94783627 
mmu-mir-720 -0.749915316 -0.950656605 1.302097226 -0.416810869 0.815285564 
mmu-mir-381-5p -0.577380188 -1.091011818 1.371056902 -0.376843734 0.674178838 
mmu-mir-140-5p -1.203907864 -0.790756602 0.412034929 0.289727814 1.292901722 
mmu-mir-540-3p 0.944279425 0.777003443 -0.990137167 0.427189216 -1.158334918 
mmu-mir-423-3p -1.186088102 -0.718220927 0.318938321 0.193130552 1.392240156 
mmu-mir-99a-5p -1.113090369 -1.0387352 0.434414226 0.762288774 0.955122569 
mmu-mir-669c-5p 0.694827875 1.321410231 -0.831933502 -0.157590928 -1.026713676 
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mmu-mir-679-5p 0.824579791 0.709465983 -1.013998126 0.649181655 -1.169229304 
mmu-mir-878-5p 1.377209228 0.734249138 -0.520817398 -0.913330732 -0.677310237 
mmu-mir-3068-5p -0.794250577 -0.797020884 -0.589654209 1.027164899 1.15376077 
mmu-mir-34b-5p -0.7264461 -0.7264461 0.123566661 -0.346705169 1.676030708 
mmu-mir-130a-5p -0.558150472 -0.780184986 0.0063819 1.713041383 -0.381087824 
mmu-mir-484 -1.082065736 -0.760729354 -0.190385491 0.745235985 1.287944596 
mmu-mir-92b-5p 1.079758214 0.781651748 -0.807504617 -1.239595921 0.185690575 
mmu-mir-92a-2-5p 0.895213486 0.643648885 0.573589104 -0.72150283 -1.390948645 
mmu-mir-337-5p 0.867061716 0.569965774 0.507186346 -0.349161781 -1.595052055 
mmu-mir-345-3p -0.876443569 -0.749698625 -0.450046087 0.64313954 1.433048741 
mmu-mir-222-5p -1.178489848 -0.999433566 0.605270598 0.71805017 0.854602646 
mmu-mir-409-3p 0.857708196 0.717017814 -1.019071681 0.604595395 -1.160249724 
mmu-mir-126-3p 0.828545555 0.914826709 -1.405927945 -0.639379484 0.301935165 
mmu-mir-363-3p 0.931106117 1.230812345 -0.559987464 -0.904563159 -0.697367838 
mmu-mir-28-5p -1.348688713 -0.773415843 0.844876893 0.802006724 0.475220938 
mmu-mir-34b-3p -1.084723442 -1.013581956 0.309248915 0.670887648 1.118168836 
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mmu-mir-218-5p -1.173214698 -0.961554815 0.441457305 0.658983595 1.034328613 
mmu-mir-214-5p -1.032612924 -1.153467334 0.767797646 0.772179585 0.646103027 
mmu-mir-369-3p 0.819625189 0.781160181 -0.053047074 0.097176893 -1.644915189 
mmu-mir-18a-5p 0.746220992 1.224820383 -0.203372725 -1.29570965 -0.471959 
mmu-mir-708-5p 1.101763741 0.741676358 -0.942318904 0.235755007 -1.136876202 
mmu-mir-429-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-380-3p 0.668480485 0.511711683 0.347536421 0.237016846 -1.764745434 
mmu-mir-320-5p -0.679690865 -1.196074522 1.258361716 -0.099561689 0.71696536 
mmu-mir-294-5p 1.211421847 0.95818742 -0.583871158 -0.882718294 -0.703019815 
mmu-mir-340-5p 0.69550888 0.672056407 0.54078614 -0.264518061 -1.643833365 
mmu-mir-145-5p -1.09963732 -1.075772515 0.532399269 0.834162668 0.808847898 
mmu-mir-32-5p 0.891877522 1.147065976 -0.786891288 -1.118864245 -0.133187964 
mmu-mir-96-5p 0.776588809 0.715423795 -0.752451342 -1.381071925 0.641510663 
mmu-mir-125a-5p -1.059450744 -1.094186567 0.420109913 0.891952186 0.841575212 
mmu-mir-181b-5p -1.082584528 -1.101841221 0.641169425 0.849211637 0.694044687 
mmu-mir-1839-5p -1.1465305 -1.013238759 0.665048427 0.970329511 0.524391321 
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mmu-mir-335-3p 1.264028168 0.896200956 -0.583447318 -0.876497174 -0.700284633 
mmu-mir-196b-5p -0.690162682 -0.811353009 0.80418794 1.342527681 -0.64519993 
mmu-mir-669a-3p 0.726714353 0.906622602 -1.023749396 0.53665152 -1.146239079 
mmu-mir-669o-3p 0.726714353 0.906622602 -1.023749396 0.53665152 -1.146239079 
mmu-mir-106a-5p 1.054224831 1.125753371 -0.600370568 -0.871242117 -0.708365517 
mmu-mir-672-5p 1.215956416 0.908228177 -0.822297148 -0.35688292 -0.945004525 
mmu-mir-467a-5p 0.558787915 1.011932252 -1.5793724 0.295268185 -0.286615953 
mmu-mir-467b-5p 0.558787915 1.011932252 -1.5793724 0.295268185 -0.286615953 
mmu-mir-26b-5p -1.411837546 -0.598910902 0.85293046 0.225172612 0.932645377 
mmu-mir-141-5p -0.683124919 -0.949821936 1.408749497 -0.445337982 0.669535341 
mmu-mir-744-5p -1.085120231 -1.049781908 0.417927051 1.047970105 0.669004984 
mmu-mir-290-5p 1.170712894 1.006818247 -0.602974493 -0.866511461 -0.708045187 
mmu-mir-25-5p 1.085125299 0.803254538 -1.400935606 -0.024788652 -0.462655579 
mmu-mir-22-5p -1.037835797 -1.151227053 0.738144724 0.733638023 0.717280104 
mmu-mir-151-5p -0.851092325 -1.289492081 0.602870246 0.585667185 0.952046975 
mmu-mir-155-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
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mmu-mir-30b-5p -0.618767879 -0.73124891 -0.273615253 -0.107271986 1.730904029 
mmu-mir-23a-5p -0.679690865 -1.196074522 1.258361716 -0.099561689 0.71696536 
mmu-mir-186-5p -1.541821219 -0.427485567 0.542695481 0.460407329 0.966203977 
mmu-mir-7b-5p 0.826763385 0.826763385 0.153515356 -1.602326123 -0.204716003 
mmu-let-7d-5p -1.203884051 -0.979387439 0.739354117 0.687533155 0.756384218 
mmu-mir-380-5p 0.598227515 0.558247561 0.354959944 0.259730428 -1.771165448 
mmu-mir-181a-5p -1.127928639 -1.04047363 0.49627515 0.857253589 0.814873529 
mmu-mir-18b-5p 1.034624059 1.14572758 -0.609237978 -0.861357186 -0.709756475 
mmu-mir-135b-5p 1.14045334 0.947155791 -0.308678931 -1.139147974 -0.639782226 
mmu-mir-302a-5p 0.735559299 1.385537086 -0.576783657 -0.856148067 -0.688164662 
mmu-mir-127-5p 0.9613894 0.597485102 0.204764599 -0.132953075 -1.630686026 
mmu-mir-20b-5p 1.075561941 1.106996325 -0.614331957 -0.857102939 -0.71112337 
mmu-let-7b-5p -1.066897099 -0.813260898 1.03943512 1.03943512 -0.198712242 
mmu-mir-100-5p -1.219127381 -0.953594186 0.774566972 0.815297837 0.582856758 
mmu-mir-98-5p -1.107001214 -1.062574038 0.664492906 0.56373245 0.941349897 
mmu-mir-210-5p -0.684066985 -0.55285817 -0.010726861 -0.482511952 1.730163968 
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mmu-mir-27a-5p -0.67767914 -1.087949457 -0.16767361 0.486977354 1.446324852 
mmu-let-7i-5p -1.389599384 -0.738349655 0.770770215 0.744919781 0.612259043 
mmu-mir-541-5p -0.504606806 -0.581060065 1.77048965 -0.481365432 -0.203457348 
mmu-mir-16-5p 0.822611165 0.822611165 -0.752960422 -1.363084249 0.470822341 
mmu-mir-29b-1-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-434-5p 0.605008535 0.490010264 0.341412624 0.341412624 -1.777844047 
mmu-mir-199b-5p -0.842720743 -0.842720743 -0.296814442 0.477866136 1.504389791 
mmu-mir-101a-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-146a-5p -1.390470708 -0.730450445 0.609265397 0.65765081 0.854004946 
mmu-mir-485-5p 0.861852819 0.520607946 0.067344699 0.257612875 -1.707418339 
mmu-mir-199a-3p -1.407392385 -0.709879868 0.82330762 0.659423717 0.634540915 
mmu-mir-292-3p 1.121258388 1.062389781 -0.625026501 -0.845638439 -0.712983229 
mmu-mir-26a-5p -0.830297047 -1.126720967 1.274323702 0.037892039 0.644802273 
mmu-mir-291a-3p 1.092272756 1.092272756 -0.628574468 -0.842218081 -0.713752964 
mmu-mir-291a-5p 1.105212865 1.079518508 -0.63082806 -0.83977092 -0.714132393 
mmu-mir-200c-5p -1.215084391 -0.646893281 1.258776203 -0.109893779 0.713095248 
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mmu-let-7e-5p -1.215284582 -0.965558401 0.696887576 0.787067832 0.696887576 
mmu-mir-17-5p 0.977440373 1.167725205 -1.021181393 -0.504779754 -0.61920443 
mmu-mir-199a-5p -1.319036373 -0.822211066 0.542679196 0.722144354 0.876423889 
mmu-mir-293-5p 1.153430098 1.029092692 -0.628697284 -0.840631323 -0.713194183 
mmu-mir-134-5p 0.710219381 0.539909413 0.202042066 0.300770245 -1.752941106 
mmu-let-7g-5p -1.292363053 -0.873880565 0.7400009 0.7400009 0.686241819 
mmu-mir-151-3p -0.88412563 -0.930078105 -0.114386927 0.474162058 1.454428604 
mmu-mir-29a-5p -0.901595368 -0.901595368 -0.153521812 0.511279918 1.445432629 
mmu-mir-423-5p 1.108862953 0.861815565 -0.307328283 -0.307328283 -1.356021953 
mmu-mir-31-5p -1.053952595 -0.670203131 0.469000265 -0.218691383 1.473846844 
mmu-mir-205-5p 0.244694415 1.550427178 -0.153173944 -1.108064327 -0.533883321 
mmu-mir-30e-5p 0.719803136 1.383467051 -0.576376699 -0.950516789 -0.576376699 
mmu-mir-411-5p 0.626926222 0.490171878 0.388004116 0.268105912 -1.773208129 
mmu-mir-191-5p 0.987192255 1.184675213 -0.558651293 -0.872454924 -0.74076125 
mmu-mir-93-5p 0.833517295 0.961958181 -1.471294349 -0.447249829 0.123068702 
mmu-mir-24-1-5p -0.974537103 -1.089211277 0.352617392 0.48436974 1.226761248 
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mmu-mir-221-5p -1.377087489 -0.71134813 0.386565446 0.850935086 0.850935086 
mmu-mir-20a-5p 0.925809899 1.224524063 -0.481638827 -0.736446689 -0.932248446 
mmu-mir-125b-5p -1.310836886 -0.805372541 0.978205517 0.688729239 0.449274671 
mmu-mir-10b-5p -1.212217844 -0.963762002 0.600441047 0.787769399 0.787769399 
mmu-mir-152-5p -0.955124441 -0.895736336 -0.253773935 0.996420704 1.108214008 
mmu-let-7c-5p -0.973808336 -0.709670569 1.167276121 0.98346296 -0.467260176 
mmu-mir-292-5p 1.139099545 1.045383642 -0.637963419 -0.83142451 -0.715095258 
mmu-mir-183-5p 1.065325947 1.065325947 -0.956751309 -0.837716013 -0.336184573 
mmu-mir-148a-5p 1.130934866 0.582334924 -0.842815071 0.368728302 -1.239183021 
mmu-mir-99b-5p -1.209238526 -0.969722518 0.775913156 0.775913156 0.627134733 
mmu-let-7a-5p -1.077520721 -1.03625814 1.069364182 0.717370602 0.327044076 
mmu-mir-203-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-378-5p -1.206254077 -0.662261248 1.258643455 -0.10506769 0.71493956 
mmu-mir-101b-5p -0.98581515 -0.98581515 1.228336864 0.003351347 0.73994209 
mmu-mir-10a-5p -1.133709768 -1.049987201 0.820644632 0.751581831 0.611470507 
mmu-mir-103-2-5p -0.575018947 -0.614724049 1.752660862 -0.456400629 -0.106517238 
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mmu-mir-143-5p -1.045425556 -1.045425556 1.021322666 0.850299703 0.219228742 
mmu-let-7f-5p -1.185270703 -0.844410222 0.96779423 0.96779423 0.094092465 
mmu-mir-7a-5p 0.956115329 0.956115329 -0.886332793 -1.168642428 0.142744562 
mmu-mir-146b-5p -1.002326176 -0.604291396 -0.007564157 -0.007564157 1.621745885 
mmu-mir-182-5p 0.653560195 0.653560195 -1.746227534 0.219553572 0.219553572 
mmu-mir-21-5p -1.317874511 -0.841751398 0.719875303 0.719875303 0.719875303 
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Appendix 11 : mouse mRNA heat map     
       
gene_Name Keratinocytes 1 miPSyam Keratinocytes 2 mES ΔNp63-/-2 ΔNp63-/-1 
Atg9b 0.941095982 -0.638169181 1.331344809 -0.714579917 -0.777433955 -0.774623836 
Rab11fip5 0.898817111 -0.862972475 1.035336778 -0.838292611 -0.612829849 -0.591556738 
Slc13a5 -0.708459579 0.820541211 -0.716276687 1.23407858 -0.716461843 -0.713369744 
BC080695 -0.418774042 0.204377529 -0.411019187 2.411686279 -0.446567645 -0.446567645 
Cdsn 0.499235746 -0.692895928 0.760569512 -0.683373047 -0.669679101 -0.679496586 
Ppp1r13l 1.094484909 -0.713277701 1.464029063 -0.742331577 -0.650151367 -0.630131869 
Mdk -0.5567058 1.823087285 -0.554514901 1.395405623 -0.525740905 -0.496513945 
Lrrn4cl 1.593031607 -0.818831771 1.570596229 -0.823649711 -0.363498385 -0.419293774 
Trim6 -0.548380717 1.533632919 -0.535988116 1.703342008 -0.54387307 -0.544873282 
Zscan4c -0.434770372 0.336806661 -0.440532612 2.378464598 -0.460695206 -0.460695206 
Aim2 -0.676190231 0.155420948 -0.680178291 1.664199257 -0.658488857 -0.682220844 
Amt -0.581620646 1.655363565 -0.531185326 1.583823882 -0.530848974 -0.531429547 
Gm13154 -0.506487753 0.889020144 -0.515714351 2.158513501 -0.519612322 -0.522108253 
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Shc2 -0.719994269 -0.270554815 -0.699427833 -0.403074714 1.57113998 1.630439963 
Cadm1 1.064519227 0.719101524 1.244631773 0.057131312 -1.117551787 -1.114772944 
Fat2 1.328607267 -0.709557508 1.290497521 -0.703193637 -0.729016487 -0.731982181 
Krtdap 1.307365699 -0.674489106 1.353968363 -0.722215645 -0.751595495 -0.744097177 
Zbtb16 1.279994175 -0.626165703 1.843559118 -0.623173396 -0.628839131 -0.625853687 
Zscan10 -0.564090185 1.441584472 -0.565294056 1.780009731 -0.56533824 -0.566086251 
Gm98 -0.749991711 0.249086941 -0.751770683 1.261641186 -0.489254371 -0.528661526 
Zfp936 -0.514036658 0.936104339 -0.512228542 2.133764719 -0.513436719 -0.513174636 
Golm1 -1.300720229 1.235413236 -1.28963945 0.83679283 0.644822778 0.485143964 
Gm13051 -0.533211379 1.3161847 -0.534639956 1.886339655 -0.534970259 -0.535072318 
Klk13 0.425643472 -0.552594843 0.228300369 -0.55592801 -0.601286861 -0.601286861 
Kcnj15 1.736519775 -0.745111521 0.966090707 -0.757658366 -0.546995016 -0.678141924 
Gm13152 -0.353553391 -0.353553391 -0.353553391 -0.353553391 -0.353553391 -0.353553391 
Gm14137 1.365935645 -0.738708376 1.182342299 -0.746276509 -0.810440101 -0.794973278 
Nynrin -0.87581302 -0.391987277 -0.863201742 -0.422501924 0.856209276 0.788152111 
Mtmr7 -0.538628835 1.479696426 -0.538628835 1.752076583 -0.538628835 -0.538628835 
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Trim71 -0.579171922 0.972057082 -0.577905039 2.101315316 -0.524160029 -0.52923168 
Pitx2 -0.461068821 2.44909245 -0.421308735 -0.083757848 -0.315268329 -0.205054064 
Txnrd1 -0.794560423 -0.25532281 -0.797573121 -0.101094726 0.880467745 2.068433611 
Rbpms -0.79444892 1.548950719 -0.827636139 1.338713292 0.207979944 0.204193115 
Sdr16c6 1.481695187 -0.684040756 1.510601139 -0.684040756 -0.684040756 -0.684040756 
G3bp2 -0.880765236 0.803904905 -0.919104855 1.862381487 -0.371743352 -0.3447307 
Rbpj -0.558388351 -0.627029509 -0.70083511 2.166501054 0.290183497 0.578089214 
Cubn -0.432309899 0.034361058 -0.434888813 2.443941833 -0.410847145 -0.416583874 
Lrp2 -0.560803854 0.918936743 -0.561176483 2.13720264 -0.385514259 -0.432767039 
Cyp2b23 -0.382667867 -0.312325823 -0.383507754 -0.24344385 -0.383507754 -0.383507754 
Spink5 1.034734272 -0.708438755 0.853883075 -0.707784702 -0.705719591 -0.707065743 
L1td1 -0.662824347 1.147063867 -0.664018257 1.837490564 -0.664018257 -0.664018257 
4833423E24Rik 1.668480508 -0.704681173 1.00783983 -0.704681173 -0.704681173 -0.704681173 
Nup62cl -0.891561862 0.840027584 -0.880777421 0.901573476 0.55486641 1.355268488 
BC100530 1.419802039 -0.678898385 1.591475313 -0.678898385 -0.678898385 -0.678898385 
2410002O22Rik 0 0 0 0 0 0 
    
  
3
0
4
 
Kif26a 1.122429888 -0.569399051 1.707205461 -0.608452203 -0.77218655 -0.783980161 
Hic1 -0.57265527 -0.476496887 -0.576971875 -0.544836484 1.664367421 1.573130961 
Duox1 0.961500663 -0.706174469 1.325919798 -0.72022412 -0.723599307 -0.726388794 
Zscan4d -0.430341415 0.33205933 -0.445504631 2.379779171 -0.459754034 -0.459754034 
Pnma5 -0.504047921 0.767545994 -0.48470734 2.218860072 -0.507953944 -0.507953944 
Foxi3 -0.57816554 1.726821895 -0.57816554 1.496088924 -0.57816554 -0.57816554 
Gm13242 -0.534595998 1.273635276 -0.534076285 1.918216476 -0.537987616 -0.537612863 
Ablim1 1.172997334 -0.70880142 1.046331549 -0.755586283 -0.713283056 -0.741523861 
Zscan4f -0.433944582 0.324549807 -0.43817706 2.381850706 -0.45929004 -0.45929004 
Ifitm1 -0.711787871 1.559339116 -0.71941954 0.979720524 -0.715193116 -0.71941954 
Arhgef10l 1.142237355 -0.71937561 1.009195374 -0.71937561 -0.71937561 -0.71937561 
Lrrc32 -0.528075554 -0.54892479 -0.520756129 -0.549785345 1.756086395 1.47495337 
Zfp534 -0.520611569 1.143719205 -0.52485038 2.008837732 -0.527367863 -0.528341867 
P4ha2 -0.493727044 1.211946547 -0.479370776 0.844704165 0.657044499 0.454018385 
1500009L16Rik -0.575108135 1.777595518 -0.540263885 1.448463338 -0.497985222 -0.482499475 
Ralgds 0.902146342 -1.315682454 1.463624877 -1.451189174 0.301794659 0.242888246 
    
  
3
0
5
 
9530008L14Rik 1.681565561 -0.670195448 1.350971224 -0.670195448 -0.670195448 -0.670195448 
Fam169a -0.663667229 1.249398446 -0.663667229 1.774901482 -0.663667229 -0.663667229 
Hopx 0.525011234 -0.586689433 0.534091313 -0.6134014 -0.654711171 -0.65754198 
Serpinb10-ps 1.724526401 -0.686587148 1.111592167 -0.698309081 -0.685639393 -0.698309081 
Triml2 -0.534337857 1.737681363 -0.539850991 1.495911451 -0.539850991 -0.539850991 
Zscan4e -0.414812234 0.325368172 -0.441981796 2.381408435 -0.463286119 -0.463286119 
Macc1 1.349310634 -0.711976415 1.119539676 -0.724173939 -0.726271095 -0.72707007 
S100a14 0.7974865 -0.694032502 0.890223666 -0.691197658 -0.694032502 -0.694032502 
Nhsl1 1.002912701 -0.901579301 1.310119151 -0.793098279 -0.519447926 -0.57914153 
Abcc4 -0.776950861 -0.401501984 -0.724499823 0.104132719 -0.063111738 0.19180664 
Lass3 1.198592754 -0.720382991 1.010616979 -0.724142279 -0.721055379 -0.722508523 
Bend4 -0.64883416 1.354280306 -0.589470316 1.709204254 -0.706084325 -0.690716216 
Dmkn 1.033815565 -0.707700414 0.94950233 -0.710380062 -0.722757723 -0.722093826 
Armcx2 -0.974343315 0.164118764 -0.922823897 0.165521508 1.292588538 1.592746174 
Med23 0 0 0 0 0 0 
Slc38a1 -1.209261848 0.018149215 -1.20043588 0.186471654 0.810179131 0.873739434 
    
  
3
0
6
 
Endou 0.997155488 -0.706792017 0.860159316 -0.706792017 -0.697714349 -0.706792017 
Aldh3b2 1.490089448 -0.70616625 1.056767409 -0.709282498 -0.728336294 -0.725690211 
EU599041 -0.533484506 1.365180717 -0.532345138 1.848080591 -0.536128743 -0.537833461 
Gm4340 -0.417554311 0.399814426 -0.455122716 2.35977565 -0.472862779 -0.472862779 
Zfp600 -0.534327271 1.240029879 -0.534327271 1.942597676 -0.534327271 -0.534327271 
Grb10 -0.556705447 -0.43375287 -0.5425412 -0.537129072 0.026683641 0.16824617 
Cyp26b1 0.599080368 -0.699820845 0.837192229 -0.697725347 -0.625923761 -0.645828377 
Rex2 -0.52001371 1.041341401 -0.522242387 2.073272586 -0.524988926 -0.5253308 
Gm10324 -0.471354929 0.496143716 -0.468253509 2.328884437 -0.471354929 -0.471354929 
Tfdp2 -0.872526098 0.403675142 -0.892697442 1.692038274 -0.280819836 -0.47725291 
Zscan4b -0.412420396 0.257522518 -0.436106032 2.399172734 -0.45296302 -0.45296302 
Armcx4 -0.989928521 1.041573905 -0.978522747 1.251615911 0.651343557 0.716061012 
H60c 0.081794082 -0.541527231 0.3295911 -0.549614283 -0.563169348 -0.561380379 
2610528A11Rik 1.839690437 -0.669623185 1.194189773 -0.674143174 -0.641998647 -0.637079922 
Usp44 -0.541807245 1.320923754 -0.549548281 1.88222031 -0.549548281 -0.527924513 
Gm13247 -0.532786998 1.277512705 -0.533580087 1.915404722 -0.535564625 -0.535564625 
    
  
3
0
7
 
Gm9573 -0.340345898 -0.357013491 -0.349778036 -0.355703855 -0.359419261 -0.358126557 
Slc7a7 -0.535859847 1.840497334 -0.535859847 1.374661745 -0.535859847 -0.535859847 
Agrp 1.728375969 -0.557285186 1.502347115 -0.556840656 -0.568408801 -0.556486223 
Alpl -0.729307529 0.657074979 -0.747144644 0.941516825 -0.597712487 -0.697605605 
Aplp1 -1.150904274 0.358573459 -1.066993483 0.469384177 0.443152825 0.550691488 
Aqp1 -0.110390712 -0.480163301 -0.177016492 -0.439644545 -0.396547671 -0.395474325 
Arg1 1.167001362 -0.709255898 0.774292245 -0.707658636 -0.706974798 -0.709681807 
Arnt2 -0.492094548 -0.363737991 -0.48660586 -0.408451545 -0.143680383 -0.07337922 
Slc7a3 -0.823828524 0.480522954 -0.933671465 0.733632228 -0.266858307 -0.178847699 
Bcat1 -1.16176139 0.014067438 -1.16176139 0.480029273 1.170691026 1.404704895 
Bmp8a 0.634363125 -0.245962615 2.043167965 -0.607111021 -0.732769273 -0.805856401 
Cbr2 1.282982671 -0.73714777 0.96933341 -0.731603941 -0.710136545 -0.729484761 
Cited1 -0.55349626 0.302150996 -0.575133754 0.275762054 -0.584263989 -0.575695073 
Col17a1 1.305072606 -0.710439165 1.43205906 -0.70869074 -0.719663676 -0.719301137 
Crabp2 1.360157114 -0.656406881 0.995735126 -0.670365788 -0.745489867 -0.771347416 
Ctsk -0.540299495 -0.540168637 -0.541649911 -0.536480231 1.682251945 1.556277818 
    
  
3
0
8
 
Cyba -1.002784804 0.231447921 -0.993775608 -0.463780576 0.987251075 1.129897459 
Twist2 -0.539154618 -0.528290126 -0.543081188 -0.543758374 1.159495412 1.997831993 
Dsc3 1.367083888 -0.698972901 1.473344585 -0.706539696 -0.708129896 -0.707922215 
Edn2 1.08905372 -0.720674717 1.727486058 -0.622292948 -0.729300773 -0.729300773 
Phc1 -0.722218913 1.385028803 -0.66966778 1.542299033 -0.700497249 -0.743372707 
Foxh1 -0.551361332 1.793526056 -0.554511526 1.42998569 -0.554511526 -0.55275506 
Fbp2 -0.709763599 0.777054633 -0.709763599 1.571385635 -0.709763599 -0.709763599 
Fgf10 -0.627202291 -0.527212556 -0.615049729 -0.2334674 1.506499825 1.702346641 
Fgf15 -0.483369821 2.28291282 -0.482436901 0.61972797 -0.488287791 -0.482796435 
Fgf7 -0.575660802 -0.540059014 -0.570523858 -0.576769107 1.530637464 1.703782533 
Fst -0.16278318 -0.446553285 -0.058359298 -0.550516534 -0.322892513 -0.290381806 
Fstl1 -0.810339592 -0.684277016 -0.810242877 -0.704495495 1.212149415 1.183432924 
Gap43 -1.118097936 1.503411578 -1.118097936 0.297227599 0.277414943 0.359123181 
Gas7 0.758645702 -0.917607514 0.857239286 -0.896567125 -0.357687143 -0.267068215 
Gata4 -0.566834307 1.281233041 -0.574511565 1.908771462 -0.57558571 -0.565669543 
Gdf3 -0.71081046 1.553275836 -0.71081046 1.19916851 -0.709359046 -0.71081046 
    
  
3
0
9
 
Gjb4 1.00897024 -0.708568321 0.932324974 -0.650925993 -0.717090426 -0.737459364 
Gclm -1.154966273 0.513722913 -1.172394452 0.875114763 0.26077208 0.170644474 
Gna14 -0.383655886 -0.323612057 -0.37782818 -0.230332745 -0.400482351 -0.398029006 
Ifi202b 0 0 0 0 0 0 
Igfals -0.425477346 -0.117133027 -0.417232669 -0.174919978 -0.442384635 -0.442384635 
Impact -1.198416628 0.24651951 -1.231319637 0.678742847 0.676535505 0.59160574 
Ivl -0.021879664 -0.475112785 -0.174834273 -0.473797264 -0.430893842 -0.396635335 
Klf2 -1.098784352 0.993230307 -1.038619258 1.545137167 0.109386645 0.175843675 
Krt15 1.40678147 -0.718382538 0.96259278 -0.718970848 -0.721830658 -0.722588259 
Krt16 0.455622147 -0.629625557 0.600532029 -0.632122949 -0.636562548 -0.635722644 
Krt19 0.678327919 -0.409658176 0.256375097 -0.695469563 -0.658197321 -0.660281906 
Krt1 0.374389895 -0.579470308 0.431839087 -0.607992125 -0.625969105 -0.625969105 
Krt4 0.935139042 -0.701353707 0.96552777 -0.706795288 -0.712589295 -0.706554823 
Lama1 -0.558561929 1.780493787 -0.557376826 1.446195714 -0.497144611 -0.523925866 
Lamb3 1.202220257 -0.671999071 1.574336734 -0.715303336 -0.726562856 -0.729086963 
Lamc2 1.252637149 -0.689529986 1.522976421 -0.740323259 -0.746012246 -0.74901837 
    
  
3
1
0
 
Lbp 1.362503147 -0.67145067 1.716250201 -0.696561709 -0.63181848 -0.669232943 
Lcn2 1.528790887 -0.724300549 1.541956307 -0.72822588 -0.592474682 -0.548570969 
Ltf 1.274663628 -0.708996243 1.031511821 -0.726501759 -0.73053875 -0.728434701 
Fxyd3 1.382727686 -0.67221684 1.389461721 -0.704198747 -0.728601332 -0.727716768 
Mcpt8 -0.493427018 -0.493427018 -0.493427018 -0.493427018 0.69609313 2.251135939 
Mest -0.583681257 0.737098115 -0.533784832 2.229401268 -0.476543416 -0.51952987 
Foxc1 1.007779568 -0.858704978 1.09189953 -0.913149464 -0.489272901 -0.486368149 
Mme -0.743835546 1.029758286 -0.747180796 1.218231186 -0.710496878 -0.7401278 
Mybl2 -0.75722612 1.198788609 -0.750582123 1.7336928 -0.661577442 -0.657862596 
Ndrg1 1.367879429 -0.906563605 1.436664028 -0.926409437 -0.459887033 -0.508497026 
Nid2 -0.635747617 1.877237672 -0.635747617 1.309198849 -0.392613227 -0.40941979 
Mycn -0.530492068 1.316949147 -0.53423115 1.885751306 -0.537640668 -0.534046292 
Notch1 1.275228271 -0.62555917 1.62107282 -0.643817223 -0.683201539 -0.754091589 
Ntn1 -0.624420094 -0.212490031 -0.625900165 -0.096733601 -0.11802255 -0.109330059 
Orm1 0.816374525 -0.647860757 0.728435646 -0.706736363 -0.664317987 -0.706736363 
Phox2b -0.354314263 -0.352719627 -0.354314263 -0.351575218 -0.354314263 -0.354314263 
    
  
3
1
1
 
Ppl 1.307062273 -0.721312923 1.409728289 -0.727488984 -0.742832711 -0.743461923 
Klk8 0.455679447 -0.528838221 0.383362751 -0.58682178 -0.641662738 -0.635273986 
Pipox -0.708326401 0.776969232 -0.704946542 1.155864061 -0.710776854 -0.710776854 
Pthlh 0.579160392 -0.676971893 1.061570239 -0.691565311 -0.691565311 -0.685688905 
Rbp2 0.142891964 -0.561480236 0.336649575 -0.542131553 -0.550876505 -0.570610684 
Bex1 -0.447051712 1.782484343 -0.398762103 1.43310929 -0.615651603 -0.611427509 
S100a9 -0.135303636 -0.452303174 -0.050591133 -0.452303174 -0.452303174 -0.452303174 
Serpinb3a -0.348725933 -0.356857222 -0.351844558 -0.355726715 -0.356771421 -0.357918991 
Sfrp2 -0.551011498 1.771552958 -0.558634659 1.454673938 -0.478675959 -0.484506235 
Six1 -0.906895511 1.417623974 -0.889846836 1.495148082 -0.01063756 0.32926831 
Serpina1e -0.350463584 -0.355595511 -0.351935177 -0.350085706 -0.355595511 -0.355595511 
Serpina3n 1.229655775 -0.648279398 1.860179609 -0.649391579 -0.608378557 -0.626832401 
Serpinb5 1.226578851 -0.708287481 1.135642 -0.719365177 -0.732775892 -0.731953758 
Sprr1b 1.018249624 -0.714735191 1.003599953 -0.714820371 -0.71762863 -0.716957041 
Tbx15 -0.682421778 -0.648247329 -0.673969345 -0.666880847 1.402483698 1.697739806 
Tcf15 -0.533939952 1.15969499 -0.537151481 1.997693955 -0.537151481 -0.537151481 
    
  
3
1
2
 
Thy1 -0.583772628 -0.495696149 -0.574205735 -0.54987645 1.555696375 1.681401764 
Trh -0.452032672 2.378991716 -0.45305686 0.335343465 -0.45305686 -0.45305686 
Tuba3a -0.5093723 1.037489652 -0.52672128 2.075596561 -0.52672128 -0.517040311 
Utf1 -0.538071724 1.446463663 -0.538785091 1.780931705 -0.539086467 -0.539086467 
Vdr 1.334791532 -0.798538306 1.406316238 -0.799380034 -0.566245717 -0.585370331 
Wnt10a 1.436813083 -0.693312448 1.498836796 -0.694840284 -0.692916955 -0.695577778 
Wnt4 1.43078486 -0.675907816 1.377876199 -0.70743916 -0.720660043 -0.721073294 
Wnt6 1.218256725 -0.620229966 1.87751918 -0.58454617 -0.652880948 -0.646970761 
Wnt7b 1.431841715 -0.658493689 1.422728434 -0.684933349 -0.728587878 -0.727738994 
Zfp42 -0.533945127 1.377710876 -0.536528756 1.838041543 -0.536528756 -0.536528756 
Zic2 -0.706401285 0.859134629 -0.707478564 0.992372855 -0.699000081 -0.70386656 
Zic3 -0.69393384 1.082610216 -0.694565993 1.736673864 -0.691011454 -0.691032134 
Actg2 -0.640583784 -0.657952047 -0.631101156 -0.659787863 1.398148636 1.717400601 
Adam19 -0.955458445 1.371256368 -0.945510023 0.753566336 0.895315851 0.63486883 
Avil -0.357425346 -0.348877485 -0.361242557 -0.353004676 -0.347642086 -0.353212798 
Apoe -0.732000401 1.542457596 -0.736374851 0.984765093 -0.680752344 -0.68879633 
    
  
3
1
3
 
Bst1 1.6901419 -0.62661501 1.363850898 -0.66833152 -0.680999509 -0.678350498 
Serping1 -0.968231153 1.454597261 -0.925418302 1.504379585 0.010659182 0.039802891 
Car2 -0.601789634 1.22769138 -0.591046318 1.930075016 -0.60477225 -0.609305973 
Casp14 1.213135328 -0.683161545 0.754816313 -0.67905195 -0.724566687 -0.719588536 
Casq2 0.055224733 -0.54559364 0.546826857 -0.543686388 -0.601153497 -0.595172858 
Ch25h -0.528528339 -0.534050986 -0.532734673 -0.543195146 1.835310488 1.381049539 
Cnn1 -0.608680797 -0.067167016 -0.478809376 -0.567318093 1.487623259 1.678073092 
Cyct -0.499559426 0.759574694 -0.484502383 2.222724819 -0.499559426 -0.499559426 
Dok2 -0.695868422 1.225524325 -0.693269303 1.684992115 -0.694173969 -0.675135325 
Usp17l5 -0.394247267 0.276917343 -0.419411959 2.393712413 -0.467025175 -0.462962701 
Lefty1 -0.484815149 2.295694283 -0.490299034 0.586792478 -0.469658379 -0.462630007 
Efna3 1.388153063 -0.669926384 1.166433755 -0.609305771 -0.79264085 -0.817902456 
Ephb2 -0.74873626 -0.177533491 -0.725301042 -0.208434193 1.733787071 1.414412729 
Khdrbs3 -0.90092311 1.498593066 -0.871103651 1.154899563 0.318556497 0.519468332 
F2rl2 0.761704044 -0.598360151 2.159637779 -0.592815279 -0.592546963 -0.598360151 
Fabp3 -0.611182739 1.79758335 -0.618742908 1.406550598 -0.398383113 -0.347437501 
    
  
3
1
4
 
Fgf4 -0.675745327 1.275608215 -0.676914794 1.711769404 -0.676914794 -0.676914794 
Fos 1.616773846 -0.691242463 1.512678301 -0.698222057 -0.687798296 -0.680232469 
Gata6 -0.792158328 1.153612333 -0.789438539 1.878485729 -0.085994363 -0.062091487 
Gbx2 -0.439975888 0.209817301 -0.439975888 2.410689949 -0.433973188 -0.434010179 
Tsc22d3 1.301217582 -0.895760555 1.444978886 -0.908952872 -0.531412265 -0.544060927 
Pdpn -0.719180641 -0.151560616 -0.658251762 -0.281528333 1.343569382 1.802395107 
Gstt2 -0.562732163 0.868278841 -0.59483155 0.023539722 -0.612398497 -0.649108226 
H2-T23 1.441330526 -0.78645999 1.304792861 -0.795553468 -0.638196411 -0.687305288 
Foxa2 -0.537829462 1.774078794 -0.54634646 1.454102845 -0.54634646 -0.54634646 
Hoxc10 -0.602075472 -0.584451444 -0.59743353 -0.596417143 1.498583166 -0.225963808 
Hspa1b 1.571792745 -0.735123381 1.407466429 -0.74246642 -0.565484238 -0.578293866 
Hspa1a 1.542906513 -0.697962666 1.520086454 -0.712310615 -0.579024242 -0.581111627 
Itga4 -0.387447692 -0.360788879 -0.387845133 -0.364727028 -0.324249026 -0.268488683 
Jup 1.164452314 -0.674396421 1.404256828 -0.72264228 -0.871678101 -0.858915736 
Kcnab1 -0.498573048 -0.484932723 -0.492987112 -0.493761443 0.678474879 2.258666453 
Fabp5 1.05363755 -0.695337653 0.702395367 -0.765312122 -0.617324939 -0.594101515 
    
  
3
1
5
 
Klk1 -0.385391807 -0.341834269 -0.385391807 -0.213401091 -0.385391807 -0.385391807 
Krt17 1.148818126 -0.712431339 1.28530709 -0.722449591 -0.731403705 -0.731950479 
Laptm5 -0.448870998 -0.189624906 -0.449581239 -0.013625371 -0.447401334 -0.447855927 
Lef1 -0.58237781 0.658935971 -0.608210388 2.20693956 -0.207265157 -0.115949824 
Lipg 1.435080685 -0.618148042 1.628286051 -0.704925378 -0.657841831 -0.607620884 
Anxa1 1.177370276 -0.81391491 1.021499134 -0.84783331 -0.599559489 -0.611025886 
Ly6d 1.374182261 -0.718922607 1.218439815 -0.721252825 -0.722899995 -0.723773757 
Mxd1 0.688164261 -0.729682106 0.971172213 -0.72461821 -0.697541091 -0.684932132 
Cd200 0.693787682 -0.690408764 1.335091387 -0.730837399 -0.622166208 -0.710801586 
Sik1 1.238107466 -0.687476606 1.537178447 -0.558447476 -0.83944718 -0.82587225 
Ndn -0.888090225 0.083831301 -0.880749558 -0.185755521 1.46640738 1.583138781 
Neurod1 -0.516791409 1.01941978 -0.51860588 2.08640509 -0.51860588 -0.51860588 
Nfe2l3 1.48670887 -0.644620848 1.559875485 -0.664113392 -0.690421488 -0.693576539 
Nefh -0.5058944 0.862816597 -0.5058944 2.172549805 -0.5058944 -0.5058944 
Nefl -0.531446643 1.17256907 -0.526942848 1.989588498 -0.52719319 -0.522992571 
Nsg1 -0.586211818 -0.460311453 -0.601921812 -0.561921325 1.555562485 1.678521555 
    
  
3
1
6
 
Orm2 1.297183158 -0.730474811 0.797456475 -0.730474811 -0.670263102 -0.730474811 
P2rx7 -0.382594163 -0.282120221 -0.37599294 -0.306720425 -0.376032446 -0.373432234 
Pla2g1b -0.53360526 1.804016519 -0.540924507 1.419141948 -0.540924507 -0.540924507 
Pou3f1 -0.521604508 1.756902599 -0.476597048 1.472711445 -0.562697109 -0.562721617 
Srgn -0.55667233 0.183821185 -0.557630428 0.25522529 -0.551718594 -0.549093524 
Mapk8ip1 -0.901582695 1.630433665 -0.857108914 1.40245616 -0.064079215 -0.144386181 
Klk6 -0.281013254 -0.384566159 -0.252672708 -0.387826064 -0.390594397 -0.390594397 
Rgs16 -0.58610727 -0.461880444 -0.5841665 -0.492497981 1.205455757 1.964598739 
Rps6ka2 -1.039819724 0.324008645 -0.979589747 0.084924672 1.157743421 1.565385791 
Scnn1a 1.619589962 -0.682642498 1.393219535 -0.700937354 -0.680916655 -0.693315865 
Ccl9 -0.295280075 -0.356877546 -0.299834271 -0.388181351 -0.374244163 -0.390161391 
Sema3f 1.394132189 -0.661579794 1.681748873 -0.683778895 -0.646756488 -0.636741118 
Slpi -0.284862564 -0.468996537 -0.219281944 -0.474503728 -0.336831469 -0.241230635 
Sox17 -0.540812735 1.605320008 -0.540812735 1.634944673 -0.540812735 -0.540812735 
Sox2 -0.701260243 0.892105592 -0.70161243 1.712178473 -0.70161243 -0.70161243 
Sox9 0.765154411 -0.824890268 1.43761933 -0.838814735 -0.585935429 -0.601156589 
    
  
3
1
7
 
Sprr2a1 1.260815141 -0.722220488 1.273660681 -0.722439929 -0.725244995 -0.724913857 
Sprr2d 0.906126676 -0.696125871 0.774044777 -0.696125871 -0.690775918 -0.696125871 
Sprr2h 0.975846873 -0.69433429 0.75909311 -0.696700887 -0.702022609 -0.697900589 
Sprr2i -0.29300693 -0.387443361 -0.246628246 -0.387191669 -0.386949061 -0.383721569 
Sprr2k -0.03158762 -0.489869227 0.067931462 -0.494977489 -0.486697034 -0.484028646 
Sdc1 1.36731704 -0.839221963 1.337546591 -0.848542783 -0.549885005 -0.59742844 
Tcea3 -0.828706013 1.046978827 -0.824635753 1.749320572 -0.449910226 -0.440550326 
Tdgf1 -0.530554109 1.944184397 -0.532343463 1.237925523 -0.532343463 -0.532343463 
Tle4 -0.756431117 1.02101106 -0.747716943 1.57099382 -0.701543103 -0.679671706 
Tfrc -1.200770932 0.909955754 -1.213331957 1.271673301 0.070897194 0.223184292 
Uchl1 -0.984838846 0.802129918 -0.984441684 0.470687374 0.984609728 1.3528062 
Zfp36 1.303046465 -0.678254301 1.421908168 -0.838587842 -0.737838682 -0.672664499 
Adam23 -0.785020121 -0.240629095 -0.760765066 -0.068763909 0.243171603 0.10430855 
Gdf15 -0.430731239 -0.379584642 -0.428289397 -0.388632635 -0.177338464 -0.245252433 
Grem2 -0.551102452 -0.531604936 -0.545825423 -0.54162802 1.524028223 1.712123603 
Klk7 0.057637128 -0.512201218 0.138312161 -0.516121402 -0.517100838 -0.518177352 
    
  
3
1
8
 
41155 -0.987211488 1.022044402 -0.964422285 0.583600822 0.802941872 1.257113804 
Spry2 -1.057133092 -0.039351558 -1.062399062 0.328383581 0.352333252 0.727005569 
Spry4 -0.906417551 0.492048278 -0.910346916 2.007350879 -0.268086985 -0.019888386 
Trex2 1.346600666 -0.717224094 1.316127591 -0.707125313 -0.723583708 -0.723583708 
Gnpda1 -0.937730316 0.81466611 -0.916846504 1.01991408 0.185983026 0.081868559 
Slc27a2 -0.537557233 1.771052531 -0.539888968 1.457946533 -0.539888968 -0.539888968 
Pla2g10 -0.542494251 1.365476291 -0.542494251 1.847775604 -0.542494251 -0.521494116 
Vsnl1 1.535536551 -0.704940416 1.037930172 -0.722830861 -0.722830861 -0.708418988 
Aoah -0.402456927 -0.309051123 -0.402456927 -0.147592093 -0.402456927 -0.402456927 
Anxa8 1.286484614 -0.76820255 1.313896146 -0.791109417 -0.754085208 -0.780809575 
Dsc2 1.11152791 -0.662928169 0.844764937 -0.689433906 -0.72280742 -0.727616911 
Gfpt2 -0.932012054 0.896508974 -0.936526519 1.553619239 0.468163345 0.62811861 
Hspb1 1.106815924 -0.679427325 1.585611538 -0.681084674 -0.764638897 -0.737621637 
Lifr -0.484676201 -0.272286096 -0.47111999 0.082755468 -0.41386805 -0.429194708 
Ltbp2 -0.558467951 -0.540512103 -0.547930391 -0.554308102 1.564976562 1.673137783 
Nodal -0.533073869 1.834111887 -0.53658307 1.382569188 -0.538890513 -0.538890513 
    
  
3
1
9
 
Odc1 -1.117191322 1.408708376 -1.135620405 0.986189639 -0.017885904 0.836963826 
Pou5f1 -0.58616316 0.297134115 -0.587042393 0.387177906 -0.587042393 -0.587042393 
 
 
 
 
 
 
Appendix 12 : mouse-human mRNA heat map      
           
Gene NHEK 
NHEK_s
hDGCR8 
NHEK_sh
ΔNp63 hiPSYam 
Keratinocytes 
1 
Keratinocytes 
2 miPSyam mES 
ΔNp63-/-
2 
ΔNp63-/-
1 
SEMA4D -0.815 -0.296 -0.348 1.459 0.986 1.301 0.266 0.526 -1.583 -1.573 
CKS2 -1.489 0.329 0.542 0.618 -0.968 -0.772 1.914 1.333 -0.730 -0.701 
FURIN 1.499 -0.534 -0.460 -0.505 -0.222 0.658 -1.460 -1.576 1.103 1.281 
MRPL51 -1.437 0.881 0.313 0.243 -0.586 -0.982 1.672 1.387 -1.037 -0.849 
    
  
3
2
0
 
PIGG 1.432 -0.409 -0.151 -0.871 1.371 1.040 -0.410 0.289 -1.441 -1.517 
SNAPIN -0.508 0.855 0.814 -1.161 0.615 0.296 -0.466 -0.802 -0.954 -0.884 
WDR60 -0.960 1.252 0.337 -0.630 0.096 0.748 -1.562 -1.530 1.008 1.278 
WBP11 -1.464 0.225 0.480 0.759 -0.995 -1.029 1.023 2.073 -0.591 -0.507 
UBE2W 1.344 -0.772 -0.752 0.180 0.267 -0.051 -1.512 -1.472 1.243 1.384 
CNTLN -1.183 0.001 -0.080 1.262 -0.375 -0.185 -1.261 -1.022 1.682 1.490 
RAD54B -1.479 0.499 0.693 0.287 -0.734 -0.734 1.495 1.865 -0.642 -0.765 
ALDH3B1 1.482 -0.481 -0.314 -0.688 -0.617 -0.273 -0.794 -0.919 0.336 -0.136 
RRP1B -1.212 0.742 0.894 -0.424 -1.280 -1.160 1.398 1.637 -0.385 -0.412 
KLHL17 -0.906 1.018 0.697 -0.809 1.364 1.550 -1.314 -1.286 0.210 0.081 
TULP4 1.483 -0.470 -0.326 -0.687 -0.599 -0.187 -1.186 -1.197 1.333 1.720 
PJA2 1.468 -0.567 -0.693 -0.209 0.683 1.003 -1.587 -1.648 0.843 0.759 
SECISBP2 -1.132 -0.003 -0.165 1.300 -0.654 -0.872 1.133 1.983 -0.294 -0.045 
GPATCH4 -1.312 0.451 1.024 -0.163 -1.402 -1.637 0.836 1.548 -0.008 0.498 
PDK2 0.009 0.925 0.457 -1.391 1.469 1.661 -0.856 -0.803 -0.745 -1.018 
HOXA7 0.479 0.765 0.219 -1.462 1.074 1.135 -1.485 -1.539 -0.107 -0.067 
    
  
3
2
1
 
SLC25A5 -0.818 0.556 1.128 -0.866 -0.773 -1.094 1.301 1.936 -0.581 -0.602 
AQP3 1.500 -0.491 -0.497 -0.511 1.773 1.575 -0.739 -0.718 -0.798 -0.791 
BRD9 -0.940 -0.567 0.180 1.327 -1.819 -1.352 0.591 0.992 0.452 1.148 
NUP188 -0.997 0.849 0.872 -0.725 -0.533 -0.626 1.001 2.210 -0.565 -0.734 
GALNT2 1.293 -0.485 0.216 -1.023 -0.221 0.132 -1.178 -1.160 1.971 1.033 
MBD1 1.498 -0.561 -0.426 -0.510 0.341 0.408 -1.705 -1.544 0.556 0.947 
SDF4 1.481 -0.313 -0.471 -0.697 1.573 1.353 -1.001 -1.620 -0.196 -0.100 
RNASEH1 -1.323 -0.148 0.464 1.007 -0.772 -0.821 1.763 1.598 -0.564 -0.507 
GNPAT -0.794 1.339 0.191 -0.735 -0.252 -0.327 1.789 1.460 -1.040 -1.003 
ANKRD49 -0.803 0.785 0.942 -0.923 -0.197 -0.871 1.571 1.574 -1.099 -1.010 
PRKRIP1 -1.335 0.499 0.974 -0.138 -1.064 -1.819 1.406 0.861 0.805 0.261 
PPME1 0.684 0.071 0.681 -1.436 -0.994 -0.941 -0.483 -0.590 1.610 1.678 
KIF1B 0.484 -0.686 -0.965 1.167 -0.325 -0.184 -1.604 -0.698 1.835 1.190 
SH2D4A 1.465 -0.752 -0.227 -0.486 2.057 1.175 -0.870 -0.590 -0.756 -0.763 
CASC5 -1.339 0.740 0.790 -0.191 -0.762 -0.774 1.106 2.169 -0.504 -0.605 
CDCA3 -1.455 0.564 0.735 0.157 -0.864 -0.753 1.582 1.614 -0.893 -0.872 
    
  
3
2
2
 
ASPM -1.236 0.783 0.842 -0.389 -0.599 -0.473 0.905 2.181 -0.934 -0.952 
NAA15 -1.482 0.619 0.584 0.279 -1.255 -1.526 0.065 1.328 0.565 1.345 
FANCA -1.377 0.746 0.733 -0.101 -1.082 -1.082 1.613 1.621 -0.393 -0.342 
PECR -1.466 0.283 0.403 0.780 -0.436 -0.692 1.842 1.528 -0.836 -0.833 
METTL1 -1.454 0.484 0.785 0.185 -0.944 -1.539 1.264 1.531 0.176 0.374 
TOPBP1 -1.158 1.015 0.628 -0.484 -1.082 -1.117 1.526 1.704 -0.251 -0.343 
KDM5C -0.573 0.662 1.011 -1.100 -0.175 1.717 -0.051 0.994 -1.358 -1.417 
DCAF5 1.444 -0.314 -0.267 -0.863 0.693 0.654 -1.649 -1.620 1.014 0.808 
OSTC -1.299 0.106 0.054 1.139 -0.678 -0.916 1.798 1.554 -0.671 -0.626 
ANAPC4 -1.435 0.356 0.199 0.880 -1.664 -1.376 0.944 1.182 0.715 0.540 
MND1 -1.482 0.359 0.416 0.707 -0.676 -0.695 1.595 1.772 -0.775 -0.845 
DNAJC3 1.343 -0.760 0.183 -0.766 -0.089 -0.241 -1.413 -0.946 1.693 1.374 
ERBB2IP 0.501 1.029 -0.255 -1.275 1.164 1.570 -1.343 -1.481 0.029 -0.184 
TREX1 1.486 -0.632 -0.543 -0.311 -0.367 -0.820 -0.750 -0.519 -0.063 -0.048 
KLC1 1.491 -0.648 -0.412 -0.432 0.790 1.161 -1.546 -1.560 0.824 0.687 
MLLT3 -0.201 0.828 0.706 -1.333 1.131 1.648 -1.078 -1.106 -0.696 -0.766 
    
  
3
2
3
 
RPS27A -1.196 -0.272 0.277 1.191 -0.948 -1.187 2.067 0.730 -0.715 -0.465 
SLC25A22 -0.903 -0.293 -0.233 1.430 -0.916 -1.623 0.314 0.294 1.488 1.215 
MRPS18A -1.474 0.240 0.554 0.680 -0.558 -0.770 2.219 0.753 -0.774 -0.962 
ING4 1.496 -0.413 -0.581 -0.502 1.320 1.539 -0.603 -1.098 -0.920 -0.980 
ARF4 1.371 -1.027 -0.233 -0.111 -0.466 -0.477 -0.978 -1.002 1.718 1.599 
SF3A1 -1.017 0.437 1.186 -0.606 -1.160 -1.277 0.923 2.006 -0.055 -0.133 
SRRM1 -1.492 0.350 0.548 0.594 -0.156 -2.126 0.934 1.307 -0.340 -0.418 
LGALS8 1.449 -0.739 -0.581 -0.129 0.427 1.968 -1.250 -1.457 0.484 -0.081 
BAG2 -1.450 0.193 0.438 0.818 -0.593 -0.826 -0.868 -0.954 1.409 1.814 
LRIG1 -1.030 -0.191 -0.151 1.371 -0.453 -0.224 -1.302 -1.275 1.439 1.506 
ALG6 -1.311 0.852 0.704 -0.245 -0.693 -0.984 1.423 1.869 -0.758 -0.611 
LMNB2 -1.391 -0.029 0.879 0.540 -0.912 -0.999 1.331 1.935 -0.426 -0.465 
XRCC1 -0.720 -0.429 -0.330 1.479 -0.874 -0.478 1.761 1.645 -0.673 -0.630 
CDKN2C -0.862 0.916 0.814 -0.868 -0.139 0.030 -1.653 -1.365 1.009 1.370 
RAB12 1.404 -0.736 -0.698 0.031 1.145 0.852 -1.329 -1.642 0.685 0.847 
RPS8 -1.458 0.819 0.319 0.319 0.720 0.135 1.390 1.233 -1.292 -1.136 
    
  
3
2
4
 
TERC -0.450 0.788 0.860 -1.199 -0.272 -0.267 1.755 1.435 -0.923 -1.066 
KLHL20 1.491 -0.535 -0.349 -0.607 -0.596 -0.758 -1.639 -0.187 1.530 1.405 
PUSL1 -1.051 0.890 0.819 -0.658 -1.693 -1.326 0.388 1.523 0.633 0.672 
BDP1 -1.066 0.779 0.923 -0.637 0.529 0.256 0.300 2.092 -1.094 -1.110 
ZFP91 1.165 -0.129 0.220 -1.256 0.617 0.399 -1.885 -1.498 0.518 0.839 
RPS6KA1 0.964 -0.548 -1.126 0.710 -0.143 0.007 0.835 1.939 -1.335 -1.299 
TMEM132B -0.462 -0.504 -0.533 1.499 2.094 1.200 -0.807 -0.790 -0.472 -0.491 
NOC4L -1.346 0.618 0.884 -0.157 -0.749 -1.436 1.542 1.623 -0.269 -0.092 
CAPN10 -1.398 0.909 0.468 0.021 -0.829 -0.853 1.878 1.492 -0.548 -0.417 
KDELR2 0.004 0.700 0.711 -1.416 -0.797 -0.224 -1.022 -1.140 1.520 1.623 
CLSPN -1.454 0.630 0.684 0.140 -1.364 -1.264 1.366 1.612 -0.058 0.110 
ATXN1L 1.456 -0.469 -0.200 -0.787 1.165 1.295 -1.540 -1.473 0.541 0.153 
DGCR6 -0.447 0.814 0.834 -1.201 1.173 1.532 -0.431 -0.970 -1.245 -0.986 
ERLIN1 0.330 1.253 -0.975 -0.609 2.152 0.825 -0.639 -1.347 -0.138 -0.435 
CIB2 -1.188 0.181 -0.220 1.227 1.380 1.710 -0.740 -0.995 -0.873 -0.894 
CHD7 -1.418 0.330 0.164 0.924 -0.578 -0.209 0.970 2.150 -1.013 -0.976 
    
  
3
2
5
 
SHCBP1 -1.204 0.373 1.145 -0.315 -0.950 -1.103 1.824 1.443 -0.506 -0.376 
DPYSL3 -0.515 -0.503 -0.482 1.500 -0.837 -0.560 -0.869 -0.780 1.323 1.962 
EXPH5 1.484 -0.499 -0.316 -0.669 1.530 1.669 -0.840 -0.842 -0.845 -0.848 
PHF11 1.387 -0.796 -0.661 0.069 -0.882 -0.882 0.142 2.278 -0.375 -0.882 
SLC35E2 1.468 -0.312 -0.380 -0.776 -1.259 -0.770 -0.187 2.331 0.047 0.389 
MKI67IP -1.491 0.648 0.439 0.404 -0.666 -1.086 1.391 1.876 -0.737 -0.596 
DCAF17 -0.020 -0.594 -0.802 1.416 -0.603 -0.714 1.550 1.870 -0.682 -0.682 
KIF15 -1.397 0.104 0.329 0.964 -0.820 -0.817 1.514 1.868 -0.604 -0.566 
RPL27A -0.934 -0.249 -0.235 1.418 0.482 -0.061 1.962 0.792 -1.354 -1.046 
SNHG3 -1.449 0.837 0.226 0.386 -1.407 -1.061 0.951 1.941 -0.434 0.071 
EIF2B5 -1.204 -0.225 0.224 1.205 -0.461 -0.804 1.429 1.730 -1.087 -0.948 
MRPS17 -1.377 0.836 0.630 -0.090 -0.807 -1.681 1.844 0.999 -0.198 0.062 
EIF1AD 0.056 0.440 0.910 -1.406 -0.543 -1.457 1.301 1.714 -0.633 -0.627 
BNIP3L 1.427 -0.580 -0.790 -0.058 1.338 1.441 -0.563 -1.360 -0.794 -0.771 
PLXNA2 1.493 -0.478 -0.387 -0.628 1.470 1.300 -1.424 -1.395 -0.077 -0.292 
ANKHD1 1.082 0.398 -0.204 -1.276 1.356 1.714 -0.914 0.361 -1.015 -1.050 
    
  
3
2
6
 
SAT1 1.500 -0.505 -0.491 -0.504 1.121 1.144 -1.448 -1.729 0.133 0.471 
DHX34 -1.425 0.639 0.748 0.039 0.039 0.524 1.130 0.465 -1.550 -1.730 
CDK2AP1 -1.042 -0.147 -0.176 1.364 -1.056 -1.187 1.483 1.689 -0.379 -0.416 
IQGAP1 0.900 -0.784 -0.944 0.827 0.889 0.859 -1.082 -1.643 1.233 0.511 
PRCC -1.116 0.799 0.888 -0.571 -0.050 0.142 1.062 1.882 -1.283 -1.242 
CKS1B -1.243 0.180 -0.123 1.186 -1.067 -1.030 2.034 1.141 -0.372 -0.380 
CCZ1 -1.279 0.195 -0.065 1.150 -1.129 -0.632 1.726 1.631 -0.542 -0.514 
NCAPG -1.384 0.808 0.653 -0.076 -0.887 -0.815 1.724 1.675 -0.589 -0.519 
KIF22 -1.495 0.484 0.402 0.608 -0.850 -0.827 1.577 1.779 -0.636 -0.661 
TCTN1 -0.403 0.894 0.734 -1.225 1.236 1.742 0.384 -0.811 -0.875 -1.212 
CALHM2 -0.569 1.498 -0.471 -0.457 -0.229 -0.003 -1.462 -1.511 1.376 0.912 
RAB17 -0.461 -0.512 -0.526 1.499 1.243 1.236 -0.986 -0.747 -0.915 -0.915 
NEK2 -1.260 0.814 0.794 -0.347 -0.949 -0.842 1.469 1.744 -0.754 -0.769 
KPNA4 0.562 -1.112 -0.530 1.080 -0.351 -1.137 -0.802 -0.479 1.748 1.470 
ITM2C -0.595 -0.493 -0.408 1.496 0.502 0.734 -1.263 -1.698 1.078 1.187 
MLPH 0.163 -0.757 -0.757 1.351 1.387 1.134 -0.964 -0.926 -0.897 -0.932 
    
  
3
2
7
 
RNASEH2B -1.500 0.503 0.511 0.486 -1.279 -1.048 1.346 1.758 -0.038 -0.311 
COMMD10 0.122 -0.699 -0.791 1.368 -0.980 -1.427 1.990 0.888 -0.020 0.213 
MTX1 -1.273 0.992 0.563 -0.281 -0.878 -0.871 1.647 1.616 -0.785 -0.273 
TOB2 1.225 -0.753 -0.877 0.405 0.856 1.398 -1.725 -1.452 0.098 0.212 
METAP2 -1.493 0.496 0.379 0.617 -0.498 -1.273 1.548 1.319 -1.009 -0.832 
DEPDC7 0.628 0.331 0.530 -1.489 1.445 1.805 -0.469 -0.432 -1.001 -1.024 
DPP8 1.149 0.271 -0.164 -1.256 0.790 0.894 -1.642 -1.649 0.762 0.737 
HTATSF1 -1.183 0.778 0.878 -0.474 0.227 -2.127 0.667 -0.650 0.615 1.421 
ABL2 1.188 -0.088 0.148 -1.248 -1.046 -0.979 -0.918 0.215 1.333 1.792 
NME1 -1.242 0.877 0.741 -0.376 -1.484 -1.711 1.366 0.579 0.571 0.555 
ARL8B 1.469 -0.254 -0.466 -0.749 0.902 0.819 -1.634 -1.685 0.729 0.595 
SMC4 -1.352 1.024 0.353 -0.025 -1.072 -0.871 1.422 1.738 -0.874 -0.496 
UBR2 -0.351 0.694 0.909 -1.252 0.592 2.033 -0.828 -1.454 0.476 -0.577 
NR1D1 1.479 -0.585 -0.637 -0.257 0.470 1.508 -1.516 -1.531 0.747 0.423 
EIF2D -0.875 0.604 1.093 -0.822 -0.146 -0.195 1.472 1.524 -1.356 -1.218 
RPN2 -1.395 -0.047 0.644 0.798 -1.471 -1.524 0.698 -0.040 1.478 0.890 
    
  
3
2
8
 
LRRC40 -1.287 0.992 0.546 -0.251 -0.604 -0.577 1.499 1.914 -0.684 -0.730 
RPL36AL -1.399 0.970 0.147 0.283 -0.228 -0.854 1.724 1.429 -1.157 -0.904 
ATP11B 1.414 -0.279 -0.195 -0.940 0.735 0.469 1.068 1.011 -1.592 -1.582 
ARHGEF17 1.453 -0.367 -0.257 -0.829 0.278 0.593 -1.534 -1.724 1.174 0.913 
FUBP1 -1.398 0.213 0.207 0.978 -0.526 -0.680 1.580 1.754 -0.767 -0.845 
NUP214 -1.453 0.712 0.602 0.139 -0.947 -1.000 0.513 2.318 0.073 -0.088 
MOB1B 1.039 -0.957 -0.749 0.667 0.531 0.727 -1.762 -1.392 1.168 0.856 
PSME3 -1.182 1.014 0.613 -0.445 -0.864 -1.727 0.615 1.930 0.058 0.236 
WLS -0.065 0.587 0.861 -1.382 0.482 0.283 -1.458 -1.536 1.424 1.051 
SLC39A6 1.293 0.222 -0.503 -1.013 0.278 0.286 -1.456 -1.434 1.306 1.369 
ST6GALNAC2 1.500 -0.492 -0.501 -0.507 -0.790 -0.876 1.878 1.468 -0.704 -0.620 
LBR -0.978 0.609 1.080 -0.711 -0.632 -0.617 1.877 1.480 -0.837 -0.716 
XPO7 -0.078 0.024 1.250 -1.196 -0.252 -0.260 1.078 2.156 -0.803 -0.809 
BRIP1 -1.431 0.874 0.411 0.146 -1.617 -1.507 0.334 1.467 0.665 0.594 
ECD -1.484 0.696 0.370 0.419 -0.748 -1.390 1.198 1.913 -0.387 -0.392 
GHDC -0.116 1.049 0.385 -1.318 0.420 1.298 -1.002 -1.553 -0.200 -0.358 
    
  
3
2
9
 
SMARCE1 -1.498 0.424 0.534 0.540 -0.736 -0.972 -0.701 -0.992 1.525 1.620 
SPAG5 -1.486 0.656 0.320 0.509 -1.136 -1.082 1.301 1.870 -0.332 -0.448 
FKTN 0.345 0.260 0.844 -1.449 -0.385 -0.529 -1.107 -0.223 1.699 1.582 
PPCS 1.408 -0.528 -0.860 -0.020 -0.610 -0.909 1.437 1.944 -0.696 -0.570 
ACER3 -1.309 0.131 1.126 0.052 1.896 0.894 -0.984 -1.473 -0.147 -0.409 
NT5DC1 -1.413 0.910 0.098 0.405 -0.366 -0.794 1.714 1.642 -0.810 -0.817 
EXOSC4 -0.749 0.528 1.144 -0.923 -0.195 -0.692 1.834 1.223 -0.999 -1.223 
TNRC18 1.365 -0.217 -0.111 -1.037 0.676 1.079 -1.635 -1.492 1.013 0.515 
CHAF1A -1.451 0.360 0.252 0.838 -1.055 -1.115 1.353 1.876 -0.284 -0.260 
OSBPL9 -0.723 0.280 -0.851 1.294 1.331 0.898 -1.805 -1.204 -0.162 0.803 
GAR1 -1.387 0.496 0.911 -0.019 -0.765 -1.093 1.833 1.427 -0.519 -0.546 
LSM3 -1.476 0.617 0.618 0.240 -0.938 -0.908 1.819 1.528 -0.631 -0.434 
RIPK1 0.129 -0.287 1.281 -1.122 -0.058 -0.307 -1.744 -1.212 1.272 1.167 
ATF7 1.470 -0.316 -0.387 -0.767 0.807 1.687 -1.629 -1.302 0.317 -0.135 
NDUFA10 0.700 -0.714 1.007 -0.993 -0.321 -0.723 2.131 0.931 -0.146 -0.304 
FOXRED1 -1.345 -0.178 0.770 0.753 -0.215 -0.459 1.792 1.294 -1.161 -1.199 
    
  
3
3
0
 
TGOLN2 1.334 -0.708 0.199 -0.825 1.091 1.407 -0.339 0.246 0.445 -1.950 
HMMR -1.434 0.279 0.264 0.892 -0.780 -0.724 1.435 1.830 -0.864 -0.818 
HOXB7 -0.825 1.059 0.648 -0.882 0.544 0.549 -1.663 -1.633 0.181 1.273 
IFNAR2 -1.029 0.630 1.055 -0.656 1.391 1.040 -1.351 -1.675 -0.084 0.108 
ZZEF1 0.535 0.172 0.750 -1.457 1.267 1.824 -1.297 -1.015 -0.259 -0.334 
ZWILCH -1.416 0.470 0.067 0.878 -0.779 -0.818 1.627 1.784 -0.630 -0.588 
MARCKS 0.551 -0.986 -0.685 1.120 -0.159 -0.018 -1.415 -1.471 1.320 1.422 
LZIC 1.398 -0.224 -0.197 -0.977 -1.491 -1.640 1.106 0.399 0.576 -0.205 
TSTD2 -0.783 -0.313 -0.372 1.467 -0.782 -1.138 -1.157 0.182 1.428 1.593 
NOM1 -1.149 1.064 0.564 -0.479 -0.665 -1.202 1.621 1.722 -0.359 -0.366 
H2AFX -1.433 0.082 0.792 0.559 -0.690 -0.670 1.422 1.977 -0.694 -0.667 
HIST1H2AD -1.030 0.767 0.943 -0.680 -0.840 -0.697 1.743 1.539 -0.711 -0.731 
STRADB -1.366 0.910 0.544 -0.088 1.016 2.056 -1.025 -1.068 -0.354 0.051 
ICMT -1.482 0.310 0.689 0.483 -0.241 -0.164 -1.213 -1.178 1.524 1.549 
ZBED4 1.460 -0.518 -0.193 -0.749 -0.469 -0.400 1.116 2.104 -0.937 -1.007 
HIST1H2AE -0.541 0.196 -0.970 1.315 -0.834 -0.713 1.925 1.312 -0.736 -0.752 
    
  
3
3
1
 
PFKFB4 1.498 -0.477 -0.443 -0.578 -0.338 0.104 -1.209 -1.134 0.261 0.365 
SPC24 -1.377 0.631 0.835 -0.089 -0.683 -0.620 1.752 1.638 -0.770 -0.844 
BCL6 1.500 -0.503 -0.520 -0.476 1.269 1.736 -1.277 -1.268 -0.103 -0.217 
NDUFV2 -0.301 -0.578 -0.606 1.486 -0.449 -1.174 2.063 0.978 -0.944 -0.457 
CSE1L -1.482 0.502 0.300 0.679 -0.921 -1.110 1.536 1.776 -0.265 -0.435 
FEN1 -1.494 0.444 0.626 0.424 -0.968 -0.979 1.434 1.854 -0.528 -0.537 
NDST2 0.161 0.648 0.651 -1.460 0.608 1.181 -1.421 -1.679 0.968 0.489 
ALDH3A2 1.495 -0.393 -0.601 -0.500 0.352 0.345 -1.424 -1.170 1.442 1.363 
PIK3CA 1.479 -0.502 -0.692 -0.285 0.373 0.885 -1.544 -1.486 1.097 1.097 
FAM136A -1.494 0.500 0.390 0.604 -0.042 -0.539 1.099 2.067 -1.009 -1.018 
LRP12 1.477 -0.574 -0.250 -0.652 -0.233 -0.330 -1.155 -1.228 1.735 1.384 
RABAC1 1.324 0.204 -0.626 -0.902 1.274 1.832 -0.637 -1.510 -0.390 -0.318 
PHF7 -0.430 0.380 1.180 -1.130 0.856 1.112 0.997 0.680 -1.548 -1.405 
ELF2 -1.469 0.491 0.738 0.239 1.056 0.766 -1.412 -1.742 0.823 0.701 
FXR2 0.094 0.960 0.344 -1.397 -0.919 -0.262 0.982 2.233 -0.634 -0.481 
MSN 1.449 -0.839 -0.381 -0.228 -0.180 0.155 -1.210 -1.226 1.577 1.517 
    
  
3
3
2
 
TBC1D22A 1.474 -0.500 -0.714 -0.260 1.093 1.728 -0.881 -0.892 -0.966 -0.884 
PDZD2 1.496 -0.533 -0.562 -0.402 1.653 1.672 -0.678 -0.648 -0.877 -0.869 
DAGLB 1.019 -0.880 -0.837 0.698 0.126 -0.353 -1.524 -1.182 1.574 1.268 
SNRPB -1.443 0.534 0.787 0.122 -1.266 -1.506 1.616 1.132 -0.029 0.298 
HTRA2 -0.950 0.684 1.026 -0.760 1.309 0.862 -0.855 -0.398 -1.093 -1.370 
HMGB3 -1.480 0.264 0.591 0.625 -1.507 -1.424 1.622 -0.066 0.643 0.771 
PUF60 -1.085 0.129 1.300 -0.344 -0.689 -0.607 1.880 1.492 -0.718 -0.888 
USP10 -1.454 0.139 0.646 0.670 -0.555 -0.817 1.788 1.642 -0.641 -0.553 
TMUB2 1.230 0.036 -0.047 -1.218 0.724 0.735 -1.532 -1.743 0.802 0.854 
TSC22D4 1.468 -0.229 -0.512 -0.728 1.109 1.638 -1.192 -1.349 -0.532 -0.404 
ATG12 0.005 -0.736 -0.681 1.412 1.398 1.187 -1.456 -1.529 0.285 0.142 
MAPRE3 1.373 -0.034 -0.340 -1.000 0.757 1.595 -1.357 -1.546 -0.095 0.175 
ATP5O -1.230 1.005 0.587 -0.362 -1.151 -1.322 2.043 0.571 -0.387 0.464 
RUNX2 1.486 -0.546 -0.309 -0.631 0.214 0.611 -1.599 -1.611 0.922 0.741 
PPIB -1.293 -0.191 0.435 1.050 -1.243 -1.366 1.317 0.911 0.648 0.832 
DLGAP4 1.395 -0.729 -0.721 0.055 0.211 0.454 -1.394 -1.564 1.188 1.376 
    
  
3
3
3
 
KDELR1 1.491 -0.444 -0.647 -0.400 1.095 1.404 -1.533 -1.515 -0.183 0.148 
MOCS1 -1.370 0.079 0.268 1.022 0.668 0.972 -1.537 -1.434 1.032 0.967 
RPL36 -1.030 0.881 0.834 -0.684 0.542 0.343 1.858 0.160 -1.568 -1.187 
MTG1 -1.294 0.914 0.647 -0.267 -0.601 -0.339 1.823 1.212 -1.145 -1.170 
SNRPD3 -1.253 0.619 0.968 -0.334 -0.744 -1.031 1.687 1.680 -0.632 -0.493 
DOLK 1.332 -0.075 -0.166 -1.092 -0.583 -0.727 -0.982 -0.917 1.229 1.937 
HGSNAT 1.337 -0.012 -0.256 -1.070 0.195 0.248 -1.520 -1.475 1.027 1.512 
ABL1 0.099 -0.757 -0.720 1.378 0.999 1.376 -1.578 0.602 0.529 -0.262 
MYBBP1A -1.254 0.719 0.887 -0.352 -0.553 -0.944 1.348 1.949 -0.756 -0.696 
MED27 -1.262 0.840 0.765 -0.343 -1.319 -1.726 1.422 0.781 0.379 0.617 
KDM5A -0.361 0.758 0.855 -1.251 1.374 1.601 -0.942 -0.652 -0.873 -0.948 
PA2G4 -1.296 0.580 0.961 -0.245 -0.812 -1.138 1.630 1.699 -0.469 -0.339 
YWHAE -1.461 0.695 0.595 0.171 -0.626 -0.851 1.005 2.132 -0.975 -0.561 
FANCI -1.246 0.862 0.753 -0.369 -0.878 -0.878 1.530 1.866 -0.454 -0.473 
FAM54A -1.287 0.981 0.563 -0.257 -1.028 -0.915 1.138 2.078 -0.573 -0.270 
NCAPD2 -1.444 0.613 0.727 0.104 -0.815 -0.611 1.365 2.015 -0.659 -0.679 
    
  
3
3
4
 
CDCA2 -1.234 0.032 -0.014 1.215 -0.758 -0.441 0.924 2.122 -0.783 -1.043 
FOXO3 1.466 -0.377 -0.304 -0.785 1.579 1.543 -1.012 -0.948 -0.579 -0.841 
GLT25D1 0.685 0.056 0.691 -1.432 0.767 -1.133 -0.293 -0.840 1.560 1.310 
LSM12 -1.405 0.962 0.250 0.194 -1.093 -1.301 -0.663 0.570 0.871 1.869 
TOR1A 0.246 0.480 0.743 -1.469 0.171 0.764 -2.368 0.634 0.357 0.858 
ANGEL2 -1.124 0.723 0.953 -0.552 1.261 1.175 -0.170 -1.487 -1.487 0.710 
KCTD3 -1.293 0.491 1.020 -0.218 -0.033 -0.289 1.380 1.723 -1.151 -1.048 
RNMTL1 -0.979 1.085 0.602 -0.709 -0.996 -1.919 0.613 0.396 1.066 1.261 
PSME1 0.307 -0.179 -1.261 1.133 -0.132 -0.249 2.278 -0.681 -1.188 -0.646 
PPP1R12B 0.153 0.840 0.446 -1.439 -0.134 0.286 -1.504 -1.188 1.917 0.698 
MTMR9 0.122 -0.840 -0.646 1.364 -0.709 -0.956 1.601 1.726 -0.610 -0.407 
MRPS34 -1.424 0.595 0.785 0.045 0.468 0.084 1.496 0.847 -1.420 -1.655 
TOP2A -1.445 0.836 0.423 0.185 -0.949 -0.806 1.501 1.747 -0.719 -0.716 
SNW1 -1.395 0.011 0.474 0.910 -0.574 -0.511 1.220 1.566 -1.354 -1.120 
RB1CC1 -1.474 0.682 0.238 0.553 1.118 1.300 -1.616 -1.417 0.551 0.233 
PEF1 -0.350 0.713 0.892 -1.254 1.352 1.498 -0.719 -1.540 -0.573 -0.649 
    
  
3
3
5
 
TSEN34 0.668 0.676 0.101 -1.445 -1.032 -1.010 1.836 1.331 -0.536 -0.270 
CDCA7 -1.477 0.355 0.385 0.737 -0.772 -0.826 1.541 1.830 -0.626 -0.607 
ADRB2 1.500 -0.493 -0.495 -0.512 1.477 1.586 -0.794 -0.837 -0.921 -0.905 
CHCHD5 -1.387 0.566 -0.048 0.868 0.556 0.534 1.259 0.987 -1.655 -1.351 
BUB3 -1.131 0.860 0.823 -0.552 -1.024 -1.220 1.845 1.339 -0.370 -0.204 
NPRL2 -1.009 0.654 1.041 -0.686 1.332 1.645 0.151 0.338 -1.240 -0.872 
CYP2W1 1.500 -0.518 -0.485 -0.497 1.871 1.189 -0.835 -0.835 -0.835 -0.835 
ECHS1 -1.123 0.985 0.685 -0.547 1.330 0.957 0.611 0.102 -1.521 -1.584 
PARP2 -1.459 0.580 0.711 0.168 -0.687 -0.659 1.953 1.368 -0.812 -0.518 
BAP1 0.131 0.316 0.956 -1.403 -0.429 -0.527 1.796 1.637 -0.686 -0.687 
ZMPSTE24 -0.089 1.184 0.156 -1.251 -0.572 -0.956 -1.085 -0.946 1.426 1.565 
RFTN1 1.434 -0.065 -0.646 -0.723 -0.642 -0.575 -0.735 -0.719 1.504 1.892 
BMP2K 1.494 -0.519 -0.381 -0.594 0.578 1.026 -1.715 -1.626 0.541 0.666 
AGPAT6 -1.150 -0.083 1.291 -0.058 -0.619 -0.859 -0.605 -0.901 1.573 1.747 
ANKMY2 -1.162 1.022 0.615 -0.475 -0.835 -1.332 1.226 1.834 -0.266 0.210 
MACROD1 -0.627 1.392 0.051 -0.817 1.461 1.916 -0.762 -0.967 -0.396 -0.568 
    
  
3
3
6
 
FAM49B -1.148 -0.206 0.076 1.278 -0.598 -0.899 1.751 1.591 -0.855 -0.540 
RPS4X -0.861 0.779 0.949 -0.867 0.095 -0.220 1.811 1.221 -1.411 -0.849 
CCDC18 -1.370 0.871 0.595 -0.096 -0.590 -0.518 1.652 1.797 -0.769 -0.635 
ARFGEF2 0.498 -0.204 1.008 -1.302 1.089 1.713 -1.781 -0.041 0.239 -0.148 
FIP1L1 -1.385 0.867 -0.056 0.573 -0.511 0.315 0.669 1.654 -1.220 -1.590 
ABCE1 -1.428 0.457 0.859 0.112 -0.817 -1.484 1.193 1.875 -0.080 0.011 
HN1L -0.767 -0.923 0.588 1.102 -0.894 -0.869 1.366 1.982 -0.499 -0.490 
SLC39A1 -1.181 0.123 -0.190 1.247 0.612 0.444 -1.381 -1.912 0.975 0.923 
NEDD4L 1.139 -0.788 -0.890 0.539 -0.590 -0.216 -0.557 -0.889 1.442 1.939 
MAD2L1 -1.390 0.896 0.515 -0.021 -1.011 -0.983 1.535 1.700 -0.588 -0.584 
RNF7 -0.171 -0.740 -0.546 1.458 -0.350 -1.318 1.650 1.562 -0.746 -0.452 
LIG3 -1.086 -0.178 -0.072 1.336 0.366 0.041 0.690 1.885 -1.288 -1.373 
PSENEN -0.443 1.217 -1.103 0.329 0.792 0.206 -0.642 -1.314 -1.156 -0.172 
KIF14 -1.385 0.752 0.714 -0.081 -0.733 -0.560 0.948 2.132 -0.830 -0.913 
IPO11 -1.228 0.839 0.791 -0.403 -0.804 -1.049 1.281 2.013 -0.176 -0.312 
PPP2R1A 1.027 -1.159 -0.478 0.611 -1.326 -1.279 0.200 0.797 1.393 1.166 
    
  
3
3
7
 
INPP5E -0.057 0.557 0.882 -1.382 0.919 0.668 -1.965 -1.333 0.639 0.774 
TRNAU1AP -1.380 0.767 -0.092 0.706 -0.692 -0.946 1.716 1.369 -0.917 -0.935 
LIF 0.322 -0.688 -0.902 1.268 -0.683 -0.729 -0.611 -0.632 0.902 2.278 
CCNA2 -1.498 0.455 0.466 0.577 -0.819 -0.839 0.997 2.052 -0.800 -0.842 
SLC37A1 -0.735 -0.373 -0.370 1.478 1.715 1.370 -0.318 -0.261 -1.204 -1.204 
LARP4 -1.271 0.489 1.039 -0.257 -0.691 -0.387 0.006 2.510 -0.765 -0.633 
ZFAND6 0.465 -0.829 -0.825 1.190 0.924 1.017 -0.255 -1.090 -0.973 -1.001 
IFT27 -1.478 0.473 0.293 0.712 -1.534 -1.464 1.582 0.565 0.154 0.329 
USE1 -0.800 1.004 0.714 -0.918 -0.769 -0.769 1.455 1.856 0.047 -0.769 
HIST1H2AI -1.217 0.533 1.049 -0.366 -0.843 -0.714 1.806 1.439 -0.723 -0.749 
ALDH9A1 -1.345 0.876 0.632 -0.163 -0.515 -0.600 2.108 1.226 -0.679 -0.629 
DDX59 -1.067 1.049 -0.609 0.626 -0.771 -0.947 1.750 1.482 -0.840 -0.351 
RNF26 -0.167 -1.186 0.107 1.246 -1.965 -0.946 -0.540 1.321 0.727 0.638 
METTL3 -1.482 0.655 0.540 0.287 -1.179 -1.179 1.285 1.362 0.324 0.374 
CCDC115 1.441 -0.826 -0.467 -0.149 -1.070 -1.403 1.075 1.771 0.122 0.239 
PSMC3IP -1.446 0.842 0.209 0.395 -1.046 -1.046 1.505 1.712 -0.474 -0.536 
    
  
3
3
8
 
NUP85 -1.225 1.014 0.579 -0.368 -0.891 -1.064 1.698 1.655 -0.456 -0.369 
EXOSC5 -1.428 0.338 0.189 0.900 -0.456 -0.766 1.809 1.592 -0.633 -0.861 
FZR1 0.491 0.308 0.683 -1.482 -0.552 -0.390 1.233 1.941 -1.065 -1.016 
DDX41 0.078 -1.251 -0.022 1.195 -0.592 -0.781 1.548 1.744 -0.822 -0.895 
CDC7 -1.233 0.792 0.835 -0.394 -0.935 -0.866 1.762 1.621 -0.301 -0.322 
TSN -1.486 0.617 0.566 0.303 -1.406 -1.492 0.520 1.337 0.699 0.904 
MTPN 0.796 -0.029 0.634 -1.401 -0.348 -0.484 -0.958 -0.993 1.738 1.613 
DST 1.500 -0.484 -0.536 -0.480 1.293 1.843 -1.092 -1.092 -0.555 -0.106 
TRAPPC4 -0.532 -0.565 -0.400 1.496 -0.536 -0.862 2.086 1.259 -0.479 -0.524 
PSMB1 -1.463 0.799 0.316 0.348 -0.041 0.207 2.094 0.480 -1.198 -1.347 
KATNB1 -0.981 0.879 0.845 -0.742 -0.992 -0.739 1.077 2.107 -0.511 -0.661 
FNTA 0.939 -0.421 -1.209 0.692 -0.388 -0.541 2.089 0.693 -0.987 -1.134 
MCL1 1.087 -0.776 -0.920 0.609 -0.380 -0.359 1.014 1.968 -1.166 -1.174 
C1D -1.324 1.102 0.174 0.047 -0.919 -1.432 1.861 1.161 0.131 -0.129 
SAC3D1 -1.229 1.018 0.569 -0.358 -0.614 -0.605 1.840 1.341 -0.949 -0.993 
EIF3B -1.361 0.235 1.042 0.084 -0.892 -1.027 1.333 1.970 -0.335 -0.458 
    
  
3
3
9
 
MRPL12 -1.180 0.929 0.722 -0.471 -0.733 -1.321 1.522 1.638 -0.677 -0.415 
HIST1H2AH -1.256 0.169 1.177 -0.090 -0.866 -0.645 1.688 1.606 -0.669 -0.701 
NUP37 -1.486 0.313 0.534 0.640 -0.563 -0.670 2.449 0.478 -0.689 -0.657 
KLF6 1.498 -0.423 -0.524 -0.551 0.838 0.993 -1.363 -1.799 0.753 0.753 
BTF3 -1.454 0.623 0.693 0.138 0.009 -0.176 1.756 1.161 -1.360 -1.253 
MRPL16 -1.435 0.074 0.616 0.745 -0.678 -0.964 2.184 1.063 -0.555 -0.565 
TMEM127 1.497 -0.481 -0.583 -0.433 0.321 0.479 -1.587 -1.602 1.062 1.050 
SRGAP1 1.459 -0.690 -0.608 -0.160 1.652 0.653 -1.114 -1.114 0.898 -1.114 
SLC5A3 1.489 -0.498 -0.346 -0.645 -0.226 0.676 -1.557 -1.565 0.912 1.243 
GGCX 0.650 0.734 0.043 -1.427 -0.643 -0.209 -1.074 -0.798 1.704 1.634 
USP21 -0.920 0.641 1.062 -0.783 -0.115 0.174 0.442 2.136 -1.175 -1.085 
ALYREF -1.273 1.020 0.519 -0.266 -1.331 -1.406 1.302 1.491 -0.266 -0.355 
SUB1 -1.344 0.280 0.007 1.057 -0.360 -0.584 2.131 1.180 -0.822 -0.846 
RALGDS 1.447 -0.394 -0.214 -0.839 1.223 1.528 -0.073 -0.502 -1.364 -1.364 
XRCC4 -1.165 0.104 -0.200 1.261 0.008 -0.425 1.139 -1.218 -0.816 -0.856 
TUBE1 -1.190 0.839 0.815 -0.464 -0.817 -0.869 1.706 1.598 -0.634 -0.688 
    
  
3
4
0
 
RBM27 -0.521 -1.150 0.899 0.772 -0.749 -0.570 -0.036 2.534 -0.175 -0.266 
ELOVL6 -0.199 -0.675 -0.594 1.467 -0.593 -0.664 1.183 2.093 -0.780 -0.717 
TMOD3 1.500 -0.503 -0.519 -0.477 1.841 1.350 -0.977 -0.979 -0.598 -0.608 
FIG4 -0.808 0.499 -0.858 1.167 -0.848 -1.225 1.148 2.008 -0.132 0.018 
MKLN1 -1.046 -0.538 1.217 0.367 1.224 1.144 -1.256 -0.973 -0.684 -0.742 
GPR19 -0.536 -0.463 -0.501 1.499 -0.450 -0.626 1.736 1.338 -1.564 -0.260 
RAD51 -1.278 0.037 0.075 1.166 -0.967 -1.012 1.692 1.657 -0.417 -0.308 
FBL -1.461 0.438 0.785 0.239 -0.978 -1.288 1.912 1.147 0.030 0.131 
NOLC1 -1.168 1.058 0.560 -0.450 -0.673 -1.017 1.964 1.123 -1.114 -0.248 
MRPL2 -1.125 0.570 1.070 -0.515 -0.994 -1.049 1.974 1.156 -0.135 0.066 
SMG5 -1.474 0.671 0.565 0.238 -0.986 -1.196 1.415 1.713 0.069 0.081 
MAP4K2 1.194 -0.646 -0.983 0.436 0.978 2.120 -1.043 -0.403 -0.480 -0.896 
MED4 -1.492 0.577 0.347 0.567 -0.633 -0.691 1.896 1.523 -0.619 -0.659 
PTRH1 1.491 -0.644 -0.377 -0.470 -0.475 -0.558 -0.773 -1.187 1.595 1.650 
NHP2 -1.099 1.020 0.651 -0.572 -0.524 -0.866 1.544 1.858 -0.747 -0.684 
ANKRD52 0.237 0.264 0.922 -1.423 -0.242 -0.045 -1.390 -1.283 1.539 1.347 
    
  
3
4
1
 
AIF1 -0.518 -0.463 -0.518 1.499 1.467 -1.232 -1.060 -1.232 1.169 0.133 
NUP205 -1.492 0.641 0.449 0.402 -0.733 -0.805 1.292 2.087 -0.440 -0.573 
GAMT 0.160 0.412 0.863 -1.435 -0.895 -0.926 -0.146 -0.451 0.441 2.417 
FBXO8 1.270 0.027 -0.126 -1.171 2.214 0.664 -0.039 -0.507 -0.916 -1.090 
FAM172A 1.465 -0.265 -0.420 -0.779 0.780 0.748 -2.265 -0.905 0.562 0.451 
WTAP -1.497 0.543 0.539 0.415 -0.713 -0.084 0.251 2.358 -0.168 -0.258 
POLR2K -1.460 0.600 0.694 0.166 -1.173 -1.433 1.817 1.047 0.221 -0.152 
CALR -0.291 -0.998 -0.094 1.382 -1.550 -1.254 1.441 1.184 0.146 0.307 
TSEN2 -1.200 0.700 0.937 -0.437 -0.763 -0.855 1.639 1.792 -0.563 -0.464 
KIFC1 -1.464 0.263 0.416 0.784 -0.964 -0.878 1.441 1.907 -0.478 -0.456 
TOMM34 -1.250 0.540 1.024 -0.314 -1.111 -1.325 1.476 1.611 0.156 -0.123 
PGLS 1.489 -0.340 -0.633 -0.515 1.435 1.326 -0.098 -1.983 -0.263 -0.030 
ZCCHC8 -1.289 0.134 0.006 1.149 -0.562 0.031 1.096 2.039 -0.875 -0.975 
RAB5B 1.496 -0.505 -0.580 -0.411 1.044 1.024 -1.645 -1.662 0.311 0.118 
ELAVL1 -1.471 0.377 0.766 0.327 -1.443 -1.480 0.277 1.700 0.236 0.697 
CDK1 -1.415 0.933 0.320 0.161 -1.098 -0.938 1.531 1.604 -0.675 -0.671 
    
  
3
4
2
 
CKAP2 -0.995 0.579 1.099 -0.683 -1.099 -0.740 1.881 1.249 -0.661 -0.671 
HDAC6 -0.156 0.840 0.667 -1.351 -1.777 0.573 1.271 1.278 0.078 -1.063 
PFN2 0.075 -0.654 -0.806 1.385 0.473 -0.072 -1.507 -1.574 0.285 0.342 
SGPP1 1.344 0.020 -0.321 -1.043 1.442 1.176 -1.467 -1.499 -0.026 -0.140 
ACSL4 -0.564 0.731 0.950 -1.116 -0.308 -0.239 -1.206 -1.206 0.388 2.164 
LCOR -0.556 1.178 0.434 -1.056 1.714 1.543 -1.127 -0.591 -0.701 -0.680 
MCM4 -1.446 0.690 0.648 0.108 -1.130 -1.142 1.439 1.778 -0.142 -0.170 
TRAIP -1.402 0.605 0.817 -0.019 -1.211 -1.177 1.287 1.752 -0.228 -0.116 
UBE2S -1.497 0.594 0.437 0.466 -0.867 -0.842 1.502 1.825 -0.661 -0.612 
SDHD -0.378 -1.014 0.040 1.352 -0.725 -0.817 2.067 1.272 -0.542 -0.396 
ETV4 -0.294 -0.606 -0.585 1.485 -1.153 -1.225 0.537 2.181 -0.136 0.073 
TRIP13 -1.320 0.800 0.751 -0.231 -0.957 -0.993 1.457 1.883 -0.447 -0.293 
EIF2B1 -0.461 0.814 0.839 -1.192 -0.715 -1.030 1.642 1.721 -0.573 -0.539 
MBD5 1.419 -0.083 -0.459 -0.877 0.879 1.337 -1.908 -0.825 0.909 0.280 
CHCHD6 -1.321 0.104 1.110 0.107 -0.371 -1.441 1.929 1.147 -0.219 -0.640 
TTF2 -1.491 0.640 0.485 0.366 -0.851 -0.871 1.602 1.815 -0.399 -0.423 
    
  
3
4
3
 
USP33 -1.274 0.757 0.837 -0.320 -0.901 -0.901 -0.901 0.646 0.561 -0.901 
UBE2A 0.979 0.078 0.331 -1.388 1.823 0.320 -2.050 -0.441 0.171 0.131 
NUDCD1 -0.931 -0.249 -0.238 1.419 -0.832 -1.247 1.822 1.444 -0.200 -0.310 
SNAP47 -0.876 0.965 0.761 -0.850 1.448 1.291 -1.203 -1.199 -0.537 -0.789 
FPGS -0.335 -0.708 -0.438 1.481 -0.743 -1.091 1.590 1.790 -0.392 -0.357 
FANCD2 -1.468 0.544 0.710 0.214 -0.807 -0.818 1.601 1.803 -0.573 -0.615 
HJURP -1.308 0.059 0.121 1.128 1.641 1.014 -1.297 -1.297 -0.319 -0.300 
CSTF2 -0.993 -0.076 1.382 -0.313 -1.061 -1.555 1.156 1.705 0.206 0.182 
GMPS -1.438 0.302 0.255 0.881 -0.863 -1.127 1.504 1.817 -0.252 -0.227 
PDDC1 1.306 -0.381 0.138 -1.063 1.056 1.781 0.218 -0.016 -1.289 -1.171 
SLC38A9 -1.363 0.350 0.004 1.009 1.286 1.429 -1.730 -1.051 0.129 -0.296 
RPS7 -1.361 0.780 0.720 -0.139 0.246 -0.676 2.185 0.860 -1.015 -0.780 
ECH1 1.112 -0.160 -1.277 0.326 1.617 1.805 -0.638 -0.481 -0.839 -0.605 
EMP2 1.482 -0.519 -0.294 -0.670 1.528 1.373 -1.243 -1.309 -0.508 -0.383 
LITAF 1.366 -0.703 -0.790 0.126 0.086 0.304 -1.292 -1.593 1.068 1.537 
TMED9 1.167 -0.730 0.491 -0.929 -0.786 -0.861 -0.025 -1.393 1.752 1.216 
    
  
3
4
4
 
CAND1 -1.384 0.477 0.926 -0.020 -0.346 -0.235 0.913 2.136 -0.685 -0.746 
CDK17 1.389 -0.039 -0.393 -0.957 -1.020 -0.892 -0.325 -0.016 1.484 1.831 
MAML1 -1.225 0.404 1.117 -0.297 0.542 0.525 -1.739 -1.285 1.208 1.086 
PALB2 -0.776 0.208 -0.764 1.331 -0.698 -0.767 1.597 1.857 -0.494 -0.612 
CASP1 1.500 -0.500 -0.500 -0.500 0.049 -0.315 -1.065 -1.065 1.309 1.794 
UHMK1 0.883 0.387 0.160 -1.430 0.885 1.456 -1.701 -1.258 0.667 -0.130 
MOCS2 -0.793 0.712 1.005 -0.924 -1.305 -1.423 -0.278 -0.341 0.210 1.003 
PASK -1.314 0.150 0.047 1.117 -0.862 -0.869 1.279 2.064 -0.336 -0.344 
MUM1 -1.342 0.373 -0.058 1.027 -0.848 -0.913 1.491 1.873 -0.207 -0.311 
ARPC1B 1.488 -0.665 -0.466 -0.357 -0.223 -0.448 -1.059 -1.551 1.451 1.423 
VPS4B 1.481 -0.612 -0.600 -0.268 1.696 0.974 -0.605 -0.599 -1.110 -1.184 
TSEN15 -1.217 0.788 0.850 -0.420 -0.973 -1.353 1.951 0.924 -0.072 -0.267 
PRMT5 -0.774 0.363 1.251 -0.840 -0.800 -1.073 0.931 2.206 -0.359 -0.378 
GART -1.283 0.649 0.922 -0.288 -0.717 -0.847 1.524 1.909 -0.515 -0.509 
MOSPD3 1.314 -0.201 -1.111 -0.001 -0.474 0.031 1.182 1.503 -1.545 -1.037 
TTF1 -1.387 0.113 0.280 0.993 -0.431 -0.171 1.265 1.978 -0.888 -1.158 
    
  
3
4
5
 
CEP70 -1.205 0.481 -0.364 1.088 -0.525 -0.475 1.920 1.478 -0.586 -0.923 
SENP1 -1.375 0.925 0.502 -0.052 -0.580 -0.762 1.545 1.519 -1.106 -0.993 
CREBL2 0.235 -0.612 -0.930 1.306 1.649 1.499 -1.014 -0.857 -0.715 -0.745 
RAB14 1.204 0.207 -0.198 -1.212 0.846 1.031 -1.786 -1.511 0.602 0.460 
EMG1 -0.417 -0.748 -0.309 1.474 -0.617 -0.648 1.800 1.658 -0.692 -0.702 
AGGF1 -0.640 1.281 0.290 -0.931 -0.334 -0.581 1.503 1.822 -0.779 -0.990 
PTPN4 -0.162 -0.662 -0.636 1.460 0.587 0.368 -0.305 2.148 -0.716 -0.844 
CHD4 -1.248 0.491 -0.297 1.055 -0.070 0.755 0.320 2.133 -0.843 -1.267 
LATS2 1.406 -0.756 -0.670 0.020 -0.105 -0.058 -1.086 -1.118 1.587 1.629 
TMEM87B 1.485 -0.379 -0.694 -0.413 0.648 1.075 -1.469 -1.532 0.822 0.971 
CYP4B1 1.500 -0.500 -0.500 -0.500 1.339 0.788 -1.499 -1.385 1.026 -0.122 
TNFSF9 1.446 -0.234 -0.359 -0.852 0.199 0.333 -0.889 -1.027 -0.446 -0.379 
RSAD1 -0.832 1.162 0.507 -0.837 0.196 -0.269 -1.690 -1.390 1.170 1.236 
CNOT6L 1.104 -0.034 0.242 -1.312 1.803 1.398 -1.155 -0.727 -0.633 -0.487 
CIRBP -1.154 0.930 0.735 -0.511 -0.464 -0.170 1.600 1.673 -1.102 -1.036 
SNAP29 -0.273 1.069 0.458 -1.254 1.315 1.064 -1.452 -1.368 -0.358 -0.379 
    
  
3
4
6
 
CARS2 1.338 -0.832 -0.694 0.187 -1.072 -1.093 1.505 1.686 -0.495 -0.260 
TAF1C -1.055 0.082 1.325 -0.352 -0.872 -0.855 1.127 2.164 -0.244 -0.460 
VPS37C 1.476 -0.591 -0.241 -0.644 1.181 1.344 -1.418 -1.461 -0.301 0.143 
NCK1 1.481 -0.588 -0.271 -0.622 1.073 0.302 -1.082 -2.093 0.450 0.087 
TBC1D8 1.348 -0.781 -0.738 0.171 0.588 0.906 1.264 0.486 -1.544 -1.570 
DPY19L4 0.141 0.587 0.725 -1.453 1.420 0.994 -1.554 -1.522 0.398 -0.108 
GTF3C2 -1.383 0.213 0.162 1.008 -0.570 -0.793 1.383 1.968 -0.795 -0.460 
DONSON -1.423 0.751 0.641 0.031 -1.064 -1.191 1.730 1.494 -0.166 -0.095 
CXCL1 1.210 -0.749 -0.889 0.429 0.348 0.916 -1.546 -1.745 0.126 0.557 
GBE1 1.147 0.469 -0.527 -1.089 -0.512 -0.610 -0.824 -0.585 1.812 1.647 
CEP170 -1.258 0.743 0.863 -0.348 -0.597 -0.436 -0.773 -0.714 1.836 1.587 
TNKS2 0.305 -0.316 -1.179 1.190 -0.165 0.101 1.571 1.535 -1.122 -1.314 
THOC2 -1.047 0.664 1.025 -0.642 1.663 1.679 -0.676 -0.146 -1.086 -0.635 
IMPDH2 -1.120 0.596 1.054 -0.530 -0.547 -0.603 1.933 1.494 -0.729 -0.797 
THRA -1.021 0.781 0.932 -0.692 1.064 1.561 -1.186 -1.542 -0.032 -0.407 
MGAT2 -0.542 0.362 1.221 -1.041 -0.445 -0.721 -1.002 -0.927 1.790 1.420 
    
  
3
4
7
 
ALAS1 0.351 0.435 0.697 -1.484 -0.376 0.809 -0.216 1.054 -1.606 -1.343 
ZMYND19 -1.246 0.934 0.669 -0.357 -0.537 -0.913 1.716 1.709 -0.505 -0.599 
CSAD 1.458 -0.166 -0.573 -0.719 0.244 0.663 0.255 1.491 -1.673 -1.471 
AKT2 1.497 -0.579 -0.475 -0.443 1.482 1.806 -0.914 -0.664 -0.346 -1.012 
PGAP3 1.200 -0.950 -0.684 0.435 1.666 1.608 -0.762 -0.485 -0.886 -0.675 
RPRD1B 0.059 1.050 0.245 -1.354 -0.088 -0.478 0.583 1.911 -1.123 -1.506 
SLC25A28 0.848 0.423 0.168 -1.440 1.523 1.523 -0.265 -0.287 -1.243 -1.242 
CEP57 -1.329 0.066 0.167 1.096 -1.055 -1.032 1.515 1.685 -0.124 -0.034 
MDC1 -1.113 0.857 0.833 -0.577 -1.117 -1.116 1.149 1.920 -0.151 -0.383 
PLA2G12A -1.313 -0.101 0.342 1.072 -1.199 -1.530 1.069 0.140 0.928 1.373 
NIPA1 1.460 -0.454 -0.222 -0.783 -0.335 -0.320 -1.160 -0.762 1.723 1.585 
METTL5 -0.633 0.699 0.994 -1.059 0.456 -0.217 1.056 1.443 -2.086 -0.301 
ARPC2 1.496 -0.598 -0.467 -0.431 0.504 0.454 -1.635 -1.714 0.224 0.834 
PPAN -1.144 0.794 0.882 -0.532 -0.686 -0.858 1.799 1.637 -0.574 -0.534 
MAGED1 -0.233 0.443 1.063 -1.273 -0.754 -0.201 -0.929 -0.877 1.721 1.574 
WFDC5 1.500 -0.501 -0.499 -0.501 -0.185 -0.168 -0.498 -0.500 -0.500 -0.500 
    
  
3
4
8
 
SOCS5 0.444 -0.723 -0.919 1.198 -0.247 -0.266 -1.011 -1.077 1.652 1.663 
ZUFSP -0.555 1.098 0.547 -1.090 1.332 1.012 -1.294 -0.048 0.569 0.486 
GJA1 -0.097 -0.677 -0.670 1.444 -0.804 -0.820 0.517 2.260 -0.741 -0.809 
GNL2 -1.484 0.535 0.649 0.300 -0.540 -0.956 1.649 1.730 -0.779 -0.543 
ARHGAP27 1.498 -0.453 -0.567 -0.479 1.698 1.401 -0.743 -0.945 -0.860 -0.857 
CENPI -1.227 0.373 1.131 -0.278 -1.300 -1.326 1.169 1.714 -0.312 -0.178 
ODF2 -0.791 0.835 0.894 -0.938 -0.836 -0.658 1.524 1.872 -0.451 -0.579 
SND1 -0.818 -0.566 -0.034 1.418 0.576 2.112 -0.998 0.689 -0.320 -0.557 
KLHL11 -0.496 0.935 0.725 -1.164 -0.442 0.920 -1.242 1.746 0.209 -1.485 
MX2 0.803 -0.862 -0.868 0.927 0.884 1.482 -0.911 -1.212 -0.403 -1.228 
PHB2 -1.357 0.767 0.740 -0.150 -0.313 -0.816 1.238 2.004 -0.687 -0.944 
RPN1 -0.747 0.431 1.208 -0.893 -0.578 -0.811 1.904 1.381 -0.726 -0.912 
CCNB1 -1.477 0.264 0.521 0.692 -0.759 -0.750 1.741 1.683 -0.693 -0.627 
ISY1 -0.903 0.863 0.868 -0.828 -0.580 -0.845 1.686 1.697 -0.810 -0.660 
RNF111 1.490 -0.651 -0.471 -0.367 -0.565 0.158 -1.560 -0.558 1.429 1.645 
NPPB -0.500 -0.500 -0.500 1.500 -0.678 0.904 1.681 1.118 -1.022 -0.784 
    
  
3
4
9
 
POP1 -0.635 0.079 1.382 -0.826 -0.781 -0.924 0.995 2.226 -0.411 -0.467 
RGMB 0.711 -0.578 -1.104 0.971 0.392 0.820 -1.350 -1.822 0.887 1.061 
ACTR10 1.087 0.352 -0.146 -1.293 -0.489 -0.288 -0.906 -1.372 1.387 1.697 
SGSH 0.668 0.128 0.656 -1.452 -0.216 -0.168 -1.127 -1.272 1.748 1.305 
NOL10 -1.228 0.712 0.910 -0.394 -1.014 -1.285 1.597 1.455 0.026 0.332 
BMPR1A -0.765 -0.274 -0.429 1.468 0.905 0.251 -1.530 -1.455 1.177 0.857 
SRM -1.339 0.823 0.704 -0.188 -0.862 -1.050 1.448 1.883 -0.326 -0.262 
ZMAT2 -1.422 0.682 0.025 0.715 -0.901 -1.078 1.654 1.656 -0.512 -0.420 
SNRNP70 -1.368 0.818 0.667 -0.118 -1.142 -1.145 1.394 1.587 0.034 -0.315 
ARHGAP19 -1.324 0.567 0.944 -0.186 -0.457 -0.405 1.369 1.943 -0.909 -0.940 
PRPS1 -1.147 0.681 0.979 -0.513 -0.482 -0.669 1.562 1.887 -0.697 -0.738 
RPS14 -1.339 0.004 1.066 0.269 0.213 -0.052 1.642 1.078 -1.328 -1.447 
PRPSAP1 -1.009 1.144 0.509 -0.644 -0.653 -0.555 1.634 1.806 -0.781 -0.690 
CSNK1E 0.089 0.528 0.815 -1.432 -0.486 0.295 -1.155 -1.370 1.176 1.700 
SETD4 -0.590 -0.600 -0.295 1.485 -0.832 -0.625 1.239 1.951 -0.635 -0.745 
PIGU -0.857 -0.462 -0.110 1.429 -0.742 -1.059 -0.631 -0.955 1.185 1.068 
    
  
3
5
0
 
MCM6 -1.498 0.426 0.512 0.560 -1.059 -1.043 1.549 1.742 -0.051 -0.245 
TMPO -1.459 0.640 0.660 0.159 1.088 -0.040 0.845 1.328 -1.123 -0.703 
GPS2 -0.973 1.304 0.221 -0.551 0.804 0.856 0.327 0.326 -1.933 -1.459 
MKKS -1.489 0.411 0.413 0.665 -0.376 -1.321 0.013 1.809 0.381 -1.321 
TRMT112 -0.997 -0.011 -0.361 1.369 -0.445 -0.757 2.090 1.199 -0.806 -0.755 
MPDZ -0.892 -0.281 -0.260 1.434 -0.710 -0.602 -0.517 -0.750 1.924 1.513 
THAP4 -1.176 0.015 -0.107 1.267 1.820 1.429 -0.487 -0.682 -0.791 -1.090 
GOLGA4 0.736 -0.203 0.801 -1.333 1.354 1.868 -1.298 -0.813 -0.194 -0.251 
GCN1L1 1.358 -0.492 -0.952 0.087 -0.407 0.413 1.075 1.820 -0.919 -1.062 
UCHL5 -0.846 0.894 0.837 -0.886 -0.540 -0.798 1.845 1.507 -0.824 -0.763 
NDUFS8 -0.932 0.897 0.832 -0.797 -1.242 -1.617 1.541 0.140 0.768 0.614 
PPRC1 -0.962 -0.235 -0.209 1.406 -0.783 -1.013 0.973 2.233 -0.281 -0.337 
SLC25A27 -0.878 0.687 1.028 -0.837 1.563 1.763 -0.227 -0.470 -0.585 -1.144 
PCCA -0.560 -0.577 -0.356 1.492 -0.001 0.426 1.563 0.926 -0.679 -0.901 
RPUSD4 -1.056 -0.651 0.827 0.881 -0.324 -0.740 1.583 1.842 -0.477 -0.548 
 
 
    
  
3
5
1
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